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ABSTRACT 
Human malaria, caused by four species of the intracellular protozoan parasite Plasmodium, is 
a major health and economic burden in the tropics where the disease is endemic. The biotin-
dependent enzyme acetyl-CoA carboxylase catalyses the commitment step in de novo fatty 
acid biosynthesis in several organisms. Acetyl-CoA carboxylase is a target for anti-parasitic 
drug development due to its relevance in membrane biogenesis. This study describes the 
detection of acetyl-CoA carboxylase and the partial characterisation of the biotinoyl domain 
of the enzyme of the mouse malaria parasite, Plasmodium yoelii.  
 
Acetyl-CoA carboxylase mRNA was detected by RT-PCR performed on total RNA isolated 
from P. yoelii 17XL-infected mouse erythrocytes using primers designed from PY01695 
ORF of the Plasmodb-published MALPY00458 gene of P. yoelii 17XNL. The RT-PCR was 
confirmed by sequencing and comparative analysis of the sequenced RT-PCR cDNA 
products. Northern blot analysis performed on total RNA using probes designed from a 1 kb 
region of the gene showed that the transcript was greater than the predicted 8.7 kb ORF.  
 
An immunogenic peptide corresponding to the P. yoelii theoretical acetyl-CoA carboxylase 
sequence was selected using epitope prediction and multiple sequence alignment algorithms. 
The immunogenic peptide was coupled to rabbit albumin carrier for immunisation in 
chickens and the affinity purified antibody titre was approximately 25 mg. The anti-peptide 
antibodies detected a 330 kD protein in P. yoelii lysate blot, which corresponds to the 
predicted size of the enzyme. The enzyme was also detected in situ by immunofluorescence 
microscopy using the anti-peptide antibodies.  
 
A 1 kb region of the P. yoelii acetyl-CoA carboxylase gene containing the biotinoyl domain 
was cloned and expressed in E. coli as 66 kD GST-tag and 45 kD His-tag protein. Both 
recombinant biotinoyl proteins were shown to contain bound biotin using peroxidase-
conjugated avidin-biotin detection system. This suggested in vivo biotinylation of the 
recombinant P. yoelii biotinoyl protein, possibly by the E. coli biotin protein ligase.  
 
The Proscan™ and the NetPhos 2.0™ algorithms were used to predict protein kinase 
phosphorylation sites on the biotin carboxylase andthe carboxyltransferase domains of the 
enzyme. The three-dimensional structure of the biotinoyl and the biotin carboxylase domains 
were predicted using the SWISS-MODEL™ homology modelling algorithm. Homology 
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modelling revealed a similarity in the 3D conformation of the predicted P. yoelii biotinoyl 
domain and the E. coli biotinoyl protein with negligible root mean square d viation. The 
model also revealed the possibility of inhibiting P. yoelii and falciparum acetyl-CoA 
carboxylases with soraphen A based on the similarity in conformation with S. cerevisiae 
biotin carboxylase and the stereochemical properties of the residues predicted to interact with 
soraphen A. 
 
This study demonstrated that malaria p rasite expresses acetyl-CoA carboxylase and, 
combined with data on other enzymes involved in fatty cid metabolism suggests that the 
parasite synthesizes fatty acids e novo. This enzyme could be a target for rational drug 
design. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW  
 
1.1 An overview of malaria 
Malaria is caused by hematoprotozoa parasites of the genus Plasmodium. It is transmitted by the 
bite of the female anopheles mosquito. Four species of the Plasmodium parasite infect man 
namely: Plasmodium falciparum, P. vivax, P. ovalae and P. malariae. These four species show 
different clinical manifestations (Maegraith 1968; White 1992; Gilles 1997; Nosten et al. 1999). 
Generally malaria infections are characterised by fever, headache painful joints and weakness 
(Gilles, 1997; Van den Ende and Van Gompel, 1997; White, 1992). The majority of mortal cases 
of malaria in humans are caused by falciparum malaria and 1 – 2% of patients infected with 
Plasmodium falciparum die as a result of the infection. The major complications of a falciparum 
infection are cerebral malaria and placental malari, often resulting in coma and pregnancy 
complications, respectively (Gilles, 1997; Hunt et al., 2006; Van den Ende and Van Gompel, 
1997; White, 1992). 90% of the world malaria cases occur in the sub-Saharan regions of Africa. 
At the moment, clinical cases of malaria in the world are approaching 500 million infections and 
over 5 million deaths per year. More than three quarter of the deaths from the disease are infants 
below five years (McKean, 2002; WHO, 2003; WHO, 2005b). The symptoms of malaria appear 
about 9 to 14 days after a bite from an infected mosquito. In the absence of drug treatment, the 
infection can progress rapidly to become severe. Malaria parasites infect and destroy red blood 
cells causing anaemia and obstruct the blood capillaries by sequestering and attaching to the 
endothelial cells that carry blood to vital organs and the brain causing cerebral malaria (Gilles, 
1997; Hunt et al., 2006; Van den Ende and Van Gompel, 1997; White, 1992). Malaria caused by 
the other species infecting humans is rarely fatal. Plasmodium vivax and Plasmodium malariae 
infections often reoccur if not properly treated. There are several drugs available to cure malaria. 
A major hindrance in malaria chemotherapy is drug resistant parasites. Quinine based drugs are 
commonly available and are still effectively used to treat the disease in malaria endemic regions 
of the world (Goldring et al., 1999; Gregson and Plowe, 2005; Menting et al., 1997; Wainwright 
and Amaral, 2005). The disease has a major economic impact in countries where it is endemic. It 
is estimated that an average of 1.3% is lost in annu l economic growth due to reduced 
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productivity in countries where the disease is endemic (Sachs and Malaney, 2002; Sachs, 2002; 
WHO, 2003; WHO, 2005b).  
 
1.2 Geographical distribution of human malaria 
Figure 1.1 shows the geographical distribution of malaria in the world. Most malaria occurs 
between the Tropic of Cancer (latitude 23.5º North) and the Tropic of Capricorn (23.5º South). 
Infection is often seasonal with peak infections occurring during the rainy season when 
mosquitoes, the parasite vector, reproduce at an elevat d rate. There are also cases of malaria 
outside these latitudes in Southern Africa, New Delhi (India) and in the Northern parts of Africa 
(WHO, 2003; WHO, 2005a; WHO, 2005b). Malaria is highly endemic in West Africa and 
Central Africa especially around the Congo basin. Most malaria cases in these parts of Africa are 
chloroquine resistant (WHO, 2005b). There are sparse cases of malaria infections in parts of 
Kenya’s Rift valley that were previously thought to be too high above sea level for malaria 
transmission. Scientists believe that this may be because of human migration and climatic 
changes (WHO, 2003; WHO, 2005b). 
 
Malaria is wide spread in other parts of the world including Asia, South America, Central 
America and Southern Mexico. Drug resistant Plasmodium falciparum is present in parts of 
Cambodia, Myannmar, Thailand and Laos (Rietveld and Kouznetsov, 1997; WHO, 2003; WHO, 
2005b). Plasmodium vivax infection is also prevalent in these areas. Malari has been eradicated 
in the Caribbean but there were reports of an outbreak of falciparum malaria in Haiti (Rietveld 
and Kouznetsov, 1997). The malaria eradication programmes of the 1940’s and 1950’s combined 
with widespread use of screening methods have proved to be successful in eliminating the disease 
in North America and Europe. However, human migration remains the possible threat to malaria 
eradication in the non-malaria regions of the world (Rietveld and Kouznetsov, 1997). 
 
1.3 Treatment and management of malaria 
The approaches currently being used in the treatment and management of malaria are vector 
control and anti-malarial drugs. Vector control has been successful over the years in controlling 
and managing malaria all over the world. In North America, malaria was eradicated in the 50s 
through the use of insecticides such as DDT (dichloro-diphenyl-trichloroethane) (Curtis and 
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Mnzava, 2000; Teklehaimanot e al., 2007). In developing countries, the use of DDT has not 
being as successful as in North America. However, th  use of household insecticides, insecticide-
treated bed nets and removal of stagnant water around the house has been quite a success over the 
years (Curtis and Mnzava, 2000). In malaria endemic regions of Africa, homes are built with 
mosquito screens to prevent mosquitoes entering the building. The use of DDT has been 
discouraged and discontinued due to the environmental impact of this compound (Curtis and 
Mnzava, 2000).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Geographical distribution of malaria. The broken lines represent the tropic of Cancer 
(23.5ºN), the equator (0ºN or S) and the tropic of Capricorn (23.5ºS). The area of dense malaria infection 
in Africa is between the tropics (Sachs, 2002; WHO, 2005b). 
 
 
Malaria cases in South Africa are limited to regions below 1000 m above sea levels such as the 
Limpopo province, Mpumalanga province and the north-east of KwaZulu-Natal (RSA, 2004). 
The transmission of malaria in South Africa is season l just as in many malaria endemic regions. 
The transmission rate is believed to be minimal during the winter and dry seasons. Three drug 
regimes are currently recommended in South Africa namely: mefloquine (taken on weekly basis), 
doxycycline (taken on daily basis) and chloroquine (taken on weekly basis). Several 
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organizations have been set up by the health ministry to combat the disease, a web-based 
awareness site such as www.malaria.org.za and research funding institutions such as the South 
African Malaria Initiatives (SAMI, http://www.acgt.co.za/sami/) are part of governmental 
approach towards management of malaria in South Africa and the rest of Africa.  
 
The use of drugs in the treatment of malaria dates back to 1891 when the dye, methylene blue 
[3, 7-bis (dimethylamino)-phenothiazinium chloride] was used to treat malaria infections 
(Brasseur et al., 1999; Gregson and Plowe, 2005; Wainwright and Amaral, 2005). This dye was 
initially used as a biological stain to stain DNA (Pearson, 1972). Although the precise mechanism 
of action of the dye was not understood, methylene blu  and its analogue were predominantly 
used as malaria chemotherapy in the early days of malaria treatments (Färber t al., 1998). Since 
the discovery of anti-parasitic effects of methylene blue, the use of drugs to treat malaria 
infection has become wide spread and has proved to be very effective in controlling the disease 
(Wainwright and Amaral, 2005; White, 1992; White et al., 1999). Thus, case management relies 
only on the use compounds such as chloroquine, artemesinin, and pyrimethamine. Some of these 
drugs are cheap and widely available in malaria endemic regions. Chloroquine and quinoline 
derivatives are believed to inhibit the parasite’s polymerisation of toxic heme to non-toxic 
hemozoin (Monti et al., 1999; Pandey et al., 1999). Quinine has also been found to be effectiv  in 
reducing the expression of monocyte surface receptors to which malaria infected erythrocytes 
adhere to (Goldring and Nemaorani, 1999).  
 
A major impediment in anti-malaria chemotherapy is the improper use of drugs against malaria 
infections (Peters, 1974; Peters, 1998; Ridley, 2002; White, 2004; White et al., 1999). This 
problem is very common in malaria endemic regions and has resulted in selection pressure on the 
human malaria parasite to develop resistance mechanisms to most anti-parasitic drugs (Gregson 
and Plowe, 2005; Menting et al., 1997; Wainwright and Amaral, 2005). The increase in malaria 
mortality amongst children in these regions is due to the evolution of drug resistant parasites. 
Chloroquine resistant strains of Plasmodium vivax and falciparum are predominant in some 
malaria endemic regions (Gregson and Plowe, 2005; Ridley, 2002; White, 2004; White t al., 
1999). An effective strategy used to combat chloroquine-resistant malaria is through the use of 
combination of drugs to treat malaria cases (Wainwright and Amaral, 2005; White, 2004; White 
 5 
et al., 1999). An example is the use of mefloquine (a quinoline derivative)-amodiaquine 
combination or sulfadoxine-pyrimethamine combination. There has not been any reported case of 
artimesinin-resistant Plasmodium; thus artemesinin has proved to be the best clinica  choice to 
treat malaria cases (Brasseur t al., 1999; Goldring and Nemaorani, 1999). 
 
1.4 The life cycle of malaria parasites 
Malaria is transmitted through the bite of the female nopheles mosquito during a blood meal as 
illustrated in Figure 1.2. The insect picks up the parasite in the blood of an infected human. In the 
gut of the mosquito, the parasite reproduces sexually ndergoing several morphological changes. 
The parasite migrates to the salivary glands of the mosquito (Matteelli et al., 1997; Meis and 
Verhave, 1988). The mosquito introduces the parasite back into humans during another blood 
meal. Therefore the Plasmodium parasite life cycle spans between human (and other malaria 
susceptible animals) and mosquito. In a single mosquito bite, approximately twenty sporozoites 
enter the human blood stream and immediately migrate to the liver (Matteelli et al., 1997; Meis 
and Verhave, 1988). The sporozoite will pass through several hepatocytes and eventually settling 
in just a single hepatocyte. This begins the liver stage of the parasite life cycle, which is also 
known as the pre-erythrocytic stage. The sporozoites develop into schizonts. In human malaria, 
the pre-erythrocytic stage varies between species. In P. falciparum, the pre-erythrocytic stage 
lasts 5 – 6 days post infection. The schizonts rupture he liver cell releasing the merozoites into 
the blood stream. The merozoites invade the red blood cells to start the erythrocytic stage. The 
clinical symptoms and pathology of malaria is experienced at this stage of the parasite life cycle 
(Gilles, 1997; Van den Ende and Van Gompel, 1997; White, 1992). 
 
Most anti-malaaria drugs target the erythrocyte stage (Macreadie et al., 2000; Ridley, 2002; 
Wainwright and Amaral, 2005). The entry into the blood stream by merozoites is of 
immunological significance because the merozoites are exposed to the immune system and 
antibodies before invading new red blood cells (Maegr ith, 1968; Matteelli et al., 1997). Once in 
the red blood cell, the merozoites begin a period of replicative asexual cycle in the erythrocytes. 
The merozoite transforms into the ring, trophozoite, and schizont stages. The time taken to go 
through these transformations varies between the diff rent species of the Plasmodium parasites; 
48 h for P. vivax and P. falciparum, 50 h for P. ovalae and 72 h for P. malariae (Matteelli et al., 
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1997). The schizonts burst the erythrocytes and invade new erythrocytes or transform into 
gametocytes. The gametocytes taken up by mosquito dring blood meal undergo fertilization in 
the gut of the mosquito to begin the insect stage of the parasite life cycle (Matteelli et al., 1997). 
 
 
 
 
Figure 1.2 Life cycle of the Plasmodium parasite. The light brown portion on the figure represents the 
insect stage of the cycle and the light green portion represents the mammalian stage of the cycle. Adapted 
from Pearson Education Inc. (2004). Published by Benjamin Cummings 
 
 
1.5 Diagnosis of malaria 
Proper management of malaria cases is based on the accuracy of diagnosis of the disease. Most 
mortality cases are as a result of late and imprecise d agnosis of malaria (Bell and Peeling, 2006; 
Bell et al., 2006; Moody, 2002; Moody and Chiodini, 2002; Tomar et al., 2006). The gold 
standard for the detection and therefore diagnosis of malaria is the use of the light microscope to 
detect the blood stage of the parasite (Moody and Chiodini, 2002; Tomar et al., 2006). The red 
blood cells are not nucleated in mammals and so will not be stained by nucleic acid dyes such as 
methylene blue and azure-B. However, the presence of the parasite in the red blood cells will 
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result in the staining of the parasite in the red blood cell due to the parsite’s nucleic acids. This 
method still remains the most accurate and standard serological method to detect and diagnose 
the disease. The method still faces numerous challenges such as ability to differentiate the 
infecting Plasmodium species and the lack of trained microscopists in malaria endemic regions 
(Moody, 2002; Moody and Chiodini, 2002).  
 
These problems resulted in the development of immunochromatographic-based detection (Bell 
and Peeling, 2006; Moody, 2002; Moody and Chiodini, 2002) techniques called RDTs (rapid 
diagnostic tests). These techniques are quite easy and straight forward to use with very rapid 
results and it requires less technically qualified p rsonnel. The most commonly available RDT is 
based on Plasmodium lactate dehydrogenase (pLDH), an enzyme that is relativ y highly 
expressed by the parasite at the blood stage of the cycl  for the parasite energy metabolism. 
Using immobilized and enzyme-labelled antibody directed against recombinant pLDH, the 
presence of pLDH could be detected for the diagnosis f malaria.  The drawbacks of RDTs are 
false positive, false negative results and the short shelf life of the detection kit (Banoo et al., 
2006; Bell and Peeling, 2006; Bell t al., 2006; Chiodini et al., 2007). Storage conditions have 
proved to be very important to the proper functioning of the detection kit and hence accurate 
diagnosis of the disease. This has been a subject of concern in impoverished malaria endemic 
regions of the world (Chiodini et al., 2007). Another approach towards antibody-mediate 
diagnosis employs the use of antibody directed against a synthetic peptide derived from a 
Plasmodium protein. Synthetic peptides deduced from molecules such as histidine-rich protein 
and lactate dehydrogenase have been used for the production of anti-peptide antibodies (Tomar et 
al., 2006). These antibodies are used in ELISA format to detect the presence of the native protein 
in the sera of infected patients. 
 
Most recently, a quantitative real time PCR-based dtection technique has been developed based 
on conserved nucleotide sequences on the Plasmodium 18S ribosomal RNA for detection of 
broad spectrum malaria infection as well as species-sp cific 18S ribosomal RNA for specie-
specific detection (Bell and Ranford-Cartwright, 200 ; Coleman et al., 2006). By using primers 
corresponding to conserved as well as specie-specific regions on the 18S subunit of the ribosomal 
RNA gene, a mixed infection and/or infection by particular specie of Plasmodium could be 
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diagnosed by PCR amplification (Bell and Ranford-Cartwright, 2002; Bell et al., 2006; Coleman 
et al., 2006; Mens et al., 2006). 
 
1.6 The influence of the Plasmodium genomics projects on antimalarial drug discovery 
The Plasmodium parasite’s metabolic pathways were revealed after sequencing the genome of P.
falciparum strain 3D7 and partial sequencing of other species of Plasmodium. Approximately 
14% of the predicted proteins in the P. falciparum strain 3D7 genome were identified as enzymes 
and thus were assigned Enzyme Commission numbers (Gardner, 1999; Gardner et al., 2002a; 
Ginsburg, 2006; Kooij et al., 2006). It was envisaged that due to the AT richness of the genome 
some redundant proteins may be involved in unknown metabolic pathways (Ginsburg, 2006; 
Kooij et al., 2006). This may be due to the evolutionary distance between the parasite and other 
organisms whose genomes are well characterized. The analysis of the P. falciparum strain 3D7 
genome revealed that the parasite possesses the metabolic “machinery” for a functional glycolytic 
pathway. There is no functional gluconeogenic pathwy because genes coding for enzymes such 
as fructose bis-phosphatase and absence of trehalos, g ycogen and storage forms of carbohydrate 
involved in this pathway were not identified in the parasite (Gardner, 1999; Gardner et al., 2002a; 
Gardner et al., 2002b). The genes coding for the enzymes of the TCA cycle were identified. 
However, it is not clear whether the TCA cycle performs the complete oxidation of products of 
glycolysis (Gardner, 1999; Gardner t al., 2002a; Gardner et al., 2002b). Genes coding for fatty 
acid biosynthesis in the Plasmodium parasite were identified. The ability of the parasite to carry 
out de novo fatty acid biosynthesis has been a subject of debate (Gardner, 1999; Gardner t al., 
2002a; Gornicki, 2003). This will be discussed in full in Section 1.12.   
 
The spread of drug resistant malaria strains requirs the development of more effective anti-
malaria drugs that the parasite cannot build up resistance to. The hunt for more effective anti-
malaria drugs has been enhanced by the complete sequencing of the P. falciparum genome 
(Hammarton et al., 2003; Macreadie et al., 2000; Olliaro and Yuthavong, 1999). Functional 
genomics and a proteomics approach are currently applied in the validation of new anti-
Plasmodium drug targets. Several synthetic and natural products have been screened for potential 
use to treat malaria. There are three major categories in which potential drugs against malaria 
parasites can be classified; they are (i) drugs targe ing the cell cycle and signal transduction (ii) 
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drugs targeting the biochemical processes of the dig stive food vacuole and (iii) drugs targeting 
macromolecular and metabolite biosynthesis (Di Girolamo et al., 2005; Ginsburg, 2006; Hoffman 
et al., 1998). Potential candidates for drug targets must be actively involved in the life cycle of 
the parasite and must differ significantly from the omologue of the host. There must be no 
salvage pathway to circumvent the inhibition of thearget. The target must have low potential for 
resistance development and must be involved in committed and rate limiting biochemical 
processes (Hammarton et al., 2003; Macreadie et al., 2000; Olliaro and Yuthavong, 1999).  
Chloroquine, artemesisnin and quinine are inhibitors f hemozoin biosynthesis; an important 
detoxification pathway of the Plasmodium parasite (Monti et al., 1999; Pandey et al., 1999). 
Pyrymethamine, cycloguanyl and sulfonamide drugs inhib t folate biosynthesis. In the apicoplast, 
the proposed site of fatty acid synthesis, triclosan, thiolactomysisn and fosimidomysin inhibits 
fatty acid elongation pathways in other apicomplexan p rasites. Therefore these drugs may be 
active against the malaria parasite (Perozzo et al., 2002; Surolia et al., 2004; Surolia and Surolia, 
2001; Waller et al., 2003).  
 
By and large, the complex nature of the Plasmodium life cycle has resulted in the slow 
identification of anti-Plasmodium drug targets. A good number of available anti-malari  drugs 
are against asexual blood stage of the parasite life cycle. The logical explanation to this is that 
most severe pathological conditions of malaria infection are experienced during the asexual life 
cycle of the parasite (Van den Ende and Van Gompel, 1997). The accessibility of the blood stage 
and the relative ease to which the asexual blood stage could be grown in vitro in laboratory 
cultures makes this stage very attractive for drug intervention studies. There are several 
approaches to target the hepatic stage of the parasite life cycle; especially in relapsing malaria. 
The transition by the parasite from asexual to sexual stage also has the potential for drug 
intervention (Hammarton et al., 2003; Olliaro and Yuthavong, 1999).  
 
1.7 Overview apicomplexa fatty acid biosynthesis 
Apicomplexa are parasitic protists that constitute a broad phylum of protozoa including 
Plasmodium, Theileria, Babesia, Cryptosporidium and Toxoplasma; which cause a wide range of 
infections in animals. They have a non-photosynthetic chloroplast-like organelle called the 
apicoplast or plastid (Carter et al., 1998; Gleeson, 2000; Menard, 2007; Ralph et al., 2004a; 
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Ralph et al., 2004b; Wilson, 2002). The origin of this organelle is not well understood, however, 
there is a general belief that the plastid in apicomplexa resulted from an evolutionarily distant 
endosymbiotic event (Carter et al., 1998; Gleeson, 2000; Ralph et al., 2004a; Ralph et al., 
2004b). This event is postulated to be a sequence of endocyotosis that began by a cyanobacterium 
endocytosed by a eukaryote to form a common ancestor of modern day algae such as 
dinoflagellates. A second endocytosis occurred by an apicomplexa ancestor engulfing a 
photosynthetic eukaryote that previously engulfed a cy nobacterium (Carter et al., 1998; 
Gleeson, 2000; Ralph et al., 2004a; Ralph et al., 2004b). Studies have shown that a homology 
exists between the ORF of the plasmodial plastid genome and the plastid of red algae (Ralph et 
al., 2004a; Ralph et al., 2004b; Wilson, 2002). There is a difference of opinion on the number of 
membranes of a single plastid in an apicomplexan. Some authors stipulated that a plastid in 
Plasmodium is two (Carter et al., 1998; Gleeson, 2000; Ralph et al., 2004a; Ralph et al., 2004b) 
while others believe that the number is greater than wo (Waller et al., 2000). 
 
The apicoplast of Plasmodium parasites comprises of a highly reduced genome made up of 68 
genes on a 35 kb circular DNA (Gardner et al., 2002a) and has been shown to contain genes 
coding for ribosomal RNA, transfer RNA and RNA proteins. The Plasmodium plastid contains 
genes for approximately 17 ribosomal proteins, 16S ribosomal RNA, 23S ribosomal RNA, 
transfer RNAs, RNA polymerase and several proteins. This suggests that the apicoplast plastid is 
able to carry out protein synthesis (Gleeson, 2000; Ralph et al., 2004b; Wilson, 2002). Although 
not all genes necessary for protein synthesis are present in the plastid genome. The gene coding 
for ribosomal protein S9, vital for protein synthesis, is not present in the Plasmodium plastid 
genome but encoded in its nuclear genome (Ralph et al., 2004b; Wilson, 2002). Initially the 
function of the apicoplast was not well understood. After the sequencing of the P. falciparum 
genome, several apicoplast targeted genes and proteins w re discovered to be related to fatty acid 
metabolism. Due to the evolutionary origin of the apicoplast, the organelle presents a range of 
metabolic pathways that differ significantly from the metabolic pathways of the host (Ralph et 
al., 2004b). In addition to apicoplast targeted proteins, ~ 551 nuclear encoded proteins may be 
targeted to the apicoplast based on bioinformatics nd laboratory based studies. About 60% of the 
putative apicoplast-targeted proteins have no defined biological functions when compared to 
other organisms. This suggests that the apicoplast m y possess unknown specialised functions 
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that could be unique to the apicomplexa parasites (Gardner et al., 2002a; Ralph et al., 2004b). 
Therefore the apicoplast offers numerous proteins and metabolic pathways that can be targeted 
for anti-parasitic chemotherapy (Gornicki, 2003; Hanada et al., 2002; Perozzo et al., 2002; 
Waller et al., 2003). By and large the plastid is believed to be involved in protein metabolism, 
haem biosynthesis, fatty acid metabolism, synthesis of essential amino acids, electron transport 
and isoprenoid biosynthesis (Gardner et al., 2002a; Gleeson, 2000; Ralph et al., 2004a; Ralph et 
al., 2004b; Zuegge t al., 2001).  
 
Fatty acids in most biological systems are synthesised by two distinctly but related de novo fatty 
acid synthase (FAS) pathways namely; the Type I FAS pathway and the Type II FAS pathway. 
The Type I FAS is a large multifunctional enzymes with five enzyme domains found in the 
cytosol of fungi and other eukaryotic organism where it catalyses reactions of fatty acid chain 
elongation. The Type II FAS consist of separate andmonofunctional enzymes. The chain 
initiation and elongation reaction of the Type II FAS is catalysed by discrete enzymes namely 
acyl carrier protein (ACP), β-ketoacyl-ACP synthase, β-ketoacyl-ACP reductase, β-hydroxyacyl-
ACP dehydrase and enoyl-ACP reductase. This enzyme co plex is found in bacteria and plant 
plastids (Gardner et al., 2002a; Ralph et al., 2004b). The Plasmodium genome encodes the genes 
for Type II fatty acid synthase (FAS).  
 
The apicoplast was earlier proposed to be an organelle for fatty acid biosynthesis in 
apicomplexan parasites after the enzyme compenents of Type II FAS enzymes were identified in 
the organelle (Prigge t al., 2003; Ryall et al., 2003; Waller et al., 2003). This postulate was later 
strengthened after the Plasmodium genome was sequenced. These findings aroused early belief 
that the Plasmodium parasite is capable of de novo Type II fatty acid biosynthesis. Enzymes such 
as acyl carrier protein (ACP) and β-keto ACP synthase III are localized in the first chromosomes 
of the Plasmodium genome to be sequenced. These proteins have an N-terminal leader peptide 
targeted to the apicoplast. Similar observations were made in Toxoplasma gondii (Gardner et al., 
2002a; Surolia and Surolia, 2001). Pyruvate present in the apicoplast of Plasmodium falciparum 
is thought to be the precursor of acetyl-CoA; the substrate that initiates de novo fatty acid 
synthesis. The pyruvate could have been formed from imported phosphoenolpyruvate by 
pyruvate kinase (Ralph et al., 2004b). Previous studies have demonstrated that P. falciparum 
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synthesises acyl carrier protein (ACP), β-keto ACP synthase III and malonyl-CoA of the Type II 
fatty acid synthase complex (Prigge et al., 2003), thus capable of initiating fatty acid biosynthesis 
in vivo. Figure 1.3 illustrates an overview of the proposed fatty acid biosynthesis pathway in 
apicomplexa parasites. The phosphoenolpyruvate is produced in the cyotosol by glycolysis and 
transported into the plastid through a membrane-bound phosphoenolpyruvate transport protein 
(Gleeson, 2000; Günther t al., 2007; Ke et al., 2000a; Ralph et al., 2004b). 
 
The phosphoenol pyruvate is converted to pyruvate by the pyruvate dehydrogenase complex. 
Pyruvate is an important source of carbon in plastid fatty acid biosynthesis in plants (Ke et al., 
2000a; Ke et al., 2000b; Ohlrogge t al., 2000). The plastid pyruvate dehydrogenase complex has 
evolutionary relationship with cyanobacteria. The cynobacteria-like pyruvate dehydrogenase 
complexes have been localised in P. falciparum and Toxoplasma gondii. Although P. falciparum 
seem to lack mitochondrial pyruvate dehydrogenase, th  parasite does have mitochondrial-
targeted subunits of keto-acid dehydrogenase and α-ketoglutarate dehydrogeanse complex (Ralph 
et al., 2004b; Waller et al., 2003). The pyruvate dehydrogenase complex is made up of four 
distinct subunits namely: E1α, E1β, E2 and E3. All enzymes and cofactors of the pyruvate 
dehydrogenase complex have been established to be pres nt in the apicoplast of P. falciparum 
(Gardner et al., 2002a). Lipoic acid is synthesised from an octanoyl-ACP precursor by the 
enzyme lipoic acid synthase (LipA). A homologue of LipA is targeted to the apicoplast of the P. 
falciparum genome. Lipoic acid is attached to the E2 subunit of he pyruvate dehydrogenase 
complex to form a transient lipoic acid-E2 complex; a process catalysed by lipoate-protein ligase 
(LipB). LipB is found in both the mitochondria and plastid. In P. falciparum, LipB contains the 
apicoplast signal peptide, suggesting that the enzyme may be targeted to the apicoplast. In the 
next step, an acetyl group is attached to the lipoic acid-E2 complex; this is catalysed by E1-
thyamine pyrophosphate complex (E1-TPP). The acetyl group is attached to coenzyme A (CoA) 
to form acetyl-CoA. The CoA is synthesised from dephospho-CoA by an enzyme called 
dephospho-CoA kinase. Other sources of CoA in the Plasmodium parasite are glycerol-
phospholipid and sphingolipid pathways. The acetyl-CoA enters the de novo biosynthesis of fatty 
acids (Mitamura and Palacpac, 2003; Ralph et al., 2004b) where it is converted to malonyl-CoA 
by acetyl-CoA carboxylase. Malonyl-CoA enters the Type II FAS-mediated chain elongation 
(discussed in Section 1.13). 
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Figure 1.3 Overview of plastid fatty acid biosynthesis Simplified from the review by 
Wilson (2002). The broken arrow represents condensation of acetyl-CoA with malonyl-ACP. 
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1.8 Overview of acetyl-CoA carboxylase 
Acetyl-CoA carboxylase (ACC) [EC 6.4.1.2] is an enzyme that catalyses the carboxylation of 
acetyl-CoA to form malonyl-CoA in the rate limiting step of de novo fatty acid biosynthesis. This 
reaction is driven by ATP hydrolysis (Abu-Elheiga et al., 2000; Abu-Elheiga et al., 1995; Al-Feel 
et al., 1992; Brownsey et al., 2006; Lu et al., 2005; Wakil et al., 1983). In addition to being 
involved in fatty acid biosynthesis, ACC may be involved in the synthesis of polyketides and 
possibly in yet unknown biosynthetic pathways leading to the production of unknown compounds 
(Al-Feel et al., 1992; Hopwood and Sherman, 1990; Sasaki et al., 1993). The product, malonyl-
CoA, formed by ACC, becomes an important substrate for fatty acid synthesis in the liver and 
lactating mammary glands of animals. Malony-CoA is a ubstrate for the chain elongation system 
of enzymes in the endoplasmic reticulum and in many tissues with fatty acid chains greater than 
20 subunits. Malonyl-CoA is involved in numerous cellular functions such as the synthesis of 
eicosanoid, glycolipids, sphingolopids and glycerolipids. Malonyl-CoA also plays an important 
function in the regulation of fatty acid oxidation by inhibiting palmitoyl-CoA transferase I 
(Brownsey et al., 2006). Therefore the availability of malonyl-CoA can alter the rate of fatty acid 
biosynthesis, β-oxidation and ketogenesis (McGarry, 2002). By and large, the role played by 
ACC in the production of malonyl-CoA emphasises the importance of ACC in carbon and energy 
metabolism in organisms expressing this enzyme. 
 
Figure 1.4 illustrates the rate limiting step in fatty acid biosynthesis catalysed by ACC. The 
enzyme transfers a carboxylate ion (COO¯  ) to acetyl-CoA (Boone t al., 2000; Brownsey et al., 
2006). The first step is the ATP-dependent phosphorylation of bicarbonate to carbamoyl 
phosphate. This step is catalysed by the carbamoyl phosphate synthatase sub-domain of the biotin 
carboxlase domain (Boone et al., 2000; Brownsey et al., 2006). In the second step, the phosphate-
activated carboxylate ion is transferred to the biotin moiety in the biotinoyl domain to form 
carboxybiotinyl ACC. The carbondioxide is subsequently detached from the biotin molecule and 
transferred to acetyl-CoA in the final step. This step is catalysed by the carboxyl transferase 
domain (Boone et al., 2000; Brownsey et al., 2006). 
 
In mammals, there are two isoforms of ACC namely ACC1 (ACC α) and ACC2 (ACC β), as 
illustrated in Figure 1.5. These two isoenzymes vary in their amino acid sequence suggesting 
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possible variation in function between these two isozymes. ACC1 is expressed in the lipogenic 
tissues as a ~ 265 kD monomeric protein, where it is involved in the rate limiting step of fatty 
acid biosynthesis. ACC2 is a 270 – 280 kD monomeric protein expressed in the skeletal and heart 
muscle where is it believed to play an important role in the regulation of fatty acid oxidation 
(Brownsey et al., 2006; Ha et al., 1996; Lu et al., 2005). 
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Figure 1.4 Formation of malonyl-CoA from acetyl-CoA and bicarbonate. Step 1 is the 
phosphorylation of the carboxylate ion to form carbamoylphosphate; Step 2 is the transfer of 
carbamoylphosphate to the biotin molecule on the biotinoyl domain to form carboxybiotinyl ACC; Step 3 
is the transfer of carboxylate ion to acetyl-CoA to form malonyl-CoA. Steps 1 and 2 are catalysed by the 
biotin carboxylase domain (or subunit) and Step 3 is catalysed by the carboxyl transferase domain. 
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The complex structure of ACC may suggest the complex nature of its catalytic and regulatory 
properties. ACC found in higher animals, protozoa (Toxoplasma gondii), plants and yeasts have 
three protein domains. The biotin carboxylase domain is situated at the N-terminal region of the 
enzyme. The biotin/lipoyl binding domain (the biotin carboxyl carrier protein or biotinoyl 
domain) is situated closer to the biotin carboxylase domain at the N-terminal region of the 
enzyme. The carboxyltransferase domain is situated t the C-terminal region. In some organisms 
including mammals, the carboxyltransferase domain is further subdivided into an N-terminal 
transferase and a C-terminal transferase domain (Brownsey et al., 2006; Cronan and Waldrop, 
2002; Ha et al., 1996; Lu et al., 2005). ACC exists in the form of a dimer or polymer of up to 
4 000 Å unit (~ 400 nm in length). In vitro studies have shown that the dimeric form of ACC 
shows low catalytic activity while the polymeric form is more active (Brownsey et al., 2006).  
 
 
 
Figure 1.5 Domain organisation of the multi-enzyme domain acetyl-CoA carboxylase. (A) Acetyl-
CoA carboxylase 1 (ACC 1) (B) Acetyl-CoA carboxylase 2 (ACC 2) with the mitochondrial signal 
sequence (filled box) at the N-terminal (Hardie andPan, 2002). 
 
 
B
io
tin
 
C N 
Biotin carboxylase Carboxyl transferase Biotin carboxyl 
carrier protein 
A 
B
io
tin
 
C N 
Biotin carboxylase Carboxyl transferase Biotin carboxyl 
carrier protein 
B 
 17 
ACC2 has a predicted molecular weight of 290 kD; larger than ACC1. ACC2 was first isolated 
from rat heart (Thampy, 1989; Thampy and Wakil, 1988a; Thampy and Wakil, 1988b). Sequence 
analysis of ACC2 showed that it has an N-terminal sequence extension. This sequence (not found 
in ACC1), which contains a mitochondrial targeting motif, differentiates ACC1 from ACC2. 
ACC is made up of an ATP binding motif, a protein kase recognition site and other numerous 
catabolite binding sites that are involved in the regulation of the enzyme. Three dimensional 
structural studies have been reported for the biotin carboxyl carrier protein of E. coli and 
Saccharomyces cerevisiae (Roberts et al., 1999; Waldrop et al., 1994) as well as the carboxyl 
transferase domain of Saccharomyces cerevisiae (Zhang et al., 2003). To date, there is no 
resolved 3D structure for mammalian, plant and protoz an ACC domains. The important nature 
of this enzyme in various organisms as a “manager” of carbon and energy metabolism makes it 
attractive to resolve its three dimensional structure.  
 
Some plants express both the multi-enzyme-domain type ACC as well as the multi-enzyme-
subunit type ACC complex. The multi-enzyme-subunit type ACC complex form is localised in 
the plastid of plant cells where de novo fatty acid biosynthesis takes place, and the multi-enzyme-
domain ACC is localised in the plant cell cytosol. De novo fatty acid biosynthesis found in plants 
is very similar to the pathway of yeast, and higher animals (Konishi et al., 1996; Sasaki et al., 
1993; Zuther et al., 1999). The plant plastid multi-enzyme-subunit ACC complex (similar to 
those found in prokaryotes) dissociates into four protein subunits namely: the biotin carboxyl 
carrier protein (biotinoyl protein), biotin carboxylase, α-carboxyltransferase and β-
carboxyltransferase (Figure 1.6). The plastid ACC is involved only in fatty acid biosynthesis, 
while the cytosolic ACC is involved in flavonoid, anthocyanin, malonated amino acids, very long 
chain fatty acid biosynthesis and other natural products found in plants (Sasaki and Nagano, 
2004; Thelen et al., 2001).  
 
Grass and some monocotyledonous plants lack the gen that codes for the multi-enzyme-domain 
ACC subunits complex, but encodes the multi-enzyme-domain ACC that is targeted to both the 
plastid and the cytosol. The lack of the multi-enzyme-subunit ACC complex in grasses confirms 
the sensitivity shown towards herbicides by these plants. Herbicides such as fenoxaprop, diclofop 
and sethoxydim (Figure 1.8) inhibit the activity of the multi-enzyme-domain ACC, while the 
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multi-enzyme-subunit ACC complex is insensitive to herbicides (Davis et al., 2000). There is no 
defined molecular weight of plant ACC. But studies have shown that the plant single multi-
enzyme-domain ACC is in the form of a dimer ranging from about 210 kD to 250 kD. The 
observed size in pea ACC is about 650 – 700 kD (Sasaki and Nagano, 2004). The usual flow of 
carbon from photosynthesis to primary and secondary metabolites in plants is controlled by ACC. 
Therefore in plants, ACC and malonyl-CoA (product of ACC) are vital for the regulation of 
metabolite flux through the fatty acid biosynthetic and degradation pathways (Jelenska et al., 
2001; Jelenska et al., 2002). 
 
 
 
Figure 1.6 The multi-enzyme acetyl-CoA carboxylase complex (Sasaki and Nagano, 2004). 
 
1.9 Transcriptional regulation of acetyl-CoA carboxylase 
Eukaryotic ACC can be regulated at the level of transcription, regulated allosterically and 
covalently (Brownsey et al., 2006; Sasaki et al., 1993). In mammals, ACC1 expression is often 
controlled by the feeding state of the animal. The diet of animals used for isolation of tissue ACC 
is often controlled to enable high level expression of the enzyme (Song and Kim, 1981; Thampy 
and Wakil, 1988a). The hepatic expression of ACC is decreased during insulin deficiency and 
starvation, and restored by feeding a low fat diet or insulin treatment (Iritani, 1992; Thampy and 
Wakil, 1988b). Therefore hepatic ACC1 transcription s controlled by factors such as low blood 
glucose, insulin, thyroid hormone hormones involved in catabolism and transcriptional factors. 
The enzyme is expressed in high levels in lactating mammary glands, which is an indication of 
the inducible nature of this enzyme (Brownsey et al., 2006; Hardie and Pan, 2002). The most 
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significant transcriptional factors are the sterol-regulating elements binding-protein-1c and other 
lipogenic enzymes (Zhang et al., 2003).  
 
The expression of ACC2 in mammals is increased during starvation, which is antagonistic to the 
ACC1 expression (Brownsey et al., 2006). This is because most fatty acid biosynthesis is 
incorporated into membrane synthesis and lipid storage. Thus fatty acid biosynthesis is required 
for early stages of cell growth and development. If these fatty acids are not exhausted, the de 
novo fatty acid biosynthesis decreases (feed back inhibition). The decrease and increase in fatty 
acid biosynthesis is therefore achieved by the expression of the key enzyme, ACC (Brownsey et 
al., 2006; Thampy and Wakil, 1988b). Eukaryotic organisms control ACC transcription by RNA 
editing. This process is universally known to affect gene regulation (Sasaki et al., 1993). ACC in 
plants is also believed to be post-translationally regulated by assembly and disassembly of the 
monomeric proteins of the heteromeric enzyme complex resulting to controlled activity of ACC 
(Sasaki and Nagano, 2004; Thelen et al., 2001). 
 
1.10 Allosteric regulation of acetyl-CoA carboxylase 
Allosteric regulation of ACC is achieved by the bindi g of citrate to the enzyme resulting in 
polymerization of the inactive dimeric form of the enzyme to the active filamentous polymer 
(Boone et al., 2000; Brownsey et al., 2006; Hardie and Pan, 2002; Munday, 2002). Other 
metabolites such as glutamate and other dicarboxylic ac ds activate ACC1; this indicates the 
possible effect of amino acid metabolism on ACC activity (Boone et al., 2000). The substrates of 
fatty acid biosynthetic pathways, including  malonyl-CoA, free CoA and fatty-acyl CoA esters, 
have been shown to inhibit ACC1 (Boone et al., 2000; Moule et al., 1992). Mammalian ACC2 
does not polymerize as readily as the ACC1, which suggests that both enzymes may have 
different allosteric regulators. ACC2 is however activated by citrate just as ACC1; a crucial 
process in skeletal muscles. Citrate is an important eagent used in most isolation procedures for 
ACC (Song and Kim, 1981; Thampy and Wakil, 1988a). The citrate binding site on ACC is yet to 
be identified (Boone t al., 2000; Hardie and Pan, 2002). 
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1.11 Regulation of acetyl-CoA carboxylase by phosphorylation 
Most studies to date on the regulation of ACC by phosphorylation and de-phosphorylation have 
focused on mammalian (especially humans) and yeast ACC. There is also evidence that ACC is 
regulated by phosphorylation in Drosophila melanogaster (Pan and Hardie, 2002). The link 
between ACC and pathologies such as diabetes and obesity has encouraged the research on the 
“phospho-regulation” of ACC in human species. ACC is regulated by phosphorylation and de-
phosphorylation by protein kinases and phosphatases (Brownsey et al., 2006; Davies et al., 1990; 
Hardie et al., 1998; Hardie and Pan, 2002).  
 
5’AMP-activated protein kinase (AMPK) phosphorylates hree serine residues of the mammalian 
ACC namely Ser79, Ser1200 and Ser1215. Ser79 lies on the N-terminal region of ACC1 before the 
biotin carboxylase domain. Ser1200 and Ser1215 lie on the central region of ACC1, between the 
biotin carboxyl carrier protein (BCCP) and the carboxyltransferase domain (Brownsey t al., 
2006; Hardie and Pan, 2002). Phosphorylation of Ser79 occurs more rapidly than the other two 
residues; confirmed by site-directed mutagenesis. In ACC1, phosphorylation of Ser79 results in 
inactivation of ACC1, which is reversed by dephosphorylation by protein phosphatase-2C 
(PP2C) or by cleavage of the N-terminal 10 – 20 kD region of ACC1 containing the Ser79 esidue 
(Brownsey et al., 2006; Hardie and Pan, 2002). 
 
In vitro studies with AMPK confirmed that there are other possible phosphorylation sites on 
ACC1 that may be phosphorylated by other protein kinases (Hardie, 2003; Hardie et al., 1998; 
Hardie and Pan, 2002; Pan and Hardie, 2002). ACC1 can be phosphorylated by protein kinase A 
(PKA) at Ser77 and Ser1200 resulting in minimal inhibition of ACC1. However, there is no 
evidence for the in vivo phosphorylation of ACC1 by PKA. AMPK is the only protein kinase that 
has shown significant relationship to energy metabolism in terms of induced expression of the 
enzyme in various physiological conditions related o energy changes (Hardie and Pan, 2002). 
The regulation of ACC2 by AMPK in the mammalian system is still not well understood. ACC2 
purified from rat muscle can be phosphorylated and inactivated in vitro by AMPK. Although the 
Ser79 residue found in ACC1 is absent in ACC2, Ser219 in ACC2 is thought to be the equivalent 
of the ACC1-Ser79 (based on the hydrophobic amino acid residues around Ser79). ACC2-Ser219 is 
phosphorylated by AMPK (Hardie t al., 1998; Hardie and Pan, 2002). 
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1.12 The apicomplexa plastid acetyl-CoA carboxylase 
Until recently, parasitic organisms such as Plasmodium were thought to be incapable of de novo 
fatty acid biosynthesis. This was based on the inabil ty of Plasmodium knowlesi to incorporate a 
radio-labelled carbon precursor to its lipids synthesised in vivo (Holtz, 1977; Ralph et al., 2004b). 
The malaria parasite was assumed to depend entirely on its host for fatty acid requirement and 
other lipid precursors for cell wall synthesis. Work carried out on the lipid composition and lipid 
turn over of malaria parasite-infected red blood cells showed that infected red blood cell 
exhibited a remarkable alteration in their lipid composition (Beaumelle and Vial, 1988a; Vial et 
al., 1984). Lipid precursors such as phosphatidylethanolamine, phosphatidylcholine, and 
phosphatidylserine are taken up by the parasite. This suggested that the Plasmodium parasite is 
capable of scavenging lipid precursors from the host. This uptake was shown to be enhanced by 
the presence of lipid transfer proteins (Beaumelle and Vial, 1988b; Beaumelle t al., 1988) and 
these lipids are incorporated into parasite membranes. Chloroquine was also shown to inhibit the 
uptake and assimilation of lipid precursors using radiolabelled inositol, 1-[14C]-palmitoyl-
lysophosphatidylcholine (Vial et al., 1988). However, this postulate was refuted after it was 
discovered that the malaria parasite expressed genes that code for de novo fatty acid biosynthesis 
as revealed by the malaria genome analysis. Work done by several authors have shown that P. 
falciparum is capable of incorporating acetate into its fatty cid synthesis (Gardner t al., 2002a; 
Mitamura and Palacpac, 2003; Ralph et al., 2004b; Surolia and Surolia, 2001; Waller et al., 
2003).  
 
In Toxoplasma gondii, ACC and the gene expressing ACC have been well chara terised. Due to 
the relatedness of this parasite to the Plasmodium parasite, it is likely that there exists a 
correlation between the apparent functional similarities of the ACC gene and protein between 
these protozoan parasites (Gornicki, 2003; Mitamura and Palacpac, 2003). The Toxoplasma 
gondii genome encodes two copies of ACC genes (ACC1 and ACC2) coding for the multi-
enzyme-domain ACC (Jelenska et al., 2001; Jelenska et al., 2002). Both enzymes are biotin-
dependent and they catalyse the first step in the de novo synthesis of fatty acids in the parasite 
(Jelenska et al., 2001; Jelenska et al., 2002; Lauer et al., 1995; Zuther et al., 1999). Studies using 
the Toxoplasma parasite lysates have shown ACC activity. The genes encoding the two ACC 
isoforms have multiple introns within their open reading frames; this is similar to the mammalian 
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and yeast ACC gene structure. Both mammalian and yeast ACC amino acid sequences share 
some common sequence motifs with the Toxoplasma ACC sequence especially in the enzyme 
domain regions. ACC1 is smaller than ACC2; a phenomenon common to the mammalian ACC. 
Jalenska et al. (2002) postulated that ACC1 is apicoplast-targeted an  is involved in the de novo 
fatty acid biosynthesis. ACC2 is the cytosolic form. They observed that ACC1 is inhibited by 
plant herbicide such as aryloxyphenoxypropionates and clodinafops. This inhibitory effect on the 
parasite ACC by herbicides underlines the potential for targeting protozoan parasite fatty acid 
synthesis for anti-parasitic drug intervention.  
 
1.13 Apicoplast Type II FAS-mediated chain elongation  
Figure 1.7 illustrates the proposed reaction steps used by apicomplexa to produce palmitic acid 
(Ralph et al., 2004b; Surolia et al., 2004; Wilson, 2002). Malonyl-CoA is attached to acyl carrier 
protein (ACP) in a ping-pong reaction mechanism catalysed by malonyl-CoA:ACP transacylase. 
This enzyme has been cloned, expressed and characterised in P. falciparum (Prigge et al., 2003). 
Although this enzyme is necessary for parasite survival, its potential as an anti-parasitic agent is 
yet to be exploited (Surolia et al., 2004). Malonyl-ACP is the substrate that is continually added 
to the fatty acid chain, thus each cycle results in the addition of two carbon moieties from 
malonyl-ACP. The chain elongation step is divided into four distinct reaction steps namely: 
condensation, reduction, dehydration and reduction (Surolia et al., 2004).  
 
The Type II FAS-catalysed chain elongation in the apicomplexa plastid begins with the 
condensation of acetyl-CoA with malonyl-ACP; unlike the Type I FAS chain elongation that uses 
acetyl-ACP as substrate for the condensation step (Surolia et al., 2004; Wilson, 2002).This first 
step is catalysed by β-ketoacyl-ACP synthase III (KAS III or FabH), while the subsequent 
condensation steps (cycles 2 – 7) are catalysed by a FabB/F (KAS I/II) isoezyme (Surolia et al., 
2004; Wilson, 2002). FabH is annotated in P. falciparum (Plasmodb ID PFB0505c, located on 
chromosome 2), vivax, knowlesi, berghei and chabaudi as a beta-ketoacyl-ACP synthase III 
precursor. FabB/F is annotated in P. falciparum (Plasmodb ID PFF1275c, located on 
chromosome 6), vivax, knowlesi, berghei, yoelii and chabaudi as the beta-ketoacyl-ACP synthase 
III precursor. P. falciparum FabH is inhibited by 1,2, dithiole-3-one (an analogue of 
thiolactomycin) with an IC50 of 0.5 – 10 µM (Prigge t al., 2003). Thiolactomycin (Figure 1.8) is 
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a competitive inhibitor of bacterial and plant ketoacyl-ACP synthase (Sasaki and Nagano, 2004; 
Surolia et al., 2004) and has been shown to inhibit P. falciparum growth in human erythrocyte at 
concentrations less than 50 µM (Gornicki, 2003). 
 
The second step in the Type II FAS chain elongation is the reduction of β-ketoacyl-ACP to β-
hydroxyacyl-ACP. This reaction step is catalysed by NADP-dependent β-ketoacyl-ACP 
reductase (Surolia et al., 2004). This enzyme is annotated in P. falciparum as putative 3-oxoacyl-
ACP reductase (Plasmodb ID: PFI1125c, located on chromosome 9), as well as in vivax, 
knowlesi, berghei, yoelii and chabaudi (Gornicki, 2003). No inhibitor of this enzyme has been 
identified. β-hydroxyacyl-ACP is dehydrated to enoyl-ACP by β-hydroxyacyl-ACP dehydrase 
(FabA/Z). The FabA isoenzyme is bifunctional, it catalyses the dehydration of β-hydroxyacyl-
ACP and the trans-isomerisation of trans-enoyl-ACP to cis-enoyl-ACP. Cis-enoyl-ACP is 
channelled into the production of unsaturated fatty cids (Surolia et al., 2004; Surolia and 
Surolia, 2001). FabZ is characterised in P. falciparum (Plasmodb ID PF13_0128, located on 
chromosome 13) (Sharma et al., 2003). Orthologues of FabZ have been identified in P. vivax, 
knowlesi, berghei, yoelii and chabaudi; and annotated as the β-hydroxyacyl-ACP dehydrase 
precursor in the Plasmodb database. In the final elongation step, enoyl-ACP is reduced to 
butyryl-ACP by enoyl-ACP redcutase (FabI). This enzyme is NADH-dependent in apicomplexa 
Type II FAS as contrasting the NADPH-dependent homol gue of the Type I FAS (Surolia et al., 
2004; Surolia and Surolia, 2001). FabI is inhibited by triclosan (Figure 1.8) a broad spectrum 
antimicrobial agent (Suguna et al., 2001; Surolia et al., 2004; Surolia and Surolia, 2001). In 
Plasmodium, triclosan inhibits FabI (Plasmodb ID PFF0730c, loated on Chromosome 6)with an 
IC50 of 0.2 – 1.2 µM. The FabI ortholgue has been annotated in P. vaivax, knowlesi, berghei, 
yoelii and chabaudi. The final product of the first elongation cycle (butyryl-ACP) enters the 
second cycle by condensing with malonyl-ACP catalysed by FabB/F. Cerulenin (Figure 1.8) is an 
inhibitor of FabB/F (Johnson et al., 1994; Lack et al., 2006). After the seventh cycle, the 
resulting product is a 16-carbon atom fatty acid called palmitioyl-ACP. This product is 
hydrolysed to palmitate (Surolia et al., 2004; Wilson, 2002).  
 
In summary, fatty acid metabolism is vital to energy and membrane biogenesis. Acetyl-CoA 
carboxylase is central to de novo fatty acid metabolism. The two major types of acetyl-CoA 
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carboxylase are the multi-enzyme domain type found in humans, yeast and monocot plants and 
the multi-subunit enzyme complex found in bacteria and dicot plants. De novo fatty acid 
synthesis is initiated by the acetyl-CoA carboxylase-mediated carboxylation of acetyl-CoA to 
form malonyl-CoA. This reaction is the committed step in fatty acid synthesis and is ATP-
dependent. Malonyl-CoA is elongated to palmitic acid via a series of repetitive steps of 
condensation, reduction and dehydration reactions catalysed by fatty acid synthase (FAS).  
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Figure 1.7 Type II fatty acid synthase-mediated synthesis of palmitate. Reaction products 
and intermediates are in blue and inhibitors are in magenta. Squiggle arrows indicate  a multi-
step and a broken arrow indicates second and subseqent condensation steps (Surolia et al., 
2004). 
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There are two types of FAS responsible for elongation of malonyl-CoA, namely the Type I FAS 
and Type II FAS. The type I FAS is a large multi-enzyme domain (multi-functional) polypeptide 
found in humans and fungi, while the Type II FAS is made up of discrete and mono-functional 
enzymes (complex) found in bacteria and plant chloroplasts. Apicomplexan parasites have been 
shown to express a nucleus-encoded acetyl-CoA carboxylase and Type II FAS, which are 
targeted to the apicoplast. However, C yptosporidium parvum (an apicomplexa) has been shown 
to express cytoplasmic-targeted acetyl-CoA carboxylase and Type I FAS (Zhu, 2004; Zhu et al., 
2004; Zhu et al., 2000). There are inhibitors of acetyl-CoA carboxylase and FAS. Fatty acid 
metabolism is targeted for anti-parasite chemotherapy due to the relevance of fatty acid 
metabolism to the survival of parasites.   
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Figure 1.8 Inhibitors of acetyl-CoA carboxylase and Type II fatty acid synthase. (Jelenska et al., 
2001; Jelenska et al., 2002; Surolia et al., 2004) 
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1.14 Aim and objectives of the study 
There are no experimental data published to date suggesting that the Plasmodium parasites 
express functional acetyl-CoA carboxylase. However, there seem to be homologues of acetyl-
CoA carboxylase in P. falciparum (Plasmodb-gene number PF14_0664), Plasmodium yoelii 
yoelii (Plasmodb-gene number PY01695), and Plasmodium berghei (Plasmodb-gene number 
PB000494.02.0) as a fragment and as hypothetically annotated proteins in Plasmodium chabaudi 
(Plasmodb-gene number PC000014.02.0). The identification of the gene that codes for acetyl-
CoA carboxylase in the malaria parasite suggests that the Plasmodium parasite is capable of 
fatty-acid synthesis. However, there is no evidence that the gene coding for acetyl-CoA 
carboxylase is expressed as a functionally active enzyme capable of initiating the rate-limiting 
step of fatty acid synthesis. It is still unclear how the parasite metabolises fatty acids in vivo. 
 
Lipid metabolism is elevated in P. falciparum-infected erythrocytes, when compared to non-
infected erythrocytes in which fatty acid metabolism is almost non-existent (Hanada et al., 2002; 
Perozzo et al., 2002; Sherman, 1979; Waller t al., 2003). The majority of the lipids synthesised 
during the intra-erythrocytic stage of Plasmodium parasite cycle are channelled towards 
membrane biogenesis including organellar and tublovessicular membrane networks in the 
cytoplasm of infected erythrocytes (Hanada et al., 2002). Other findings (Beaumelle and Vial, 
1988b; Moll et al., 1988) propose that Plasmodium parasites meet the demand for important 
lipids by simultaneously importing lipids from its hosts and employing de novo pathways. 
Perhaps this is a clever adaptation by the parasite to maximise cellular energy turnover, since de 
novo biosynthetic pathways are often energy consuming. Therefore, there is the possibility that 
Plasmodium parasites exhibit a well developed mechanism of lipid biosynthesis needed to meet 
its lipid demands for its atypical form of cell proliferation and survival in its host environment 
(Hanada et al., 2002; Lauer et al., 1995). 
Based on the available data on Plasmodium lipid metabolism, much is yet to be understood about 
the Plasmodium fatty acid synthesis, the fate of acetyl-CoA carboxylase and how the parasite 
manages carbon and other energy sources. The significance of these biochemical processes for 
parasite survival can not be overlooked as potential pathways for anti-Plasmodium drug 
intervention. The gene encoding acetyl-CoA carboxylase in P. yoelii strain 17XNL has been 
sequenced and published (Plasmodb ID: PY01695). The ability of the parasite to synthesise fatty 
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acids de novo via the acetyl-CoA carboxylase-mediated commitment step of malonyl-CoA 
formation depends on the transcription of the gene and synthesis of the enzyme.  
This study was aimed at establishing the presence of acetyl-CoA carboxylase and the mRNA 
transcript encoding the enzyme at the eythrocytic stage of P. yoelii strain 17XL propagated in 
BALB/c mice. Therefore the objectives are as follows: 
1. The presence of the mRNA transcript will be established by RT-PCR using primers 
designed to amplify the region of the open reading frame. The RT-PCR cDNA products 
will be sequenced to confirm the RT-PCR results. The size of the transcript will be 
determined by Northern blot analysis. 
2. Anti-peptide antibodies produced in chickens against Plasmodium proteins have shown to 
be an effective tool in the detection and characterisation of plasmodial proteins. 
Antibodies will be produced in chickens against an immunogenic region of the theoretical 
acetyl-CoA carboxylase amino acid sequence published in the Plasmodb database. The 
presence of the enzyme in parasite lysates and in a P. yoelii-infected-red blood cell will be 
evaluated using anti-peptide antibodies on a Western blot and by immunofluorescent 
microscopy.  
3. The DNA coding for the predicted biotinoyl domain of the enzyme in P. yoelii 17XL will 
be cloned into E. coli expression systems. The expressed protein will be chara terised for 
the presence of attached biotin. 
4. Homology modelling of the P. yoelii acetyl-CoA carboxylase biotinoyl protein and biotin 
carboxylase domains will be carried out. Insights gained from the modelling will assist in 
possible identification of potential enzyme inhibitors. 
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
 
2.1 Introduction 
This chapter describes several basic biochemical, immunochemical, parasitological and 
molecular biology techniques used in this study.  
 
2.2 Materials 
The following reagents and antibodies were purchased from Sigma-Aldrich-Fluka (Steinheim 
Germany) β-mercarptoethanol, 4-chloro-1-naphthol, acrylamide, agarose, ampicillin, avidin, 
Biomax® X-ray film, bisacrylamide, bromophenol blue, carbenicillin, chloramphenicol, 
Coomassie Brilliant Blue G-250, Coomassie Brilliant Blue R-250, diethyl pyrocarbonate 
(DEPC), Ellman’s Reagent, Ficoll Type 400, formamide, Freund’s complete adjuvant, Freund’s 
incomplete adjuvant, Giemsa stain, glycine, guanidine thiocyanate, guanidine-HCl, Herring 
sperm DNA, isopropyl thioglucopyranoside (IPTG), L-cysteine kanamycin, maleimidobenzoyl-
N-hydroxysuccinimide ester (MBS), molecular biology rade phenol, mouse monoclonal anti-
biotin IgG, N-laurylsarcosine, ovalbumin, peroxidase-conjugated avidin, p-iodophenol, 
polyvinypyrrolidine, Ponceau S, rabbit serum albumin, saponin, Sephadex G-25, Sephadex G-10, 
Semi-dry blot unit, N,N,N’,N’-tetramethyethylenediamine (TEMED), Triton X-100, tryptone, 
Tween-20, urea and yeast extract. Bovine serum albumin and Expand High Fidelity PCR® system 
were purchased from Roche (Mannheim, Germany). Equipment purchased from BioRad 
(California USA) were Poly Prep® affinity column, Mini Protean II™ vertical PAGE unit, III™ 
vertical PAGE unit and VesaDoc™ imaging system. The following were purchased from 
Fermentas (Vilinius, Lithuania): 10× T4 DNA ligase buffer, T4 DNA ligase, Biotin DecaLabel™ 
DNA labeling kit, dATP, DNA MassRuler™, dNTP mix, EcoRI, molecular biology grade DTT, 
NotI, Buffer O™, shrimp alkaline phosphatase (SAP) and PageRuler™ Unstained Protein Ladder. 
Single stranded RNA ladder was purchased from New England BioLabs. Molecular biology 
reagents were purchased from Solis Biodyne (Tartu Estonia) 10× PCR buffer (MgCl2 and 
detergent-free) PCR MgCl2 [25 mM] solution and Taq polymerase. Cells, plasmid and antibodies 
purchased from Novagen (Damstadt, Germany) were BL 21 cells (glycerol stock), JM109 cells 
(glycerol stock), and Rosetta (DE3) pLysS commercial ompetent cells, pET-28a and mouse 
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monoclonal anti-His-Tag IgG, peroxidase-conjugated sheep monoclonal anti mouse IgG. PEG 
6000 was purchased from Merck Biosciences (Damstadt, Germany). G333c™ fixer and 
STRUCTURIX G128™ were purchased from AGFA® (Morstel, Belguim). ABTS was purchased 
from Boehringer (Mannheim, Germany). Orbital shaking cubator was purchased from New 
Brunswick Scientific (New Jersey USA). SulfoLink™ Coupling Gel and Snake skin™ dialysis 
membrane were purchased from Pierce Perbio Science (Erembodegem, Belgium). pGEX-4T-1, 
Hybond-C™ Extra nitrocellulose membrane, HMW protein standards and Ultrspec 2100pro 
UV/visible spectrophotometer were purchased from GE Healthcare (Buckinghamshire England). 
Biotin-conjugated monoclonal anti-GST antibody was purchased from Anaspec (California 
USA). Peroxidase-conjugated rabbit anti-IgY antibody and FITC-conjugated donkey anti-
chicken-IgY were from Jackson Immunochemicals (Pennsylvania, USA). TALON® metal 
affinity resin was from Clontech (California, USA). Improm II® Reverse Transcription System 
was purchased from Promega (Wisconsin, USA). Oligonucleotide primers were synthesized by 
ProLigos™ (Paris, France). Synthetic pLDH peptide was synthesized by GeneScript (New Jersey, 
USA) while Synthetic PyACC peptide was synthesized by Auspep (Melbourne, Australia). 
VersaMax™ ELISA plate reader was purchased from Molecular Devices Corporation 
(California, USA). Nunc Maxi Sorp™ 96-well ELISA plate was from Nunc products (Roskilde 
Denmark). DNA purification kit was purchased from PEQLAB Biotechnologie (Erlangen, 
Germany). Avanti™ J-26 XPI centrifuge was from Beckman Coulter (California USA). 
GeneAmp™ PCR thermocyler was from Applied Biosystems (California USA). Virosonic™ cell 
disruptor was purchased from VirTis (New York, USA).  
 
2.3 Biochemical and immunochemical techniques 
This section describes routine biochemical and immunochemical techniques that were used in 
this study. 
 
2.3.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
The discontinuous Sodium dodecyl sulfate polyacrylamide gel electrophoresis (Laemmli, 1970) 
was used to anaylse (i) the purification profile of the anti-peptide IgY, (ii) recombinant protein 
expression and (iii) purification of recombinant proteins.  
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2.3.1.1 Materials  
Monomer solution [30% (w/v) acrylamide, 2.7% (w/v) bis-acrylamide]. Acrylamide (73 g) and 
bis-acrylamide (2 g) were dissolved and made up to 250 ml with distilled water. The solution was 
stirred, filtered though Whatman No. 1 filter paper and stored in an amber bottle at 4°C. 
 
Separating gel buffer [1.5 M Tris-HCl, pH 8.8]. Tris (45.37 g) was dissolved in 200 ml of 
distilled water, stirred, pH adjusted to 8.8 with HCl and the volume made up to 250 ml with 
distilled water. The solution was filtered with Whatman No. 1 filter paper and stored at 4ºC. 
 
Stacking gel buffer [500 mM Tris-HCl, pH 6.8]  Tris (3 g) was dissolved in 40 ml of distilled 
water, adjusted to pH 6.8 with HCl, and the volume was made up to 50 ml with distilled water. 
The solution was filtered with Whatman No. 1 filter paper and stored at 4ºC.  
 
10% (w/v) Sodium dodecylsulfate (SDS). SDS (10g) was dissolved in 100 ml of distilled water 
and stirred continuously until the detergent had dissolved and stored at RT. 
 
Initiator reagent [10% (w/v) ammonium persulfate]. Ammonium persulfate (0.1 g) was dissolved 
in 1 ml of distilled water and stored at 4ºC.  
 
Tank buffer [250 mM Tris-HCl, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3]. Tris (15 g) and 
glycine (72 g) were dissolved in about 5 L of distilled water and stirred. Before use, SDS (1 g) 
was added to 1 L of the buffer. 
 
Reducing sample buffer [125 mM Tris-HCl, 4% (w/v) SD , 20 % (v/v) glycerol, 10% (v/v) β-
mercaptoethanol, pH 6.8]  Stacking gel buffer (2.5 ml) was mixed 4 ml of 10% SDS, glycerol 
(2 ml) and β-mercaptoethanol (1 ml), mixed thoroughly and made up to 10 ml with distilled 
water. 35 µg of bromophenol blue was added as tracking dye and stored at RT. 
 
Non-reducing sample buffer [125 mM Tris-HCl, 4% (w/v) SDS, 20 % (v/v) glycerol, pH 6.8]. 
Stacking gel buffer (2.5 ml), 4 ml of 10% SDS and glycerol (2 ml) were mixed thoroughly and 
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made up to 10 ml with distilled water. Bromophenol blue (35 µg) was added as tracking dye and 
stored at RT. 
 
Coomassie stain solution [0.1 % (w/v) Coomassie dye in 1:5:4 (v/v/v) acetic acid-methanol-water 
solution]. Coomassie dye (0.1 g) was completely resusupended in 1:5:4 (v/v/v) acetic acid-
methanol-water solution.  
 
2.3.1.2 Method 
Reducing or non-reducing SDS-PAGE was carried out as described by Laemmli (1970) using a 
Bio-Rad vertical slab electrophoresis apparatus. Running (separating) and stacking gels were 
prepared according to Table 2.1. Prior to casting of the gel mixture, the Bio-Rad Mini PROTEAN 
II vertical slab electrophoresis accessory unit was pre-cleaned and rinsed with dH2O. The unit 
was made up of a gel-casting stand with casting gaskets, two ten-well gel combs (1.5 mm thick), 
two 81.5 mm × 101.5 mm and 72.5 mm × 101.5 mm glass plates. The gel-casting unit was 
assembled according to the manufacturers’ instructions.  
 
Table 2.1 Recipe for two 72.5 × 101.5 × 1.5 mm3 Laemmli SDS-polyacrylamide gels  
Separating gel Stacking gel Reagent 
12.5% 10.0% 5.5% 4%a 3%b 
Monomer solution 6.25 ml 3.75 ml 2.75 ml 940 µl 720 µl 
Separating gel buffer 3.75 ml 3.75 ml 3.75 ml 0 0 
Stacking gel buffer 0 0 0 1.75 ml 1.75 ml 
10% SDS 150 µl 150 µl 150 µl 70 µl 70 µl 
Distilled water  4.75 ml 7.25 ml 8.25 ml 4.3 ml 4.7 ml 
Initiator reagent 75 µl 75 µl 75 µl 35 µl 35 µl 
TEMED 7.5 µl 7.5 µl 7.5 µl 15 µl 15 µl 
a Stacking gel for 12.5% and 10.0% separating gel 
b Stacking gel for 5.5% separating gel. 
 
Unpolymerised running gel solution were applied between the glass plates to a height of about 
6 cm from the base and overlaid with water to prevent oxidative inhibition of polymerisation of 
the acrylamide. Once polymerised, the water overlay w s removed and then the stacking gel 
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slurry was applied up to the brim of the glass plates and the gel comb was immediately inserted 
in the stacking gel and allowed to polymerise. Samples were loaded and the gel unit was 
immediately connected to a power pack. Electrophoresis was performed at 36 mA (18 mA per gel 
slab) until the dye front was about 0.5 cm from the bottom. The gels were immediately removed 
from the unit, stained with Coomassie Blue R 250 staining solution and destained. The 
electrophoregram was imaged using the BioRad VesaDocTM image documentation system. The 
molecular weight of the protein band was determined using the graph of Log molecular weight of 
standards against distance migrated (mm) into the running gel. 
 
2.3.2 Western blot 
Proteins resolved on SDS-PAGE gel and subsequently lectro-transferred onto a membrane such 
as nitrocellulose, PVDF and nylon and are detected using antibodies or probes that recognize the 
blotted protein. The Western blot method used in this study was basically that of Towbin et al. 
(Towbin et al., 1979). This technique was used in this work to detect recombinantly expressed 
protein in E. coli cell lysate resolved by SDS-PAGE and i  vivo expressed protein inPlasmodium 
cell lysate resolved by SDS-PAGE.  
 
2.3.2.1 Materials  
Blotting solution [50 mM Tris, 0.2 M glycine, 20% (v/v) methanol, 0.1% (w/v) SDS]. Tris 
(6.05 g), glycine (15.01 g) and methanol (200 ml) were made up to 1 L with dH2O and stored at 
4ºC. Prior to use, SDS (1 g) was added. 
 
Ponceau S reagent [0.2% (w/v) in 1% (v/v) acetic acd]. Ponceau S (20 mg) was resuspended in 
1ml of glacial acetic acid. The volume was made up to 100 ml with dH2O and stored at RT. 
 
Tris buffered saline (TBS) [20 mM Tris-HCl, pH 7.4, 0.2 M NaCl]. Tris (2.42 g) and NaCl 
(11.69 g) were dissolved in 950 ml of dH2O. The pH was adjusted to 7.4 with HCl and the 
volume made up to 1 L with dH2O. The solution was stored at 4ºC. 
 
Blocking solution [5% (w/v) non-fat powdered milk in TBS]. Locally sourced (Elite®) fat-free 
powdered milk (5 g) was suspended in 100 ml of TBS. This solution was prepared fresh. 
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BSA-TBS [0.5% (w/v) BSA in TBS]. BSA (0.25 g) was dissolved in 50 ml TBS. This soluti n 
was used fresh. 
 
Substrate reagent [0.06% (w/v) 4-chloro-1-naphthol, 0.0015% (v/v) H2O2, 20% (v/v) methanol in 
TBS]. 4-chloro-1-naphthol (30 mg) was dissolved in methanol (10 ml). Four ml of this solution 
was made up to 20 ml with TBS and H2O2 (10 µl of a 30% solution) was added and kept away 
from light. This solution was used fresh.  
 
2.3.2.2 Method 
After SDS-PAGE, one of the duplicate gels was stained to display the protein band patterns and 
the other gel was used for blotting. Nitrocellulose m mbrane was cut to the dimension of the gel 
(7.2 cm × 10.5 cm) and six pieces of blotting paper w e cut to the dimension of 8.2 cm × 
10.5 cm. The gel was carefully placed on the nitrocellulose membrane from one side to avoid 
trapping air bubbles. The nitrocellulose membrane-gel was sandwiched between the six blotting 
papers (three on either side) and placed in between the electrode plates of the semi-dry blotting 
apparatus with the nitrocellulose membrane towards the anode. The semi-dry blotting apparatus 
was connected to a power supply unit {(7.0 V, 250 mA, 16 h) or (17.0 V, 250 mA, 1.5 h)}. After 
transfer, proteins on the nitrocellulose membrane were visualized with Ponceau S Reagent and 
the molecular weight marker proteins marked with a pencil. The nitrocellulose membrane paper 
was destained in dH2O and blocked for 1 h with the Blocking Buffer. Subsequent steps were 
carried out on a “belly dancer”. The nitrocellulose m mbrane was then washed 3× (5 min/wash) 
with TBS and incubated for 2 h in the required dilution of the primary antibody or probe 
resuspended in BSA-TBS. The nitrocellulose membrane was washed 3× (5 min/wash) in TBS 
and incubated in the appropriate dilution of secondary antibody or probe diluted in BSA-TBS. 
The nitrocellulose membrane was washed 3× (5 min/wash) in TBS and incubated in the substrate 
reagent until the band suggestive of the detected protein appeared on the membrane. The image 
was captured with the VesaDoc imaging system and the blot stored. 
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2.3.3 Bradford standard protein assay 
2.3.3.1 Materials  
Bradford dye reagent [0.06% (w/v) Coomassie Brilliant Blue G-250 in 2% (v/v) perchloric acid]. 
Coomassie Brilliant Blue G-250 (0.3 g) was resuspended in 500 ml of 2% (v/v) perchloric acid in 
dH2O. The solution was stirred for 1 h at RT, filtered with Whatman No.1 filter paper into a 
brown bottle and stored at RT.  
 
Ovalbumin stock solution [0.5 mg/ml of buffer]. Ovalbumin (1 mg) was dissolved in 2 ml of the 
appropriate buffer. Different stock solutions were p pared for each experiment. 
 
Protein standards [0 – 50 µg ovalbumin/100 µl of buffer]. Proteins standards were prepared by re-
suspending 10 to 50 µg ovalbumin in 100 µl of buffer. Three independent working solutions were 
prepared for each experiment. 
 
2.3.3.2 Method 
Dye Reagent (0.9 ml) was mixed with the solution of the protein standards (0.1 ml) in a 
microfuge tube. The dye-protein solution was allowed to react at RT for 30 min and the 
absorbance value for each solution was read at 595 nm. The mean absorbance value for each 
protein concentration and for the two experiments was recorded. The absorbance value was 
plotted against the amount of protein in an x-y scatter. The solution with the unknown protein 
concentration was treated in a similar way and the protein concentration derived by interpolation 
on the standard curve. 
 
2.3.4 Coupling synthetic peptides to rabbit albumin carrier for antibody production 
Synthetic peptides derived from P. yoelii acetyl CoA carboxylase precursor related (Plasmodb 
ID: PY01695) and P. yoelii L-lactate dehydrogenase (Plasmodb ID PY03885) for anti-peptide 
antibody production in chickens were coupled to rabbit albumin carrier molecule. They are 
coupled to a carrier because the molecular weight of the peptides ranges from 1500 – 2000 Da 
and thus the peptides alone are unable to elicit an immunogenic reaction in the host. The peptides 
were designed and synthesized to have a terminal cystine residue that provided a functional 
sulfhydryl (SH) group that enabled the covalent attachment to the carrier and to the affinity 
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matrix. Prior to coupling, the cystine residue was reduced with DTT in order to acquire free 
terminal SH residues. The rabbit albumin carrier was activated with MBS; a hetero-bifunctional 
linker that links a primary amine fuctional group on ne molecule to a sulfhydryl functional 
group on another molecule (Hermanson, 1996). Therefore activation of a protein molecule by 
MBS involves the covalent modification of the ε-amine groups of lysine residues on the protein 
molecule. The MBS-rabbit albumin complex was purified on Sephadex G-10 and Sephadex G-25 
size chromatography columns (1.5 × 12.0 cm2, linear flow rate of 8.5 cm/h) to separate coupled 
activated rabbit albumin from unreacted MBS and smaller reaction products. 
 
2.3.4.1 Materials  
Phosphate buffered saline (PBS), pH 7.2. NaCl (8 g), KCl (0.2 g), Na2HPO4 (1.15 g) and 
KH2PO4 (0.2 g) were dissolved in 1 L of dH2O. 
 
MEC Buffer [0.1 M NaH2PO4.2H2O, pH 7.0, 0.02% (w/v) NaN3, 1 mM Na2-EDTA]. 
NaH2PO4.2H2O (15.6 g), Na2-EDTA (0.3724 g) and sodium azide (0.2 g) were dissolved in 
900 ml of dH2O. The pH was adjusted to 7.0 with NaOH and the volume was made up to 1 L 
with dH2O. 
 
Peptide reducing buffer [0.1 M Tris-HCl, pH 8.0, 1 mM Na2-EDTA]. Tris (2.24 g) and Na2-
EDTA (0.3724 g) were dissolved in 150 ml of dH2O. The pH was adjusted to 8.0 with HCl and 
the volume was finally made up to 200 ml with dH2O. 
 
Ellman’s reagent buffer [0.1 M Tris-HCl, pH 8.0, 1 mM Na2-EDTA, 0.1% (w/v) SDS]. Tris 
(1.21 g), Na2-EDTA (0.3724 g) and SDS (0.1 g) were dissolved in 90 ml of dH2O. The pH was 
adjusted to 8.0 with HCl and the volume was finally made up to 100 ml with dH2O. 
 
Dithiothrietol [10 mM]. Dithiothrietol (7.71 mg) was dissolved in 5 ml of peptide reducing 
buffer. 
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2.3.4.2 Method 
This laboratory had previously determined empirically that 4 mg of a synthetic peptide is enough 
to produce between 4 – 10 mg affinity purified polyclonal antibody in a chicken between 12 – 15 
weeks of four immunisation schedules (Goldring and Coetzer, 2003).  
 
Calculations 
The peptide was coupled to the rabbit albumin carrier at 40:1 peptide-carrier ratio. The amount of 
rabbit albumin (carrier) to be coupled to 4 mg of synthetic peptide was determined by the 
formula: 
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The molar mass of rabbit albumin in 68 200 Daltons. 
 
The carrier was activated with MBS at 1:40 carrier-MBS ratio. The amount of MBS needed to 
activate the calculated amount of rabbit albumin (carrier) was determined by the formula: 
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mgcarrier =×××  
Where 314.26 is the molar mass of MBS. 
 
Activating the carrier with MBS 
MBS (1 mg) was dissolved in 50 µl of DMF, made up to 200 µl with PBS and the volume of the 
solution containing the required molar quantity of MBS was added to 0.8 ml solution of the 
rabbit albumin (estimated amount) in PBS. The soluti n was mixed gently for 30 min at RT on a 
rotary mixer. The mixture was loaded onto Sephadex G-25 size exclusion chromatography 
column (1.5 cm × 12.5 cm) pre-equilibrated with the MEC buffer. The MBS-rabbit albumin 
complex was eluted with the MEC buffer by collecting fractions (1 ml). The A280 nm of the eluate 
was determined for each fraction. The first set of fractions with A280 nm > 0.5 were pooled (~ 2 ml 
total volume).  
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Reducing the peptide with DTT 
Peptide (4 mg) was initially resuspended in 50 µl of DMSO and the volume was made up to 
0.5 ml with the peptide reducing buffer. DTT reagent (0.5 ml) was added to the peptide and 
allowed to react (1 h, 37ºC) with occasional mixing. The reduced peptide mixture was loaded 
onto Sephadex G-10 MEC column (1.5 cm × 11 cm) and eluted with the MEC buffer. Fractions 
of 1 ml were collected and a sample from each fraction was analysed for free –SH residue with 
the Ellman’s Reagent (10 µl of fraction + 10 µl of Ellman’s Reagent). The first set of fractions 
showing intense yellow colour compared to the firstractions were pooled (~ 2 ml total volume). 
 
Reacting the reduced peptide with the MBS-activated carrier 
The pooled MBS-rabbit albumin solution was mixed with the pooled reduced peptide solution. 
The mixture was incubated at RT overnight. The solution was aliquoted equally into four 
microfuge tubes and stored at –20ºC. 
 
2.3.5 Preparation of immunogen for immunisation in chickens 
The peptide-carrier complex used for production of anti-peptide antibody in chickens was mixed 
with Freund’s complete (FCA) or incomplete adjuvant (FIA). The FCA is made up of heat 
attenuated and dried Mycobacterium mixed in mineral oil to elicit cell-mediated immunity that 
will result in production of antibody against the pptide as well as the carrier. The FIA is mineral 
oil without the Mycobacterium products.  
 
2.3.5.1 Method 
The peptide-carrier complex solution was allowed to thaw at RT and dispensed into a 20 ml 
scintillation vial containing equal volume of FCA or FIA. The mixture is triturated using a 2.5 ml 
syringe until an emulsion was formed and the emulsion was loaded into a 2.5 ml syringe. 
Chickens were immunised intra-muscularly on the large breast muscles with approximately 
0.4 ml of the immunogen containing ~ 125 µg of the synthetic peptides. The first immunisation 
was carried out with FCA and the three subsequent booster immunisations were carried out with 
FIA at two-week interval with a similar dose. Eggs from each chicken were collected daily, 
labelled and stored at 4ºC until the isolation of antibody. 
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2.3.6 Isolation of immunoglobulin Y (IgY) from chicken egg yolk 
The solubility of proteins in an aqueous environment depends largely on the surface availability 
of hydrophilic amino acids of the protein. These hydrophilic amino acids form hydrogen bonds 
with water molecules in the hydration shell (layer of water molecules surrounding an ion or 
molecule in an aqueous solution) of the protein molecules. Dextran and PEG are widely used as 
protein precipitation agents. These polymers (dextran and PEG) are preferentially excluded from 
the hydration shells around the proteins. This brings the protein solution to it solubility limit 
(Chun et al., 1967; Ingham, 1984; Polson et al., 1985). Polyethylene glycol (PEG) is a linear 
water-soluble non-ionic polymer with molecular weight varying from 0.2 kD to 20 kD depending 
on the extent of polymerization. It is widely used to extract proteins at room temperature without 
denaturation of the proteins (Ingham, 1984; Polson et al., 1985). PEG with MW 4 kD to 6 kD is 
routinely used in protein precipitation. Polymers larger than this offer no advantage, since their 
solutions are more viscous (Atha and Ingham, 1981; Ingham, 1984). By and large, the shorter 
time required for precipitation of proteins by PEG and little effect on the stability of the proteins 
makes PEG a molecule of choice for protein isolation compared to organic solvents and 
ammonium sulphate.  
 
In this study, PEG 6000 (MW ~ 6 kD) extraction was used to isolate IgY from eggs collected 
from chickens immunised with the synthetic peptides-rabbit albumin complex using the method 
of Polson et al., (1985). The buffer system was sodium dihydrogen phos ate buffer, pH 7.6 
containing sodium azide as an anti-microbial preservative. Chickens were housed and cared for at 
the University of KwaZulu-Natal Farms at Ukulinga, Pietermaritzburg. The use of chickens for 
this study was approved by the University’s Ethical Committee with ethical clearance project 
number: AE/GOLDRING/99/08 for 2001 and 025/04/Animal for 2008. 
 
2.3.6.1 Materials  
Isolation buffer [0.1 M NaH2PO4.2H2O pH 7.6, 0.02% (w/v) NaN3]. NaH2PO4.2H2O (15.6 g) and 
0.2g (NaN3) were dissolved in 950 ml of dH2O, titrated to pH 7.6 with NaOH and made up to 1 L 
with dH2O. 
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IgY Storage Buffer [0.1 M NaH2PO4.2H2O pH 7.6, 0.1% (w/v) NaN3]. NaH2PO4.2H2O (15.6 g) 
and 1g (NaN3) were dissolved in 950 ml of dH2O, titrated to pH 7.6 with NaOH and made up to 
1 L with dH2O. 
 
2.3.6.2 Method 
Egg yolks were separated from albumin and carefully washed under slow running tap water in 
order to remove traces of albumin. The yolk sacs were punctured and squeezed carefully into a 
measuring cylinder to determine the yolk volume. Two yolk volumes of the isolation buffer were 
added and stirred slowly to mix with the yolk. Solid PEG-6000 [3.5% (w/v)] was added and 
stirred continuously until the entire PEG-6000 dissolved. The precipitated vitellin fraction was 
removed by centrifuging (4420 g, 30 min, RT). The supernatant was filtered though a funnel 
packed with cotton wool. The volume of the filtrate was measured and PEG [8.5% (w/v)] was 
added to the filtrate and stirred thoroughly. The solution was centrifuged (4420 g, 10 min, RT) to 
pellet the precipitate. The supernatant was discarded and the pellet dissolved in a buffer volume 
equivalent to the original egg yolk volume. PEG-6000 [12% (w/v)] was added stirred thoroughly 
and centrifuged (4420 g, 10 min, RT). The final pellet was dissolved in the buffer with volume 
equivalent to 1/6 the original yolk volume. The purification profile was analyzed by applying 
samples collected at each step of the isolation method on a reducing-SDS-PAGE (Laemmli, 
1970). The final IgY concentration was determined using the extinction coefficient of 
25.1
280
/1
=
nm
mlmg
E (Coetzer et al., 1985). 
 
2.3.7 Preparing affinity chromatography matrices and purification of anti-peptide IgY 
Affinity purification offers specificity-based separation of biomolecules based on unique 
biological interactions. The matrix consist of polyacrylamide, dextran or agarose polymerized 
beads. The matrix is insoluble and is usually commercially synthesized to acquire specific 
functional groups such as aldehyde, carboxylic acid, hy roxyl, amine and hydrazide. The ligand 
is immobilized on the matrix (solid) support by means of several coupling reactions. Molecules 
to be purified adsorb on the immobilized ligands when passed though the affinity column. The 
remaining components in the mixture are washed off the column. The column is washed with 5× 
the appropriate column buffer before eluting the adsorbed molecules. A buffer of low pH or high 
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ionic strength is often used to disrupt the affinity-based interaction between the adsorbed 
molecules and the ligand.  
 
SulfoLink® Coupling Gel is a 6% beaded agarose that has been d rivatized to have iodoacetyl 
group spaced by a 12-atom structure (Pierce SulfoLink manual). This enables the covalent 
bonding of molecules such as peptides and proteins ligands with free SH functional groups to the 
iodoacetyl functional group on the affinity support. The 12-atom spacer is designed to decrease 
steric hindrance between the coupled ligand and the affinity-bound molecule, enhancing the 
binding of the molecule to its ligand. The molecule to be coupled must be in monomeric units 
without a disulfide linkage. Thus, the molecule must be reduced with DTT to acquire free SH 
reactive functional group prior to coupling to the affinity support. The reducing agent (DTT) 
must be removed to prevent competing with the peptid  for bonding on the iodoacetyl functional 
group on the affinity matrix. The SH group reacts with the iodide on the iodoacetyl functional 
group on the matrix to form a stable thioether bond.  
 
2.3.7.1 Materials  
Coupling buffer [0.05 M Tris-HCl, pH 8.5, 5 mM Na2-EDTA]. Tris (6.5 g) and Na2-EDTA 
(1.86 g) were dissolved in 900 ml of dH2O. The pH was adjusted to 8.5 with HCl and the volume 
made up to 1 L. 
 
Blocking buffer [0.05 M L-cysteine in coupling buffer]. L-cysteine (2.2 g) was dissolved in 
250 ml of coupling buffer. 
 
Wash solution [1 M NaCl]. NaCl (58.44 g) was dissolved in 1 L of dH2O. 
 
Equilibration buffer [0.1 M NaH2PO4.2H2O, pH 7.6, 0.1% (w/v) NaN3]. NaH2PO4.2H2O (15.6 g) 
and 1g (NaN3) were dissolved in 950 ml of dH2O. The pH was adjusted to 7.6 with NaOH and 
the volume made up to 1 L with dH2O. 
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Affinity column-washing buffer [100 mM NaH2PO4.2H2O, 0.02% (w/v) NaN3, pH 6.5]. 
NaH2PO4.2H2O (15.6 g) and NaN3 (0.2 g) were dissolved in 800 ml of dH2O, stirred and adjusted 
to pH 6.5 with NaOH. The volume was made up to 1 L.
 
Elution buffer [100 mM glycine, 0.02% NaN3 (w/v), pH 2.8]. Glycine (0.75 g) and NaN3 (0.02 g) 
were dissolved in 80 ml of dH2O, adjusted to pH 2.8 with HCl and the volume finally made up 
100 ml. 
 
Neutralizing buffer [1 M NaH2PO4.2H2O, 0.02% NaN3 (w/v), pH 8.5]. NaH2PO4.2H2O (15.6 g) 
and NaN3 (0.02 g) were dissolved in 80 ml of dH2O, stirred, adjusted to pH 8.5 with concentrated 
NaOH and the volume finally made up to 100 ml. 
 
2.3.7.2 Method 
Coupling of peptides to SulfoLink™ affinity matrix 
For coupling of peptides to affinity matrix, 7.5 mg of the peptide was reduced as described in 
Section 2.3.4. SulfoLink™ matrix (3 ml of 50% slurry = 1.5 ml column volume) was dispensed 
into a BioRad Poly-Prep® affinity column. The matrix was equilibrated with 5 column volumes 
of coupling buffer. The buffer was allowed to flow through the matrix until the meniscus was just 
above the matrix. The reduced peptide solution was added to the matrix and the column was 
capped with the outlet closed. The suspension was mixed on a rotary mixer (15 min, RT), and 
was further incubated (30 min, RT) while standing. The cap and the outlet were opened to let the 
solution containing a reaction by-products and uncopled peptides to elute. The matrix was 
washed with 5 column volumes of the coupling buffer, the outlet was closed and 1 ml of the 
blocking buffer was added to the matrix and capped. The suspension was mixed once again 
(15 min, RT) on a rotary mixer and the allowed to stand (30 min, RT). The column outlet and cap 
were opened allowing the buffer to drain out. The matrix was washed with 5 column volumes of 
the wash solution and equilibrated with 5 column volumes of the equilibration buffer. The 
affinity matrix was stored at 4ºC until use. 
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Affinity purification 
The affinity column was first washed with 20 column volumes of washing buffer. The isolated 
IgY was filtered with Whatman No.1 filter paper to remove insoluble materials that may clog the 
affinity column. The filtrate was cycled through the column overnight (in a reverse direction) and 
the unbound antibodies were washed off the column with 20 column volumes of affinity column-
washing buffer in the forward direction. The bound antibodies were eluted in the forward 
direction (flow rate of 200 µl/ min) up to 1 ml with the elution buffer into microfuge tubes 
containing 100 µl of the neutralizing buffer. The A280 nm was read and then the elution profile was 
obtained by plotting the A280 nm against elution volume. Fractions with A280 nm >0.2 were pooled 
together. The affinity purified polyclonal anti-peptide IgY was stored at 4°C in a 100 mM sodium 
phosphate buffer, pH 7.2 containing 0.1% sodium azide.  
 
2.3.8 Enzyme linked immunosorbent assay for anti-peptide IgY titre 
Enzyme linked immunosorbent assay (ELISA) involves s veral parts that makes up a complete 
immunoassay system namely: a solid phase on which te antigen or antibody to be assayed is 
immobilized; antigen or antibody to be assayed; blocking molecule, which is usually protein that 
does not interfere with the assay; primary antibody, which interacts with the antigen or antibody 
immobilized on the solid phase. Depending on the ELISA format the primary antibody may be 
linked to the detecting enzyme in direct ELISA system. In an indirect ELISA system a secondary 
antibody that interacts with the primary antibody is linked to the detecting enzyme in the direct 
ELISA. Peroxidase, glucose oxidase and alkaline phos atase are widely used as detecting 
enzymes in ELISA. These enzymes catalyse the conversion of colourless substrates or non-
fluorescent molecules into coloured or fluorescent molecules that are quantified by 
spectrophotometry or fluorimetry. These substrates form part of the ELISA system (Nakamura et 
al., 1986). In this study, ELISA was used to determine the weekly anti-peptide IgY titre for each 
immunised chicken in an indirect ELISA technique. 
 
2.3.8.1 Materials  
Phosphate buffered saline (PBS). NaCl (8 g), KCl (0.2 g), Na2HPO4 (1.15 g) and KH2PO4 (0.2 g) 
were dissolved in 1 L of dH2O. 
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Blocking solution [0.5% (w/v) bovine serum albumin-PBS]. BSA (0.5 g) was dissolved in 100 ml 
of PBS. 
 
Tween-PBS washing solution [0.1% (v/v) Tween-PBS]. Tween-20 (1 ml) was made up to 1 L 
with PBS. 
 
0.15 M citrate-phosphate buffer at pH 5.0. A solution of citric acid monohydrate (21 g/L) was 
titrated with a solution of Na2HPO4.2H2O (35.6 g/L) to pH 5. 
 
Substrate solution [0.05% (w/v) ABTS and 0.0015% (v/v) H2O2 in citrate-phosphate buffer]. 
ABTS (7.5 mg) and H2O2 (7.5 µl) were dissolved in citrate-phosphate buffer at pH 5 (15 ml). 
 
2.3.8.2 Method 
A 96-well microtitre plate (Nunc Maxi SorpTM) was coated with 150 µl of 1 µg/ml of peptide in 
PBS over night at 4ºC. The following day, the plate was washed with Tween-PBS and blocked 
with 0.5% BSA-PBS (30 min, RT). After blocking, the plate was washed 3× with Tween-PBS. 
The plate was incubated with 150 µl (100 µg/ml) of crude IgY isolate or IgY isolated from pre-
immune egg as control as primary antibody (2 h, 37ºC), washed 3× with Tween-PBS. The rabbit-
anti-chicken-HRPO secondary antibody (150 µl of 1:20 000 dilution) was added to each well and 
incubated (1 h, 37ºC). After incubation, the plate was washed 3× with Tween-PBS and 150 µl of 
substrate solution was added to each well. The plate was incubated at RT until the colour 
developed and the absorbance was read at 405 nm with the VersaMax™ ELISA plate reader. 
 
2.4 Parasitological techniques 
Rodent malaria parasites including P. yoelii, P. berghei, P. vinckei and P. chabaudi are adapted 
for laboratory studies. All four rodent malaria parasites infect mice. The study of interaction 
between the host and the erythrocytic stage of the malaria parasite makes the mouse a very useful 
host for malaria infection models to study immunological, molecular and biochemical aspects of 
the parasite (Sanni et al., 2002). There is a degree of variation in virulenc  in various mouse 
malaria model species and strains. There are strain of P. yoelii that are lethal in mice whereas 
some other P. yoelii strains are non-virulent in mice. 
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This section describes several techniques used in the propagation, isolation and purification of P. 
yoelii; a rodent malaria parasite. In this study, the lethal P. yoelii stain 17XL was used. Parasites 
were propagated in 6 – 8 weeks old male BALB/c mice through intraperitoneal injection of 
100 µl of 107 parasitized red blood cells. Mice used in this study were kept in the University 
Animal housing facility in a temperature range of 19 – 22ºC. Each animal was kept in a single 
cage with a plastic bottom and steel mesh. Cages, saw dust, water and food were autoclaved prior 
to use. Food and water were available ad libitum. Parasitemia was monitored daily through thin 
blood smear made from the tail blood. 
 
2.4.1 Propagation of P. yoelii parasite in BALB/c mice and cryo-preservation 
2.4.1.1 Materials  
Phosphate buffered saline (PBS), pH 7.2. NaCl (8 g), KCl (0.2 g), Na2HPO4 (1.15 g) and 
KH2PO4 (0.2 g) were dissolved in 1 L of dH2O.  
 
Cryo-preservative [10% (v/v) glycerol-PBS]. Glycerol (1 ml) was added to 9 ml of PBS. The 
solution was stirred and autoclaved.  
 
2.4.1.2 Method  
Parasites were propagated in male BALB/c mice by intra-peritoneal injection of parasite stabilate 
(107 parasitized red blood cells). The lower abdomen was cleaned with 70% ethanol and the 
mouse held upside down for the organs to partially drop. The syringe (insulin syringe, 1 cc) was 
inserted ~ 0.5 cm into the skin and the stabilate slowly released into the mouse. The syringe was 
slowly withdrawn to prevent exuding of the stabilate fter injection. The mouse was immediately 
release into its cage and monitored for 5 – 10 min post injection. Parasitemia was monitored with 
daily thin smear of tail blood. The thin smear was air-dried and fixed in methanol for 1 min at RT 
and was allowed to dry at RT. The smear was stained with Giemsa stain for 20 – 30 min at RT, 
washed under slow running water and air-dried and viewed at 1000× magnification (oil 
immersion). The number of infected RBC was expressed as a percentage of total RBC. The 
parasites were preserved in 10%-glycerol-PBS at 107 parasitized-RBC (pRBC) per 100 µl of 
stabilate. The stabilate was immediately stored in liquid nitrogen.  
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2.4.2 Isolation of P. yoelii parasites from infected mouse red blood cells 
2.4.2.1 Materials  
Phosphate buffered saline (PBS), pH 7.2. NaCl (8 g), KCl (0.2 g), Na2HPO4 (1.15 g) and 
KH2PO4 (0.2 g) were dissolved in 1 L of dH2O. 
 
Saponin-PBS [0.05% (w/v) saponin in PBS]. aponin (5 mg) is dissolved in 10 ml of PBS. This 
reagent is kept on ice prior to use. 
 
Plasmodipur® 
 
Heparinzed vacuum tubes 
 
2.4.2.2 Method 
At 30 – 40% parasitemia, the infected mouse was sacrificed. The blood was dispensed into a 
heparinzed vacuum tube and kept on ice. The blood was diluted (1:4) with ice cold PBS and 
filtered with Plasmodipur® according to the manufacturer’s instructions to remove host white 
blood cells. The filtrate was centrifuged (700 g, 15 min at 4ºC) to pellet the infected RBC. The 
cells were washed 3× with ice cold PBS (5 volumes of the original blood volume) and re-
suspended in 5 volumes of saponin-PBS. The cell suspension was incubated at RT for 30 min for 
complete hemolysis. A dark red colour indicates hemolysis of the RBC. The suspension was 
centrifuged (3500 g, 15 min at 4ºC) to pellet the released parasites. The supernatant was removed 
carefully leaving behind a small volume of the supernatant in order not to disturb the parasite 
pellet. The parasite pellet was washed 2× with 5 volumes of PBS. 
 
2.4.3 Immunofluorescence microscopy 
2.4.3.1 Materials 
Fixing reagent [4% (w/v) paraformaldehyde-0.0075% (w/v) glutaraldehyde]. Paraformaldehyde 
(0.4 g) was suspended in 9 ml of ddH2O. Drops of 1M NaOH were added while stirring in a 
boling water bath. The solution was made up to 10 ml with ddH2O. Glutaraldehyde (1.5 µl of 
50% solution) was added. The solution was filtered through a 0.22 µm syringe filter. 
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Quenching solution (0.1 mg/ml NaCNBH4 in PBS). NaCNBH4 (1.0 mg) was dissolived in 10 ml 
of PBS. The solution was filtered through a 0.22 µm syringe filter. 
 
Phosphate buffered saline (PBS). NaCl (8 g), KCl (0.2 g), Na2HPO4 (1.15 g) and KH2PO4 (0.2 g) 
were dissolved in 1 L of dH2O. The solution was filtered through a 0.22 µm syringe filter. 
 
Permeabilizing solution (0.1% Triton X-100 in PBS). Triton X-100 (10 µl) was made up to 10 ml 
with PBS. The solution was filtered through a 0.22 µm syringe filter. 
 
Saline solution. NaCl, (0.9 g) was made up to 10 ml with dH2O. The solution was sterilized by 
filtration (0.22 µm syringe filter). The solution was filtered through a 0.22 µm syringe filter. 
 
BSA-PBS solution [3% (w/v) BSA in PBS]. BSA (0.3 g) was dissolved in PBS (10 ml). The 
solution was filtered through a 0.22 µm syringe filter. 
 
BSA-PBS solution [5% (w/v) BSA in PBS]. BSA (0.5 g) was dissolved in PBS (10 ml). The 
solution was filtered through a 0.22 µm syringe filter. 
 
DAPI solution [5 µg/ml in PBS]. DAPI (2.5 µl of a 2 mg/ml solution) was made up to 1 ml with 
PBS. The solution was filtered through a 0.22 µm syringe filter. 
 
2.4.3.2 Method 
P. yoelii-infected mouse blood (300 µl) collected in a heparinised-tube was centrifuged (700 g, 
10 min, 4ºC), the plasma was discarded and packed cells were resuspended in 1 ml of PBS and 
washed 5× with PBS (800 g, 10 min, 4ºC) until the supernatant became very clear. The packed 
cells were resuspended to 2× original blood volume (600 µl) with the Fixing reagent and 
incubated on ice for 30 min. The cells were washed 5× (800 g, 5 min, 4ºC) with saline solution, 
resuspended in the quenching reagent (0.5 ml) for 10 min on ice and washed 5× (800 g, 5 min, 
4ºC) with saline solution. The cell were incubated in the permibilizing reagent (0.5 ml) for 
10 min and washed 3× (800 g, 5 min, RT) with saline solution. The cells were blocked with 0.5 
ml of BSA-PBS reagent (1 h, RT); aliquots of 100 µl were transferred to fresh microfuge tubes 
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and cells were pelleted (800 g, 5 min, RT). The cells were incubated in 5 – 20 µg/ml primary 
antibody in 3% BSA-PBS (overnight and 4ºC). The cells were equilibrated to room temperature 
(1 – 2 h), washed 5× (800 g, 5 min, RT) with saline solution and incubated with donkey anti-IgY-
FITC secondary antibody (1/50 in 5% BSA-PBS) for 1 h at RT (away from light). The cells were 
washed 5× (800 g, 5 min, RT) with saline solution, stained with DAPI solution (away from light), 
washed 5× (800 g, 5 min, RT) with saline solution and resuspended to approximately 50 µl with 
PBS. A thin smear was made on a microscope slide an cells were allowed to dry overnight in a 
desiccated vacuum chamber away from light and mounted with SlowFade using coverslip. The 
edges of the cover slip were sealed with clear nail varnish. There was 5 min incubation period 
between each wash steps. The cells were viewed with Olympus AX70 fluorescent microscope 
using a green and UV filters for FITC and DAPI, resp ctively. Images were captured with CC12 
Soft Imaging System™ colour camera and processed with the analySIS™ software. 
 
2.5 Molecular biology methods 
This section describes several methods that were used to obtain parasite nucleic acids used for 
downstream applications such as PCR, ligation, cloning, subcloning, analysis of expression by 
RT-PCR, Northern blot and expression of recombinant P. yoelii proteins. The design of 
oligonucleotides used for cloning and expression are based on sequences published on the 
plasmodb web site (www.plasmodb.org). Molecular grade reagents were used to ensure quality 
of the products.  
 
2.5.1 Agarose gel electrophoresis 
2.5.1.1 Materials   
Na2EDTA [0.5 M]. Na2EDTA (18.6 g) was dissolved in 80 ml of dH2O, pH was adjusted to 8 and 
the volume was made up to 100 ml with dH2O. 
  
50× TAE electrophoresis buffer. Tris (242 g) was dissolved in 500 ml of dH2O, 100 ml of 0.5 M 
Na2EDTA solution (pH 8) and glacial acetic acid (57.1 ml) were added. The solution was made 
up to 1 L with dH2O and stored at RT.  
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Ethidium bromide staining reagent [10 mg/ml in 1× TAE]. Ethidium bromide (0.1 g) was 
resuspended in 1× TAE (10 ml) and stirred at RT for 30 min. The dye solution was filtered with 
Whatman No.1 filter paper and stored in an amber bottle at RT. 
 
10× sample loading buffer. Bromophenol blue (0.25 g) was resuspended in 33 ml of 1× TAE and 
glycerol (60 ml) was added and the solution made up to 100 ml with 1× TAE. The reagent was 
stored at RT. 
 
2.5.1.2 Method 
The required amount of agarose was weighed and resusp nded in the required amount of 1× 
TAE, heated in a microwave oven and removed from the oven after complete melting of the 
agarose powder granules. Ethidium bromide reagent was added to a final concentration of 
0.5 µg/ml of agarose gel. The gel was poured into the casting tray and allowed to solidify at RT. 
The sample was mixed (9:1 sample-sample loading buffer ratio) with the loading buffer and 
loaded into the wells. The image of the electrophoregram was captured with the VesaDocTM gel 
documentation system under UV light. The size of the DNA bands were interpolated from the 
graph of Log DNA standards (bp) against distance migrated (mm) from the well. 
 
2.5.2 Isolation of Plasmodium yoelii total RNA  
2.5.2.1 Materials   
Sodium citrate buffer [0.75 M, pH 7]. Tri-Na citrate (9.7 g) was dissolved in 40 ml of ddH2O and 
the pH was adjusted to 7 with 1 M citric acid solution. The volume was made up to 50 ml with 
ddH2O. 
 
10% (w/v) N-laurylsarcosine. N-laurylsarcosine (1 g) was dissolved in ddH2O and the volume 
made up to 10 ml with ddH2O. 
 
RNA extraction buffer [4 M guanidine thiocyanate, 45 mM sodium citrate (pH 7), 0.9% (w/v) N-
laurylsarcosine, 0.7% (v/v) 2-mercaptoethanol]. Stock reagent of 100 ml was prepared by mixing 
guanidine thiocyanate (47.3 g), 0.75 M citrate buffer (6 ml) and 10% N-laurylsarcosine (9 ml) in 
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50 ml of ddH2O and stirred. The volume was made up to 100 ml with ddH2O. β-mercaptoethanol 
(70 µl) was added to 10 ml of the stock reagent before use.  
 
Sodium acetate [2 M, pH 4]. Anhydrous sodium acetate (16.4 g) was dissolved in 40 ml of 
ddH2O and the pH was adjusted to 4 with acetic acid. 
 
Water-saturated-acidic phenol. Molecular grade phenol (carbolic acid) was mixed with equal 
volume of ddH2O and stirred continuously for 30 min. The mixture was transferred into a 
separation funnel and allowed to stand for more than four hours at RT until the mixture separates 
into two phases. The lower phenol phase was carefully removed and stored in 1 ml aliquots at   –
20ºC, away from light. 
 
Chloroform-isoamylalcohol [49:1]. Chloroform (49 ml) was mixed with isoamylalcohol (1 ml) 
and stored at –20ºC. 
 
DEPC-treated ddH2O. DEPC was mixed to a final concentration of 0.1% (v/v) with ddH2O. The 
mixture was incubated overnight at 37ºC and then autoclaved to remove residual DEPC. 
 
70% ethanol in DEPC-ddH2O. Absolute ethanol (35 ml) was made up to 50 ml with DEPC-
treated ddH2O in a sterile atmosphere. 
 
DEPC-treated TE buffer [10 mM Tris (pH 8), 1 mM EDTA (pH 8)]. Tris (10 ml of 1 M solution 
at pH 8) was mixed with EDTA (2ml of 0.5 M solution at pH 8). The volume was made up to 1 L 
with ddH2O. DEPC was added to 0.1% (v/v), incubated at 37ºC overnight and autoclaved. 
 
Formamide gel-loading buffer. Formamide (160 µl) was mixed with DEPC-treated TE buffer 
(40 µl) and bromophenol blue dye was added. 
 
2.5.2.2 Method 
In this method (Voss, 2002), the packed cell volume was 1.2 ml and the parasitemia was 
approximately 45%. The parasite was isolated from whole blood as described earlier in Section 
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2.4.2. The parasite pellet was resuspended in 2.4 ml (2 packed cell volumes) of the RNA 
extraction buffer and mixed rapidly to completely resuspend and lyse the parasites. Na-acetate 
(0.2 ml) was added and gently mixed by inverting the ube 20×. Water-saturated acidic phenol 
reagent (2.4 ml) was added and the tube inverted gently 20× to mix properly. Chloroform-
isoamylalcohol (1.6 ml) was added and the tube inverted 20× to mix. The tube was incubated on 
ice for 5 min and centrifuged (3500 g, 4ºC, 30 min). The upper aqueous layer (0.8 ml/tube) was 
carefully removed and transferred into RNase-free microfuge tube containing 0.7 ml of propan-2-
ol, and the tube was incubated at –20ºC for 1 h to precipitate RNA. The tube was centrifuged 
(15 000 g, 4ºC, 20 min) to pellet the RNA. The supernatant was carefully removed and the tube 
dried for 5 min by inverting on filter paper. The RNA pellet was resuspended in 0.45 ml of the 
RNA extraction buffer, 50 µl of 2 M Na-acetate and 0.5 ml of water-saturated acidic phenol were 
added and mixed properly by inverting 20×. Chlorofom-isoamylalcohol (0.33 ml) was added and 
mixed by inverting the tube 20×. The mixture was centrifuged (15 000 g, 4ºC, 10 min). The 
upper aqueous layer was transferred into a fresh RNase-free microfuge tube containing 0.9× the 
volume of the aqueous supernatant and the RNA precipitated at –20ºC for 1 h. The supernatant 
was carefully removed and the pellet washed with 1 ml of 70% ethanol-DEPC treated water and 
centrifuged (15 000 g, 4ºC, 5 min). The supernatant was gently removed and the pellet dried for 
5 min, The RNA pellet was resuspended in 50 µl of formamide (for Northern blot analysis) or 
50 µl of DEPC-treated water (for RT-PCR).  
 
The purity of the RNA was analysed by electrophoresis on a 1.2% agarose gel. The RNA sample 
(5µl) was mixed with the formamide gel-loading buffer (10 µl) and the sample incubated at 65ºC 
for 10 min to denature the RNA. Agarose gel electrophoresis was performed. After 
electrophoresis the gel was viewed under UV and the image was captured. The concentration of 
RNA was determined spectophotometrically at 260 nm. 
 
2.5.3 Isolation of Plasmodium yoelii genomic DNA  
In this study, genomic DNA was isolated for molecular cloning of PCR-amplified fragment. Thus 
the FermentasTM DNA purification kit was used with modification toensure higher DNA yields. 
This kit is designed to isolate genomic DNA from various materials such as whole blood, cell and 
tissue culture and bacterial culture. The kit is baed on one step lysis and selective precipitation 
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of genomic DNA in alkali conditions. Although the kit specifies extraction of DNA from whole 
blood, rather purified parasites (150 µl) was used instead. The blood was collected in a microfuge 
tube containing 0.5 ml of PBS instead of a heparinized tube according to the manufacturer’s 
instruction. The blood cells were washed 3× with PBS before isolating the parasite. Moreover, 
the precipitation step was prolonged by cooling at –20ºC for 30 min to enhance DNA 
precipitation. The DNA pellet was resuspended in sterile ddH2O and stored in aliquots at –70ºC. 
DNA yield and purity were analysed by spectrophotometry and standard 0.5% agarose gel 
electrophoresis 
 
2.5.4 Primers for RT-PCR of PY01695, cloning and subcloning of PyBCCP cDNA 
Primers were derived from published sequences from the partially sequenced P. yoelii genome in 
the plasmodbTM database. An internet software (www.basic.northwestern.edu/biotools/oligocalc) 
was used for designing primers with engineered restriction sites for cloning and expression. 
Secondary structures such as hair pin formation were avoided when designing these primers. 
Table 2.2 shows the primers used in the study. 
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Table 2.2 Primers used in the study  
Single and double underlines represent added EcoRI and NotI restriction sites for cloning. Lower case italics are extra bases added to the primers. 
 
Primer name Sequence (5’→3’) Derived from 
(Plasmodb ID) 
Application 
PyACCBC-fwd GCTAATAATGGTATGGCTGCATTAAAATGTATATTGTC PY01695 
PyACCBC-rev GCAATTTCTCTTGTTTCCCCTTTTGCAAATATATGGCC PY01695 
RT-PCR analysis of the expression of PY01695 
mRNA. Expected size of amplicon is 1424 bp. 
Production of probe for Northern blot analysis 
PyACCntCxT-fwd GGAAATAGGACAAAATAAAATGAGCGTAATCGG PY01695 
PyACCntCxT-rev GAGATATTCCATTTTTCATCATAATATTTACACCTCC PY01695 
RT-PCR analysis of the expression of PY01695 
mRNA. Expected size of amplicon is 699 bp 
PyACCctCxT-fwd GATGTTCTTGGGGAATCAACAAAATCATTTCAC PY01695 
PyACCctCxT-rev CTCCTTCATACATGATGATACATCATGTAGATCTGC PY01695 
RT-PCR analysis of the expression of PY01695 
mRNA. Expected size of amplicon is 1128 bp 
PyBCCP-Fwd gaGAATTCACGGAAGATAGCCTAAATAGGGAAG PY01695 
PyBCCP-Rev ttGCGGCCGCATCTCTGGAGTTACTTTCTATATTCG PY01695 
Cloning and expression of PyACC-BCCP domain 
and production of probe for Northern blot analysis. 
Expected size of amplicon is 1041bp. 
PyLDH-fwd GGATCTGGTATGATTGGAGGTGTTATGGCC PY03885 
PyLDH-rev TTCGATTACTTGTTCTACACCATTACCACC PY03885 
Positive control in PCR, RT-PCR and Northern 
blot analysis. Expected size of amplicon is 850 bp. 
 54 
2.5.5 Polymerase chain reaction (PCR)  
Taq polymerase was used for routine PCR such as expression analysis and colony PCR. But 
due to mutational errors often introduced by Taq polymerase, Expand High FidelityTM PCR 
system containing a blend of Pwo and Taq DNA polymerases was used to limit potential 
mutations in the PCR-amplified DNA fragment used for cloning and expression.  PCR was 
optimized for each set of primers. Parameters such as annealing temperature, MgCl2 
concentration (especially after the reverse transcription reaction) and cycle number (limited to 
35 cycles) were varied during optimization. The initial denaturation temperature was 94ºC; 
extension temperature of 60ºC was used throughout te study as against 72ºC standard PCR 
extension temperature. The final elongation temperature was 72 ºC. Table 2.3 illustrates the 
various primers and specific conditions with which those primers were used. The 10× PCR 
buffer used was detergent and MgCl2 free. PCR products used for cloning were purified rom 
agarose gel (Section 2.5.7) before cloning. 
 
Table 2.3 Primer properties, MgCl2 concentration and thermo cycle condition for PCR 
Primer name Tm (ºC) [Primer] 
(µM) 
[MgCl2] 
(µM) 
PCR cycle conditions [ºC (time)] No. of 
Cycle 
PyACCBC-fwd 63 0.5 
PyACCBC-rev 71 0.5 
2.5 94 (30 s)→55 (30 s) →60 (2 min) 35 
PyACCntCxT-fwd 64 0.5 
PyACCntCxT-rev 62 0.5 
2.5 94 (30 s) →55 (30 s) →60 (2 min) 35 
PyACCctCxT-fwd 66 0.5 
PyACCctCxT-rev 64 0.5 
2.5 94 (30 s) →55 (30 s) →60 (2 min) 35 
PyBCCP-Fwd 63 0.8 
PyBCCP-Rev 72 0.8 
2.5 94 (30 s) →55 (1 min) →60 (2 min) 30 
PyLDH-fwd 65 0.5 
PyLDH-rev 67 0.5 
2.5 94 (30 s) →55 (30 s) →60 (2 min) 25 
 
 
2.5.6 Reverse transcriptase polymerase chain reaction for PY01695 expression analysis 
Reverse transcriptase polymerase chain reaction (RT-PCR) was carried out with Improm IITM 
(Promega) Reverse Transcription System kit according the manufacturer’s instruction. P. 
yoelii total RNA isolated from purified parasite (Section 2.4.2) was used as template. The first 
strand synthesis was amplified with oligodT, or random oligonucleotide hexamers provided 
by the kit, according to the manufacturer’s instructions. The reverse transcriptase product 
from both oligodT and random oligonucleotide hexamers were subsequently used for PCR 
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amplification using the following primers: PyACCBC-fwd, PyACCBC-rev, PyACCntCxT-
fwd, PyACCntCxT-rev, PyACCctCxT-fwd, PyACCctCxT-rev, PyLDH-fwd and PyLDH-rev 
(Table 2.2). The conditions for PCR have already been described in Section 2.5.5 and Table 
2.3. The amplified PCR product was resolved on a 1% agarose gel and the image captured 
with VesaDocTM image documentation system. 
 
2.5.7 Purification of DNA from agarose gel  
In this study, purification of cDNA and plasmids was carried out with the peQLabTM gel 
purification kit. Both kits were designed to rapidly purify a DNA fragment of 100 bp – 10 kb 
that has been previously resolved on an agarose gel using mini-spin columns with a silica 
membrane. The kit is based on the capability of guanidine thiocyanate to denature agarose gel 
at 60 – 65ºC and extract the DNA fragment, which binds tightly to the silica membrane and 
reaction by-products, buffer ions in the agarose gel flow through the membrane. Using TE or 
sterile deionised water, the DNA fragment is eluted an  concentrated into small volumes in 
purer form after several washes with an ethanol-based washing solution. DNA purification 
was carried out according to the manufacturer’s instructions. The sample containing the DNA 
fragment was initially resolved on agarose gel as de cribed in Section 2.5.1. The band that 
corresponded to the wanted DNA fragment was excised from the gel under UV light in 10 sec 
exposure to prevent UV-mediated cutting of DNA fragment. Aliquots of the samples before 
and after purification were kept for agarose gel analysis.  
 
2.5.8 PyBCCP cDNA ligation using T4 ligase 
DNA ligation is a biochemical reaction catalysed by DNA ligase; an enzyme that forms 
covalent phosphodiester bonds between 3’ hydroxyl end of one nucleotide to the 5’ phosphate 
end of another nucleotide. This technique thus enabl s successful cloning of DNA fragments 
obtained by PCR or excised from genomic DNA into plasmid vectors for creation of a cDNA 
library or for recombinant expression of the protein encoded by the DNA fragment 
(Sambrook, 1989a). T4 DNA ligase is widely used in molecular biology for ligation reactions. 
This enzyme originates from bacteriophage T4 but recombinantly expressed in E. coli. T4 
DNA ligase and 10× T4 DNA ligase buffer were obtained from FermentasTM.  
 
2.5.8.1 Materials 
10× T4 buffer (Fermentas #EL0016), T4 ligase (Fermentas #EL0016), cDNA insert, linear 
DNA plasmid and sterile ddH2O. 
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2.5.8.2 Method 
All the processes were carried out on ice. cDNA from PCR or after restriction digestion or 
restriction endonuclease-digested plasmid was initially purified from agarose gel as described 
in Section 2.5.7. The approximate amount of the DNA was determined using the Fermentas 
DNA MassRulerTM or by absorbance at 260 nm. The ligation reaction volume was 10 µl. The 
insert DNA and the plasmid DNA were added at 4:1 insert-plasmid ratio. The ligation 
reaction components were added as illustrated in Table 2.4 and the volume made up to 10 µl 
with sterile ddH2O. The reaction mix was vortexed gently briefly centrifuged and incubated 
(4ºC, 16 h). The reaction mix was used directly fortransformation of E. coli without 
deactivation of the enzyme. 
 
Table 2.4 T4 Ligase reaction parameters 
Components Quantity 
10× T4 ligase buffer 1.0 µl 
Insert DNA 4× [plasmid] 
Plasmid 0.25× [insert DNA] 
T4 ligase 2.5 U 
Sterile ddH2O Variable 
Total volume 10 µl 
 
 
2.5.9 Cloning of PyBCCP cDNA fragment into pJET1® blunt end cloning plasmid 
pJET1 cloning vector (Figure 2.1) is a 3.128 kb linear plasmid DNA that has been designed to 
clone blunt end PCR fragments generated by DNA polymerases with a 3’ → 5’ exonuclease 
(proof reading) activity. The vector encodes a multiple cloning site (MCS) with an upstream 
PlacUV5 promoter region. The insert position interrupts a gene eco47IR (GeneBank ID: 
X82105), which codes for a restriction endonuclease lethal to most E. coli strains used for 
cloning. Thus only cells with the recombinant plasmid will grow. pJET1 also codes for an 
ampicillin resistance gene bla (β-lactamase). The recombinant plasmid can be digested with 
the restriction enzymes encoded by the cloned fragment to excise the fragment (GeneJET™ 
cloning technical manual, www.fermentas.com). In this study, blunt end PY01695 gene 
fragment derived from PCR amplification of P. yoelii genomic DNA using PyBCCP-Fwd, 
PyBCCP-Rev encoding an EcoRI and a NotI sites was cloned into pJET1 to produce pJET-
PyBCCP recombinant plasmid. The gene of interest was subsequently excised from the 
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recombinant pJET1-PyBCCP plasmid with EcoRI and NotI restriction enzymes to generate 
gene fragments with sticky non-complementary ends used for subcloning into pET-28a and 
pGEX-4T-1 expression vectors (Section 2.5.11). 
 
 
 
 
 
Figure 2.1 A map of the pJET1 blunt end cloning vector . The plasmid encodes a toxic gene 
eco47IR that is lethal to host cells with circularized plasmid without insert. The insert is cloned into 
the region between XhoI and XbaI (Fermentas, 2006). 
 
 
2.5.10 Plasmid isolation  
In this study, plasmid was isolated by the phenol-chloroform-isoamyl method (Sambrook, 
1989b). The method is based on the underlying principles of differential precipitation between 
chromosomal DNA and plasmid DNA in a bacterial lysate. Purity of the isolated plasmid was 
evaluated by agarose gel electrophoresis.  
 
2.5.10.1 Materials 
GTE solution [50 mM glucose, 25 mM Tris-HCl pH 8, 10 mM di-Na-EDTA]. Glucose (1 g), 
Tris (0.3 g) and di-Na-EDTA (0.37 g) was dissolved in 80 ml of dH2O, pH was adjusted to 8 
with HCl and volume made up to 100 ml with dH2O. The solution was autoclaved and stored 
at 4ºC. 
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Lysis reagent [1% (w/v) SDS, 0.2 M NaOH]. NaOH (0.08 g) and SDS (0.1 g) was dissolved 
in 10 ml of dH2O. This solution was store at 4ºC for 1 week. 
 
Potassium acetate [3 M KOH pH 4.8]. KOH pellet (16.8 g) was dissolved in 25 ml of aceti  
acid. The pH was checked after neutralisation and subsequently adjusted to 4.8 with acetic 
acid. The volume was made up to 100 ml with dH2O and stored at 4ºC. 
 
Phenol-chloroform-isoamyl alcohol [25:24:1 (v/v)]. Liquefied phenol (50 ml), chloroform 
(48 ml) and isoamyl alcohol (2 ml) was mixed and stored at RT in an amber bottle. 
 
Chloroform-isoamyl alcohol [24:1 (v/v)]. Chloroform (48 ml) and isoamyl alcohol (2 ml) was 
mixed and stored at RT. 
 
Sodium acetate [3 M NaOH pH 5.5]. NaOH pellet (12 g) was dissolved in 25 ml of acetic 
acid. The pH was checked after neutralization and subsequently adjusted to 5.5 with acetic 
acid. The volume was made up to 100 ml with dH2O and stored at 4ºC. 
 
70% (v/v) ethanol in dH2O. Absolute ethanol (70 ml) was made up to 100 ml with dH2O and 
stored at –20ºC.  
 
2.5.10.2 Method 
This method was adapted for the isolation of plasmid from a 50 ml overnight E. coli culture 
and was carried out in a 15 ml Falcon tube (RNase and DNase free). The culture was 
centrifuged (3500 g, 15 min, 4ºC) to pellet the cells. The cell pellet was resuspended in 
1/100th the culture volume (0.5 ml) with GTE, RNase A was added (10 U/1 ml) to the cell 
suspension and transferred to a 15 ml Falcon tube. Lysis reagent (0.5 ml) was added and the 
cells were mixed until the cells were completely lysed. Potassium acetate (1 ml) was added 
and mixed for 5 min and centrifuged (11 500 g, 30 min, RT). The supernatant containing the 
plasmid was carefully removed without carrying over the white pellet into a fresh 15 ml 
falcon tube. An equal volume of phenol-chloroform-isoamyl alcohol was added to the 
supernatant and mixed gently for 5 min. The mixture was centrifuged (11 500 g, 30 min, RT); 
the upper aqueous phase was gently transferred into a fresh 15 ml falcon tube and mixed with 
equal volume of chloroform-isoamyl alcohol for 2 min at RT.  The mixture was centrifuged 
(11 500 g, 30 min, RT); the upper aqueous phase was gently transferred into a fresh 15 ml 
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falcon tube. Sodium acetate (1/10th the volume of aqueous supernatant) and ice-cold 100% 
ethanol (2.5 volume of the aqueous supernatant), mixed and incubated at –20ºC for 1 h. The 
precipitated plasmid was pelleted (11 500 g, 30 min, 4ºC), washed twice with ice-cold 70% 
ethanol and resuspended in sterile 1× TE buffer. The plasmid resolved on a 1% agarose gel 
for purity evaluation. 
 
2.5.11 Expression plasmids used in the study 
pET-28a 
In this study, pET-28a (Figure 2.2) was used to expr ss recombinant P. yoelii biotin carboxyl 
carrier protein (PyBCCP). The 1 kb gene fragment cotaining the BCCP domain was cloned 
into the vector at the EcoRI and NotI site. The product was expected to have an additional 48 
to 50 amino acid residue as a result of the insert position relative to the start codon (bp 296 on 
the plasmid) situated at the NcoI site. The host strain used for pET-28a expression in this 
study was E. coli Rosetta (DE3) pLysS strain. The construct and the recombinant cells will be 
referred to as pT-PyBCCP and Rosetta-pT-PyBCCP respectively. 
 
Figure 2.2 A map of the pET-28a expression plasmid. The figure illustrates restriction sites and 
important features of the pET-28a plasmid including the kanamycin resistant gene (kan) and the 
multiple cloning region. The gene of interest was in erted in the NotI and EcoRI sites, in frame with 
the N-terminal His6-tag (pET-28a-c(+) and Vectors, 1998). 
 60 
pGEX-4T-1 
pGEX-4T-1 (Figure 2.3) was used to express recombinant GST-PyBCCP. The 1 kb gene 
fragment containing the biotin carboxyl carrier protein (or biotinoyl) domain was cloned into 
the vector at the EcoRI and NotI sites in frame with the N-terminal GST-tag protein. The host 
strain used was E. coli BL21. The construct and the recombinant cells willbe referred to as 
pGX-PyBCCP and BL21-pGX-PyBCCP respectively. 
 
 
 
 
Figure 2.3 A map of pGEX-4T-1 expression plasmid. The figure illustrates restriction sites and 
important features of the plasmid including the glutathione S-transferase (GST) gene, the ampicillin 
resistant gene (Ampr), the inducible Ptac promoter and the multiple cloning region. The gene of interest 
was inserted in the NotI and EcoRI sites, in frame with the GST gene (AmershamBiosciences, 2002).  
 
 
2.5.12 Restriction endonuclease digestion of plasmids 
The expression plasmids used in this study encoded an EcoRI site and a NotI site in their 
multiple cloning sites. Therefore the forward primers were designed to encode an EcoRI site 
(5’GAATTC3’) while the reverse primers were designed to encode the palindromic NotI site 
(5’GCGGCCGC3’).  The primer design allowed for cloning of the cDNA as fusion protein in 
pGEX-4T-1 (GST-fusion) and pET-28a (His6-T7-tagged). To prepare the plasmids for ligation 
and cloning of the cDNA it was necessary to digest the expression plasmid with EcoRI and 
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NotI to create non-complementary sticky ends for the ligation of gene of interest. The 
presence of a 5’-phosphate group may result in circula ization of the plasmid and was avoided 
by dephosphorylation of the digested plasmid with shrimp alkaline phosphatase (SAP). The 
digestion was analysed on an agarose gel (1%). The digested plasmids was purified from 
agarose gel to eliminate nucleic acid fragments, buffer components, enzymes and nucleotides 
that may compromise the cloning of the target gene into the plasmid. The insert DNA to be 
subcloned into an expression plasmid was initially c oned into pJET1 for propagation in E.
coli. This strategy reduces the likelihood of PCR-introduced mutations when PCR product is 
cloned directly into an expression vector. The inserts were cut out of the vector using EcoRI 
and NotI restriction enzymes and purified from the agarose gel.  
 
2.5.12.1 Materials 
EcoRI restriction enzyme, NotI restriction enzyme, shrimp alkaline phosphatatse (SAP), 
Fermentas 10× Orange BufferTM (Buffer O) and recombinant/non-recombinant super coiled 
plasmid DNA 
 
2.5.12.2 Method 
E. coli cells containing a recombinant (with insert DNA) cloning or expression plasmid in 
glycerol stock was streaked on LB-agar plate containing the appropriate antibiotic and 
incubated (37°C, overnight). The following day, a single colony was picked with a sterile 
toothpick and used to inoculate 10 ml of 2×YT with the antibiotic and grown with shaking 
(37°C, 250 rpm, overnight). The culture was transferred into a 15 ml falcon tube and the cells 
pelleted by centrifugation (3500 g, 15 min,  25°C). Plasmid isolation was carried outas 
described in Section 2.5.10. A 100 µl reaction volume was set up in the following order: 10× 
Buffer O (10 µl), plasmid (89 µl), first (EcoRI) restriction enzyme (1 µl). The reaction mix 
was vortexed gently, centrifuged briefly to collect the mix at the bottom of the tube and 
incubated (30°C, 5 h). The first enzyme was deactivted (65°C, 20 min) and the tube chilled 
on ice. 2 µl of the mix was analysed by agarose gel electrophoresis (Section 2.5.1) before the 
next restriction digestion step. Thereafter 1 µl of the second enzyme (NotI) was added directly 
to the mix and incubated (RT, overnight). After incubation, the enzyme was deactivated 
(85°C, 15 min) and chilled on ice. 2 µl of the mix was analysed on agarose gel prior to 
dephosphorylation of the plasmid. SAP (1.5 µl) was added to the plasmid digestion mix and 
immediately incubated (37°C, 2.5 h). The cDNA fragment restricted from the cloning 
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plasmids was not dephosphorylated. The dephosphorylated plasmid and the cDNA fragment 
were purified from agarose gel (Section 2.5.7) before the ligation reaction. 
 
2.5.13 E. coli hosts used for cloning and expression of recombinant proteins 
 
Table 2.5 E. coli hosts used for cloning and expression of recombinant proteins 
E. coli strain Genotype Application 
JM109  F´ traD36 proA+B+ lacIq 
∆(lacZ)M15/ ∆(lac-proAB) 
glnV44 e14- gyrA96 recA1 relA1 
ndA1 thi hsdR17 
Maintenance and propagation of 
recombinant plasmids for 
transformation into expression 
cells 
 
BL21p  F – ompT hsdSB ( rB
– mB
 – )gal dcm Expression of recombinant pGEX-
4T-1 
 
Rosetta (DE3) pLysSTM p F – ompT hsdSB ( rB
– mB
 – )gal dcm 
(DE3)  pLysS RARE26 (CamR) 
Expression of recombinant pET- 
28a vectors 
 
p deficient in lon protease 
 
2.5.14 Transformation and culturing of E. coli transformants 
2.5.14.1 Materials 
MgCl2.6H2O [1 M]. MgCl2.6H2O (2.03 g) was dissolved in a final volume of 10 ml with 
ddH2O and filter sterilised with a 0.2 µm syringe filter. The solution was used for SOC media. 
 
MgSO4 [1 M]. MgSO4 (1.2 g) was dissolved in a final volume of 10 ml with ddH2O and filter 
sterilised with a 0.2 µM syringe filter. The solution was used for SOC media. 
 
Glucose monohydrate [1 M]. Glucose monohydrate (1.98 g) was dissolved in a fi al volume 
of 10 ml with ddH2O and filter sterilised with a 0.2 µM syringe filter. The solution was used 
for SOC media. 
 
SOC Medium[2% (w/v) tryptone, 0.5% (w/v) yeast extrac , 10 mM NaCl, 2.5 mM MgCl2, 
10 mM MgSO4 and 20 mM Glucose].Tryptone (0.5 g), NaCl (0.015 g) and yeast extracts 
(0.125 g) were suspended in 25 ml of dH2O and autoclaved. The media was cooled to ~ 55°C. 
MgCl2.6H2O (125 µl), MgSO4 (500 µl) and glucose (1 ml) were added to the media and the 
volume was made up to 50 ml with sterile (autoclaved) ddH2O. The media was aliquoted into 
sterile microfuge tubes and stored at –20°C. 
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LB-agar [1% (w/v) tryptone, 0.5% (w/v) yeast extracs, 1.5% (w/v) agar, 10% (w/v) NaCl, 
pH 7.4]. Tryptone (10 g), yeast extracts (5 g) and NaCl (10 g) were completely resuspended 
in 900 ml of dH2O with continuous stirring. The pH was adjusted to 7.4 with NaOH, agar 
(15 g) was added and the volume made up to 1 L withdH2O. The media was autoclaved 
(121ºC, 20 min), cooled to ~ 55ºC and antibiotics added as illustrated in Table 2.6 depending 
on the requirement of the E. coli to be cultivated. The media was dispensed into sterile plastic 
culture plates, allowed to solidify and sealed with Parafilm™. Plates were stored at 4ºC.  
 
2×YT [1.6% (w/v) tryptone, 1% (w/v) yeast extracts and 0.5% (w/v) NaCl, pH 7.4]. Tryptone 
(16 g), yeast extracts (10 g) and NaCl (5 g) were completely resuspended in 900 ml dH2O 
with continuous stirring and the pH was adjusted to 7.4 with NaOH. The media was 
autoclaved, allowed to cool to RT and required amount f antibiotics added (see Table 2.6). 
 
Potassium acetate [1 M, pH 7.5]. Potassium acetate (9.8 g) was dissolved 60 ml of ddH2O, pH 
adjusted to 7.5 with KOH and volume made up to 100 ml with of ddH2O. The solution was 
sterilised by filtration through a 0.22 µm syringe filter. This reagent was used in FSB and 
DTT-DMSO reagents. 
 
Frozen stock buffer (FSB) [100 mM KCl, 45 mM MnCl2.4H2O, 10 mM CaCl2.2H2O, 3 mM 
hexamine cobalt chloride (HACoCl3) 10 mM potassium acetate and 10% (w/v) glycerol, 
pH 6.2]. K-acetate (1 ml), KCl (0.74 g), MnCl2.4H2O (0.98 g), CaCl2.2H2O (0.15 g), 
HACoCl3 (80 mg) and glycerol (10 g) were dissolved in 80 ml of ddH2O, pH adjusted to 6.2 
and volume made up to 100 ml with ddH2O. The buffer was sterilised by filtration through a 
0.22 µm syringe filter and used immediately to prepa  competent E. coli cells. 
 
DTT-DMSO [1 M DTT, 10 mM potassium acetate and 90% (v/v) DMSO]. Molecular biology 
grade DTT (1.54 g), K-acetate (0.1 ml) and DMSO (9 ml) were made up to 10 ml with sterile 
ddH2O. This reagent was used immediately or stored at –20°C. 
 
2.5.14.2 Method  
Preparation of competent cells 
An overnight culture made from a single E. coli colony was diluted 1/10 with fresh media and 
grown to OD600 nm ≈ 0.6 at 30ºC shaking. The cells were pelleted (1000 g, 15 min, 4 ºC), 
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drained thoroughly and resuspended in 1/10
th the culture volume with cold FSB. The cell 
suspension was incubated on ice for 15 min and pelleted (1000 g, 15 min, 4 ºC). The cells 
were resuspended in 1/50th the culture volume with cold FSB, 17.5 µl of DTT-DMSO was 
added, mixed gently and incubated on ice for 10 min. 17.5 µl of DTT-DMSO was added the 
second time, mixed gently and incubated on ice for 20 min. 100 µl of the cell suspension was 
aliquoted into cold sterile microfuge tubes using chilled sterile pipette tips. The cells were 
quick-frozen in liquid nitrogen (5 min) and stored at –70ºC until use. 
 
Transformation of competent E. coli cells 
Ligation mix (5 µl) was added directly to the competent cells, the transformation mix was 
incubated on ice for 60 min and heat shocked at 42ºC for 90 sec. The cells were incubated on 
ice for 2 min, SOC (200 µl) was added to the cells and incubated at 37ºC for 60 min shaking. 
The cells were plated on LB-amp plates (ampicillin resistant encoded plasmids) and incubated 
at 37ºC.  
 
2.5.15 Antibiotics used for positive selection and maintenance of E. coli transformants 
Stock solutions of the antibiotics were prepared in ddH2O or methanol and sterilized by 
filtration through a 0.22 µm syringe filter into sterile microfuge tubes in a sterile environment 
and stored an –20°C. Chloramphenicol was dissolved in methanol because it is insoluble in 
water and stored at –20°C. Table 2.6 illustrates th applications, concentration of stock and 
working solutions of antibiotics used in this study. 
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Table 2.6 Selective antibiotic: concentrations and applications  
Antibiotic [Stock] 
(mg/ml) 
[Working] 
(µg/ml) 
Application 
Ampicillin 
 
 
Carbenicillin 
 
 
 
 
Chloramphenicol 
 
 
 
 
Kanamycin  
 
50 
 
 
50 
 
 
 
 
30a 
 
 
 
 
34 
100 
 
 
100 
 
 
 
 
30 
 
 
 
 
34 
Used in LB-agar plates for selection of E. coli with 
ampicillin-encoded pJET1 and pGEX-4T-1. 
 
 
 
Used for overnight culture, out growth and 
induction of expression in E. coli with ampicillin 
resistant pGEX-4T-1 expression plasmid. A more 
stable β-lactam analogue of ampicillin. 
 
 
 
 
 
 
Used in LB-agar plates and 2×YT broth for 
selection of Rosetta (DE3) pLysSTM E. coli strains 
with the pLysS encoded plasmid for tight 
regulation of IPTG-expression. 
 
 
 
 
 
 
Used in LB-agar plates and 2×YT broth for 
selection of transformed Rosetta (DE3) pLysSTM 
E. coli strains with recombinant pET-28a for 
expression. 
 
a Stock solution prepared in 100% methanol    
 
2.5.16 Preparation of probes for Northern blot analysis 
Probes for Northern blot analysis were prepared with B otin DecaLabel™ DNA labeling kit 
according to the manufacturers instruction. PCR product from amplification of PyBCCP using 
PyBCCP-fwd and PyBCCP-rev and PyLDH using PyLDH-fwd PyLDH-rev were used as 
DNA template. PCR products were purified from agarose gel as described in Section 2.5.7 
prior to labelling. 
 
2.5.17 Northern blotting, hybridisation and enhanced chemiluminescence detection  
2.5.17.1 Materials 
DEPC-treated TE buffer (Section 2.5.2.1). 
 
Formamide gel-loading buffer (Section 2.5.2.1).  
 
5× SSC [0.75 M NaCl, 0.1M citric acid, pH 7]. NaCl (43.8 g) and citric acid (20.5 g) 
dissolved in 800 ml of ddH2O, pH adjusted to 7 and volume made up to 1 L. The buffer 
treated with 0.1% DEPC and autoclaved. 
 
Transfer buffer [5× SSC, 10 mM NaOH]. 1 ml of 1 M NaOH was added to 99 ml of 5× SCC.  
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5× SSC-NaH2PO4 [50 mM NaH2PO4, 0.75 M NaCl, 0.1 M citric acid, pH 6.5]  NaCl (4.38 g), 
citric acid (2.05 g) and NaH2PO4 (0.6 g) were dissolved in 80 ml of de-ionised dH2O, pH 
adjusted to 6.5 and volume made up to 100 ml. The buffer treated with 0.1% DEPC and 
autoclaved. 
 
50× Denhardt solution [BSA (1% w/v), polyvinylpyrrolidone 40 000 (1% w/v) and ficoll 400 
(1% w/v)]. BSA (1 g), polyvinylpyrrolidone (1 g) and ficoll (1 g) were dissolved in 80 ml of 
DEPC-treated ddH2O, made up to 100 ml with DEPC-treated ddH2O and filter-sterilised. The 
solution was stored at –20ºC. 
 
Pre-hybridisation buffer. Formamide (25 ml), 50× Denhardt solution (0.5 ml), herring sperm 
DNA (0.25 g) were made up to 50 ml with 5× SSC-50 mM NaH2PO4. 
 
Hybridisation buffer. Biotinylated DNA probe (0.1 µg) was denatured at 100ºC for 10 min, 
cooled on ice and added to the pre-hybridisation buffer. 
 
2× SSC-Tween (wash solution 1). 5× SSC (40 ml) was mixed with Tween-20 (1 ml) and the 
volume was made up to 100 ml with DEPC-treated ddH2O. 
 
0.1× SSC-Tween (wash solution 2). 5× SSC (2 ml) was mixed with Tween-20 (1 ml) and the 
volume was made up to 100 ml with DEPC-treated ddH2O. 
 
0.1 M Tris-HCl, pH 7.5. Tris (1.21 g) was dissolved in DEPC-treated ddH2O, pH adjusted to 
7.5 with HCl and volume made up to 100 ml with DEPC-treated ddH2O. 
 
BSA-Tris-HCl. BSA (0.5 g) was dissolved in 100 ml of 0.1 M Tris-HCl, pH 7.5. 
 
Avidin-peroxidase solution. 1/500 dilution of avidin-peroxidase was prepared in BSA-Tris-
HCl. 
 
Stock luminol solution [40 mg/ml]. Luminol (40 mg) was dissolved in DMSO (1 ml) and 
stored at –20ºC for up to 6 months.  
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Stock p-iodophenol solution [0.1 M]. p-iodophenol (22 mg) was dissolved in DMSO (1 ml) 
and stored at –20ºC for 6 months. 
 
ECL reagent. Luminol stock (50 µl), p-iodophenol stock (25 µl) and 30% H2O2 (25 µl) were 
made up to 10 ml with 0.1 M Tris-HCl buffer. The reag nt was stored on ice away from light 
until use. 
 
2.5.17.2 Method 
Separation of total RNA by agarose gel electrophoresis 
The RNA sample was prepared by mixing an appropriate amount (25 µg) with formamide 
gel-loading buffer (20 µl). The sample was incubated at 65ºC for 10 min. The sample was 
loaded onto 1.2% agarose gel (ethidium bromide concentration at 0.01 mg/ml). 
Electrophoresis was performed at 25 V for 8 cm long gel (3 – 4 V/cm gel). After 
electrophoresis, the gel was incubated in 7% (v/v) formamide for 10 min to enhance transfer 
of the resolved RNA onto a nitrocellulose membrane (Pélle and Murphy, 1993). A single 
stranded RNA marker was used to estimate the size of the RNA band on the gel using the 
graph of Log RNA base pair (bp) against distance migrated (mm) from the well. 
 
Transfer to nitrocellulose membrane and cross linking of RNA to membrane 
The blotting papers and the nitrocellulose membrane were wet with the transfer buffer to 
avoid trapping air bubbles between the membrane and the blotting paper. The bottom of the 
gel was also wet with the transfer buffer and the membrane was carefully laid over the gel 
placed upside down avoiding trapping of air bubbles tween the gel and the membrane. The 
transfer was allowed to proceed overnight at RT withou  disturbing the assembly. The 
membrane is removed and pictured under UV to establi h transfer of RNA. The blot was 
dried and baked at 80ºC for 2 h to cross-link the blotted RNA to the nitrocellulose membrane. 
The position of the molecular weight markers on the membrane was marked with pencil under 
UV. 
 
Pre-hybridisation and hybridisation  
The nitrocellulose membrane was incubated with minial volume of prehybridisation buffer 
(enough to cover the membrane) in an RNase free Tupper ware container with lid in a water 
bath (42ºC for 20 h). This was followed with the hybridization buffer (42ºC for 24 h). The 
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membrane was washed 4× with wash solution 1 (5 min each at RT), followed by 2× with 
wash solution 2 (15 min each at 50ºC). 
  
Avidin-peroxidase labeling and enhanced chemiluminescence detection 
The nitrocellulose membrane was equilibrated by washing the nitrocellulose membrane in 
BSA-Tris (3×, 10 min each). The nitrocellulose membrane was incubated in avidin-
peroxidase reagent overnight at 4ºC on a slow rocke, washed 5× with 0.1 M Tris-HCl, pH 7.5 
(RT, 5 min per wash) and the ECL reagent applied on the nitrocellulose membrane; just 
enough to cover the entire membrane. The nitrocellulose membrane was covered with a cling 
wrap film avoiding trapping air bubbles. An X-ray film was placed over the membrane 
aligning the cut out sections on both the nitrocellulose membrane and the X-ray film and 
incubated placed in a film cassette for 35 min at RT.  
 
Developing the X-ray film 
Prior to exposure to exposure of the membrane to the X-ray film, the developer 
(STRUCTURIX G128™) and the fixer (G333c™) were diluted 1/3 and 1/4, respectively, 
with ddH2O in separate baths. Immediately after exposure, the X-ray film was immersed in 
the developer for 5 min and transferred in the fixing solution for 2 min (in a dark room). The 
X-ray film was washed with tap water (under light) and allowed to dry while hanging.  
 
2.6 Recombinant protein techniques 
This section describes all techniques that were employed for the expression of recombinant 
PyBCCP from pT-PyBCCP and pGX-PyBCCP (pET-28a and pGEX-4T-1 constructs 
respectively). Biotinylation of rabbit albumin as a control for the biotinylation study is also 
described. SDS-PAGE analysis and Western blotting techniques had been described in 
Sections 2.3.1 and 2.3.2, respectively. 
 
2.6.1 Expression of His6-PyBCCP and GST-PyBCCP 
2.6.1.1 Materials 
Cell resuspension buffer [0.02 M Tris-HCl, 0.25 M NaCl, 0.1% (w/v) NaN3, 1 mM DTT, 5% 
(v/v) glycerol, 0.5 mM PMSF, pH 7]. Tris (0.24 g), NaCl (1.5 g), PMSF (8.7 mg), NaN3 
(0.1 g), DTT (15 mg) and glycerol (5 ml) were complete y dissolved in 85 ml of dH2O, pH 
adjusted to 8 with HCl and volume made up to 100 ml with dH2O.  
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2.6.1.2 Method 
Expression of His6-PyBCCP 
Three-way streak of cells containing the recombinant plasmid (pT-PyBCCP in Rosetta (DE3) 
pLysS) was made on 2×YT-agar plate supplemented with kanamycin (34 µg/ml) and 
chloramphenicol (30 µg/ml) and incubated (37ºC, 16 h). A single colony was used to 
inoculate 2×YT-media (5 ml) supplemented with kanamycin and chloramphenicol (2×YT-
kan-cam) and the culture was incubated (37ºC, 16 h). The culture was diluted 1/100 with fresh 
2×YT-kan-cam and incubated at 37ºC until the culture had an OD of 0.6 (at 600 nm) after 
which the culture was induced with or without IPTG (0.5 mM) and incubated (37ºC, 5 h or 
18ºC, 16 h). Cells were harvested by centrifugation (3500 g, 15 min, 4ºC) and suspended in 
1/100th of the culture volume with cell resuspension buffer. The cell suspension was subjected 
to three freeze-thaw cycles between 37ºC and –196ºC (liquid nitrogen for 2 min) and further 
disrupted by sonication on ice (10 cycles, 5 sec/burst, 1 min between bursts). The total cell 
lysate was analysed for expression by SDS-PAGE and Western blotting using monoclonal 
anti-His-tag antibody.  
 
Expression of GST-PyBCCP 
Three-way streak of cells containing the recombinant plasmid (pGX-PyBCCP in BL21) was 
made on 2×YT-agar plate supplemented with ampicillin (100 µg/ml) and incubated (37ºC, 
16 h). A single colony was used to inoculate 2×YT-media (5 ml) supplemented with 
ampicillin 2×YT-amp) and the culture was incubated (37ºC, 16h). The cells were washed 2× 
(1000 g, 5 min, RT) with fresh media to reduce the effect of β-lactamase secreted into the 
media by the cells. The culture was diluted 1/100 with fresh 2×YT-amp and incubated at 37ºC 
until OD600 nm of the culture was approximately 0.6 after which the culture was induced with 
or without IPTG (0.5 mM) and incubated (37ºC, 5 h). The culture was continuously 
supplemented with ampicillin (100 µg/ml) every hour during expression. For prolonged 
expression (18ºC, 16 h), the 2×YT media was supplemented with carbenicillin (100 µg/ml). 
Cells were harvested by centrifugation (3500 g, 15 min, 4ºC) and suspended in 1/100th of the 
culture volume with cell resuspension buffer contaiing egg white lysozyme (1 mg/ml) and 
incubated (37ºC, 20 min). The cell suspension was subjected to three cycles of freeze thaw 
between 37ºC and –196ºC (liquid nitrogen for 2 min) a d further disrupted by sonication on 
ice (10 cycles, 5 sec/burst, 1 min between bursts). The total cell lysate was analysed for 
expression by SDS-PAGE and Western blotting using monoclonal anti-GST antibody.  
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2.6.2 Purification and refolding of His6-PyBCCP 
2.6.2.1 Materials 
TALON® metal affinity resin (1.5 ml matrix volume). 
 
Pellet wash buffer [2 M Urea, 0.02 M Tris-HCl, 2.5% (v/v) Triton X-100, pH 8]. Urea (60 g), 
Tris (1.2 g) and Triton X-100 (12.5 ml) were complete y dissolved in 350 ml of dH2O, pH 
adjusted to 8 with HCl and volume made up to 500 ml with dH2O. The buffer was stored at 
RT. 
 
Solubilisation buffer [6 M guanidine-HCl, 0.02 M Tris-HCl, 0.25 M NaCl, 0.02 M imidazole, 
pH 8]. Guanidine-HCl (57.3 g), Tris (0.24 g), NaCl (1.5 g), and imidazole (1.4 g) were 
completely dissolved in ~ 25 ml of dH2O, pH adjusted to 8 with HCl and volume made up to 
100 ml with dH2O. The buffer was stored at RT. 
 
Wash buffer 1 [8 M urea, 0.02 M Tris-HCl, 0.5 M NaCl, pH 8]. Urea (24 g), Tris (0.12 g) and 
NaCl (1.45 g) were completely dissolved in ~ 10 ml of dH2O, pH adjusted to 8 with HCl and 
volume made up to 50 ml with dH2O. The buffer was stored at RT. 
 
Wash buffer 2 [8 M urea, 0.02 M Tris-HCl, 0.03 M imidazole, pH 8.0]. Urea (24 g), Tris 
(0.12 g) and imidazole (0.1 g) were completely dissolved in ~ 10 ml of dH2O, pH adjusted to 
8 with HCl and volume made up to 50 ml with dH2O. The buffer was stored at RT. 
 
Elution buffer [8 M urea, 0.02 M Tris-HCl, 1 M imidazole, pH 8]. Urea (24 g), Tris (0.12 g) 
and imidazole (3.4 g) were completely dissolved in ~ 10 ml of dH2O, pH adjusted to 8 with 
HCl and volume made up to 50 ml with dH2O. The buffer was stored at RT. 
 
Dialysis buffer 1 [4 M urea, 0.02 M Tris-HCl, 0.25 M L-arginine, 5% (v/v) glycerol, pH 8]. 
Urea (120 g), Tris (1.21 g), L-arginine (21.8 g) and glycerol (25 ml) were completely 
dissolved in 250 ml of dH2O, pH adjusted to 8 with HCl and volume made up to 500 ml with 
dH2O.  
 
Dialysis buffer 2 [2 M urea, 0.02 M Tris-HCl, 0.25 M L-arginine, 10% (v/v) glycerol, pH 8]. 
Urea (120 g), Tris (2.4 g), L-arginine (43.6 g) and glycerol (100 ml) were completely 
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dissolved in 850 ml of dH2O, pH adjusted to 8 with HCl and volume made up to 1 L with 
dH2O.  
 
Dialysis buffer 3 [1 M urea, 0.02 M Tris-HCl, 0.25 M L-arginine, 15% (v/v) glycerol, pH 8]. 
Urea (60 g), Tris (2.4 g), L-arginine (43.6 g) and glycerol (150 ml) were completely dissolved 
in 750 ml of dH2O, pH adjusted to 8 with HCl and volume made up to 1 L with dH2O.  
 
Dialysis buffer 4 [0.5 M urea, 0.02 M Tris-HCl, 0.25 M L-arginine, 20% (v/v) glycerol, pH 
8]. Urea (30 g), Tris (2.4 g), L-arginine (43.6 g) and glycerol (200 ml) were completely 
dissolved in 650 ml of dH2O, pH adjusted to 8.0 with HCl and volume made up to 1 L with 
dH2O.  
 
Equilibration buffer [0.02 M Tris-HCl, 0.25 M L-arginine, 0.5 mM PMSF, 0.1% (w/v) NaN3 
20% (v/v) glycerol, pH 8]. Tris (2.4 g), L-arginine (43.6 g), PMSF (87  mg), NaN3 (1 g) and 
glycerol (200 ml) were completely dissolved in 650 ml of dH2O, pH adjusted to 8 with HCl 
and volume made up to 1 L with dH2O.  
 
2.6.2.2 Method 
Purification of insoluble recombinant His6-PyBCCP 
TALON resin slurry (3 ml) containing ~ 1.5 ml of resin was placed into a BioRad affinity 
column washed with 10 column volumes (15 ml) of Solubilisation buffer. Insoluble protein 
pellet obtained from large scale expression (5 L) was ashed 3 times with pellet wash buffer 
(12 000 g, 30 min, 4ºC). The protein pellet was dissolved in 50 ml of Solubilisation buffer and 
centrifuged (12 000 g, 30 min, 4ºC) to remove insoluble materials that my block the affinity 
column. The protein sample was continuously circulated over the affinity matrix (16 h, RT, 
0.25 ml/min) in a reverse direction. The matrix was washed with 10 column volume of the 
following in this order: Solubilisation buffer, wash buffer 1 and wash buffer 2. Bound 
proteins were eluted from the matrix with the elution buffer (0.25 ml/min, 1 ml/fraction, 
15 ml) and A280 nm of each fraction was recorded. Fractions with A280 nm > 0.5 were pooled 
and the purification profile was analysed by SDS-PAGE (Section 2.3.1).  
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Refolding of recombinant His6-PyBCCP 
Dialysis membrane (10 kD MWCO) was washed; the eluted protein sample (2 ml) was placed 
in the dialysis bag and sealed. The protein was dialysed by continuous stirring against the 
buffers as illustrated in Table 2.7. 
 
 
Table 2.7 Dialysis schedule for refolding of His6-PyBCCP 
 
Buffer Vol 
(ml) 
Time 
(h) 
Temp Number 
of 
changes 
[Urea] 
(M) 
Estimated [urea] (mM) at 
equilibrium 
Dialysis buffer 1 250 6 RT 2 4.0 32.0 
Dialysis buffer 2 1000 18 RT 1 2.0 0.064 
Dialysis buffer 3 500 6 RT 2 1.0 1.28 × 10– 4 
Dialysis buffer 4 1000 6 4ºC 2 0.5 1.28 × 10– 7 
Equilibration buffer 1 1000 6 4ºC 3 0 8.53× 10– 11 
 
 
The final protein sample was concentrated with CentriconTM (30 kD MWCO) to a final 
volume of 0.85 ml and stored at –20 ºC. The refolding profile was analysed with SDS-PAGE 
and final protein concentration estimated by Bradford (Section 2.3.3). 
 
2.6.3 Biotinylation of rabbit albumin 
2.6.3.1 Materials 
Reaction buffer [0.1 M NaH2PO4.2H2O, 0.15 M NaCl, 0.1% (w/v) NaN3, pH 7.5].  
NaH2PO4.2H2O (7.8 g), NaCl (4.4 g) and NaN3 (0.5 g) were dissolved in 450 ml of dH2O, pH 
was adjusted to 7.5 and the volume was made up to 500 ml with dH2O. 
 
NHS-biotin solution [10 mg/ml]. NHS-biotin (1 mg) was dissolved in DMSO (100 µl). 
 
Rabbit albumin solution [20 mg/ml]. Rabbit albumin (10 mg) was dissolved in 500 ml of 
reaction buffer. 
 
2.6.3.2 Method 
The amount of NHS-biotin (MW 341.38) to be coupled to 10 mg of rabbit albumin at a ratio 
of 20:1 NHS-biotin is to rabbit albumin was derived to be 1 mg of NHS-biotin/10 mg rabbit 
albumin. The reaction was initiated by mixing NHS-biotin solution (100 µl) with rabbit 
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albumin solution (400 µl) and incubating on a rotary mixer (1h, RT). The mixture was loaded 
onto Sephadex G-25 size exclusion chromatography column pre-equilibrated with the reaction 
buffer (10 column volumes). The biotin-rabbit albumin complex was eluted with the reaction 
buffer by collecting fractions (1 ml). The A280 nm of the eluted fractions was determined for 
each fraction. The first set of fractions with A280 nm > 0.5 were pooled together (~ 4 ml total 
volume). 
 
2.6.4 Biotinylation analysis of recombinant His6-PyBCCP and GST-PyBCCP 
2.6.4.1 Materials  
D-biotin solution [100 mM in 0.01 M NaOH]. D-biotin (0.24 g) was dissolved in 10 mM 
NaOH solution and sterilised by filtration through a 0.22 µm syringe filter. The solution was 
stored at –20ºC. 
 
2×YT-D-biotin-kan-cam. 2×YT was prepared as described in Section 2.5.14.1. D-biotin, 
kanamycin and chloramphenicol were added to a finalconcentration of 0.2 mM, 34 µg/ml and 
30 µg/ml respectively after autoclaving for Rosetta-pT-PyBCCP cells. 
 
2×YT-D-biotin-amp. 2×YT was prepared as described in Section 2.5.14.1. D-biotin and 
ampicillin were added to a final concentration of 0.2 mM and 100 µg/ml respectively after 
autoclaving for BL21-pGX-PyBCCP cells and P. yoelii putative copper transporter gene 
fragment cloned into pGEX-4T-1 in BL21 E. coli strain. 
 
2.6.4.2 Method 
A similar expression protocol described in Section 2.6.1.2 was employed for this study except 
that the out-growth 2×YT media was used with or without 0.2 mM D-biotin. The overnight 
culture was grown to OD600 nm of approximately 0.6 in 2×YT ± 0.2 mM D-biotin containing 
the appropriate selective antibiotics (12 ml) and further split into two cultures (5 ml). One of 
the two was induced with IPTG (0.5 mM) and incubated (37ºC, 5 h or 18ºC, 16 h). For a 
negative control experiment, P. yoelii putative copper transporter gene fragment cloned into 
pGEX-4T-1 in BL21 E. coli strain was expressed using the same conditions as BL21-pGX-
PyBCCP. Table 2.8 illustrates the conditions used. 
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Table 2.8 Culture treatment for biotinylation study 
Culture set  1 2 3 4 
0.5 mM IPTG – + – + 
0.2 mM D-biotin – – + + 
 
 
The cells were harvested as described in Section 2.6.1.  The total cell lysate was resolved on 
10% acrylamide gel by SDS-PAGE (Section 2.3.1) and electro-blotted onto nitrocellulose 
membrane (Section 2.3.2). The blot was blocked with fresh 5% (w/v) fat-free milk in TBS 
(Section 2.3.2.1), incubated with or without avidin-peroxidase or monoclonal anti-biotin IgG 
in the presence or absence of D-biotin (10 mM) or avidin (10 µg/ml) as negative control. 
 
2.7 Bioinformatics methods 
2.7.1 Sequence analysis 
Sequences for acetyl-CoA carboxylase were extracted from the NCBI (National Centre for 
Biotechnology Information), swissprot/TrEMBL™ and the Plasmodb™ database. The 
sequences were saved as text files in FASTA format. The molecular mass and pI values were  
computed using the ProtParam (Gasteiger et al., 2005) programme on the expasy web site 
(www.expasy.org). The ScanProsite™ (de Castro et al., 2006; Gattiker et al., 2002) and 
InterPro Scan™ (Mulder et al., 2002) were used to obtain the amino acid sequence domains 
corresponding to the biotin carboxylase, biotinoyl (or biotin carboxyl carrier protein), the N-
terminal carboxyl transferase and the C-terminal carboxyl transferase. This programme has a 
web interface with the Prosite™ (Falquet et al., 2002; Hulo et al., 2006; Sigrist et al., 2002) 
database containing families of proteins. The Prosite Scan™ (Proscan™) (Bairoch et al., 
1997) and the NetPhos 2.0™ (Blom et al., 1999) programmes were used to predict protein 
kinase phosphorylation sites on the biotin carboxylase, biotinoyl and the carboxyl transferase 
(N and C terminal) amino acid sequences. Sequence similarity serach was carried out by 
protein-protein basic local alignment search tool (pBLAST) on the NCBI web site using 
default parameters (Altschul et al., 1997) and aligned with ClustalW algorithm implemented 
on the BioEdit™ editor programme (v 7.0.9.0) using 1000 bootstrap analysis with  the  
Neighbor  Joining algorithm  (BioEdit™ v 7.0.9.0). Both alignment programmes run on the 
ClustalW™ algorithm (Thompson et al., 1994). 
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2.7.2 Three-dimensional homology modelling 
A three-dimensional (3D) model for the P. yoelii 17XNL biotin carboxylase and carboxyl 
transferase domains, as well as the P. yoelii 17XL biotinoyl domains were constructed by 
comparative (homology) modelling  using the SWISS-MODEL™ automated server (Kopp 
and Schwede, 2004). The biotin carboxylase and the carboxylase transferase 3D models were 
built using the crystal structure of Saccharomyses cerevisiae cetyl-CoA carboxylase biotin 
carboxylase domain (PDB ID: 1w93, 2.5 Å resolution, resolved by X-ray diffraction; (Zhang 
et al., 2004; Zhang et al., 2003) and acetyl-CoA carboxylase carboxyl transferase domain 
(PDB ID: 1bdo, 2.7 Å resolution, resolved by X-ray diffraction; (Shen et al., 2004) as 
templates, respectively. The 3D structure of the biotinoyl domain was built using the E. coli 
acetyl-CoA carboxylase biotinoyl protein as template (PDB ID: 1bdo, 1.8 Å resolution, 
resolved by X-ray diffraction method; (Athappilly and Hendrickson, 1995). The ClustalW™ 
(Thompson et al., 1994) alignment file obtained between the target s quence (P. yoelii 
sequences) and the template sequences were submitted to he SWISS-MODEL™ alignment 
interface and the resulting model was downloaded as pdb file. Quality evaluations of the 
models were carried out by the atomic empirical mean force potential (ANOLEA™) 
algorithm (Melo and Feytmans, 1998) and the Ramachandran analysis available on the 
SWISS-MODEL™ server. The ANOLEA™ algorithm calculates the packing qualities of the 
amino residues in the 3D model. The 3D models were viewed and refined (GROMOS™) with 
the Swiss-pdb viewer v 3.7 (downloaded from the SWIS-MODEL™ server). ProCheck™ 
was used validate the models for proper stereochemical conformation of the residues. Imaging 
was carried out with Adobe Photoshop 7.0™. 
 
2.7.3 Phylogenetic tree construction 
The acetyl-CoA carboxylase amino acid sequences were uploaded into the CLC™ free 
workbench (downloaded from www.clcbio.com). The sequences were aligned using the 
ClustalW™ (Thompson et al., 1994) alignment tool present in the programme. The 
phylogenetic tree was constructed using the slow and accurate option, 1000 bootstrap analysis 
and the Neighbour Joining™ tree method. The tree diagram was downloaded as a PDF file 
and the image edited with the Microsoft™ image editor programme. 
  
2.7.4 Predict7™ epitope prediction 
The production of synthetic peptide vaccines and synthetic peptide antigen for antibody 
production relies on precise prediction of the antigen c sites on a protein molecule (Stern 
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1991). Immunogenic regions on P. yoelii 17XNL acetyl-CoA carboxylase and the P. yoelii 
17XNL lactate dehydrogenase were predicted using the Predict7™ (Cármenes et al., 1989) 
prediction programme. The programme calculates seven features of an amino acid sequence 
namely: antigenicity (Welling and Fries, 1985; Welling et al., 1985), hydrophilicity (Hopp 
and Woods, 1981), side chain flexibility, surface probability (Emini et al., 1985), hydropathy, 
secondary structure and N-glycosylation sites. For this study, P. yoelii 17XNL acetyl-CoA 
carboxylase and the P. yoelii 17XNL lactate dehydrogenase sequences (saved as text files) 
were uploaded in the programme and regions satisfying anitgenicity, hydrophilicity, surface 
probability and side chain flexibility criteria were selected. The prediction file was saved as a 
text file and the graphics of the four predictions were plotted using Microsoft Excel™ 
programme. Protein-protein BLAST were carried out on the chosen peptide to ensure that the 
peptide sequence is absent in G. gallus (antibody production host) and M. musculus (parasite 
host). Cysteine residue was added to the peptide sequence to enable conjugation to a carrier 
molecule. 
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CHAPTER 3 
DETECTION OF PLASMODIUM YOELII (17XL) ACETYL-COA CARBOXYLASE 
mRNA 
 
3.1 Introduction 
The sequencing of the P. falciparum 3D7 genome as well as the partial sequencing of the 
genome of the other Plasmodium species has in many ways enhanced research in malaria 
aimed at identifying new metabolic targets or pathways for both vaccine and 
chemotherapeutic intervention against malaria (Di Girolamo et al., 2005; Gardner, 1999; 
Gardner et al., 2002a; Ginsburg, 2006; Hoffman et al., 1998). One metabolic pathway that has 
not been well explored is the de novo synthesis of fatty acids in the Plasmodium parasite 
(Gornicki, 2003; Tong and Harwood, 2006). Whether the Plasmodium parasite initiates de 
novo fatty acid biosynthesis from acetyl-CoA precursor has yet to be shown experimentally 
and would require the detection of the acetyl-CoA carboxylase mRNA transcript and protein. 
Published genome sequences of several Plasmodium species showed the presence of a gene, 
which codes for the enzyme (Plasmodb data base). However there appeared to be inconsistent 
annotation of the enzyme in several Plasmodium acetyl-CoA carboxylase orthologues as well 
as partial sequence of the gene in some Plasmodium species such as P. berghei and P. 
chabaudi (Plasmodb data base).  
 
The study was designed to demonstrate (i) that the mRNA transcript that codes for acetyl-
CoA carboxylase is present using reverse transcriptase PCR (RT-PCR) and (ii) that by using 
Northern blot analysis, the size of the transcript, which may be larger than the predicted 
8.7 kb ORF due to untranslated regions, can be established. The study also looked at whether 
the Plasmodium acetyl-CoA carboxylase is a multi-enzyme-domain type acetyl-CoA 
carboxylase found in eukaryotes including mammals, insect, yeast and some green plants or 
the multi-enzyme-subunit (complex) acetyl-CoA carboxylase form found in bacteria and 
some dicotyledonous green plants (Jelenska et l., 2001; Sasaki and Nagano, 2004; Thelen et 
al., 2001).  
 
3.2 Results 
3.2.1 Primer design and detection of acetyl-CoA carboxylase mRNA by RT-PCR 
PY01695, as illustrated in the Plasmodb database, is an 8.7 kb oligonucleotide open reading 
frame. The primary transcript is made up of two 8.5kb and 221 bp exons separated by a 
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235 bp intron at the 3’ end of the gene. Figure 3.1 illustrates the 18.8 kb partially sequenced 
chromosome 13 of P. yoelii strain 17XNL, which consist of PY01695, the gene coding for 
acetyl-CoA carboxylase. The positions of the primers relative to the ORF are as follows: 
PyACCBC-fwd: bp 1275 to bp 1313; PyACCBC-rev: bp 266  to bp 2699; PyACCntCxT-
fwd: bp 6729 to bp 6761; PyACCntCxT-rev: bp 7390 to bp 7426; PyACCctCxT-fwd: bp 7513 
to bp 7545 and PyACCctCxT-rev: bp 8605 to bp 8640 (relative to bp 8840 to bp 8876 on the 
primary transcript). Table 3.1 shows the primer sequences and properties. Figure 3.2 
illustrates the position of PyACCctCxT-rev on the ORF of the enzyme with respect to the 
acetyl-CoA carboxylase gene.  
 
RT-PCR was carried out with Improm IITM (Promega) reverse transcriptase kit using P. yoelii 
total RNA isolated from purified parasites (Section 2.5.2). The first strand was amplified with 
oligodT or random oligonucleotide hexamers provided by the kit according to the 
manufacturer’s instruction. The reverse transcriptase product from both oligodT and random 
oligonucleotide hexamers were subsequently used for PCR amplification using the primers in 
Table 3.1. The amplified PCR product was resolved by electrophoresis on a 1% agarose gel. 
Figure 3.3 shows the electrophoregram of the RT-PCR. PyACCBC primers (forward and 
reverse) amplified a product approximately 1500 bp, PyACCntCxT primers amplified a 
700 bp product and PyACCctCxT primers amplified a product estimated at 1150 bp. The PCR 
products were purified from agarose gel and sequenced using the primers corresponding to 
each product. The two sequences corresponding to the 5’ and 3’ directions were merged and 
compared to the published sequence of P. yoelii PY01695 using the ClustalW™ algorithm 
(Figures 3.4 – 3.6). The results confirmed the products amplified by RT-PCR corresponded to 
the expected regions. However, the products appeared to be more identical to P. berghei 
acetyl-CoA carboxylase sequence by BLAST analysis. 
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Figure 3.1 Schematic illustration of the MALPY00458 region of P. yoelii and PY01695 mRNA 
transcript . The positions of the primers (▬) are shown to correspond to the region on the protein 
encoded by the amplified products. The figures above the ORF represent the length (bp) of the two 
exons (1 – 8514 and 8749 – 8970).  
18.8 kb partially sequenced 
MALPY00458 (chromosome 13) 
PY01695 mRNA 8.7 kb ORF coding for 
Acetyl-CoA carboxylase 1 precursor-related 
1424 bp
cDNA
699 bp 
cDNA
1128 bp
cDNA
Biotin carboxylase BCCP Carboxyl transferase 
1 8514
8742 8970 
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Table 3.1 Primers used to amplify the biotin carboxylase, N-terminal and C-terminal carboxyl transferase domains of P. yoelii acetyl-CoA carboxylase by 
RT-PCR 
Primer Sequence (5’ → 3’) size  
(bp) 
Tm 
(ºC) 
Protein domain region of the 
amplified cDNA 
PyACCBC-fwd GCTAATAATGGTATGGCTGCATTAAAATGTATATTGTC 38 63 Biotin carboxylase 
PyACCBC-rev GCAATTTCTCTTGTTTCCCCTTTTGCAAATATATGGCC 38 71 Biotin carboxylase 
PyACCntCxT-fwd GGAAATAGGACAAAATAAAATGAGCGTAATCGG 33 64 N-terminal carboxyl transferase 
PyACCntCxT-rev GAGATATTCCATTTTTCATCATAATATTTACACCTCC 37 62 N-terminal carboxyl transferase 
PyACCctCxT-fwd GATGTTCTTGGGGAATCAACAAAATCATTTCAC 33 66 C-terminal carboxyl transferase 
PyACCctCxT-rev CTCCTTCATACATGATGATACATCATGTAGATCTGC 36 64 C-terminal carboxyl transferase 
 
 
 
 
 81 
 
PyACC-ORF.       TGCAGATACTAATAGTAAAGGTGGAATATTAGAACCTCCAGGATTAGTAGAAGTCAAATT 8432 
MALPY00458.      TGCAGATACTAATAGTAAAGGTGGAATATTAGAACCTCCAGGATTAGTAGAAGTCAAATT 9840 
                 ************************************************************ 
 
PyACC-ORF.       TAAGTTCGCAGAAATTAAGAAATTAATGAATAACAGTGATCCATATATAATAGAACTAAA 8492 
MALPY00458.      TAAGTTCGCAGAAATTAAGAAATTAATGAATAACAGTGATCCATATATAATAGAACTAAA 9900 
                 ************************************************************ 
 
PyACC-ORF.       TCAGAAACTCGCGACTCTTCAG-------------------------------------- 8514 
MALPY00458.      TCAGAAACTCGCGACTCTTCAGGTAAACCAATAAATATTCATAATAAGAATTGAAAGATT 9960 
                 **********************                                       
 
PyACC-ORF.       ------------------------------------------------------------ 
MALPY00458.      ATTAAAATAAAAGAATCAAATGAATAATAAAAGTAGATTGTTACATGCATGATACTCTAT 10020 
                                                                              
 
PyACC-ORF.       ------------------------------------------------------------ 
MALPY00458.      ATTTAAAAATTATGCAAAGTGAATATATGCATATTTATGAATTCGTTTTATATGGAAATA 10080 
                                                                              
 
PyACC-ORF.       ------------------------------------------------------------ 
MALPY00458.      TAAATACCTATTTACTATTATTACTTTTTGTATTGTGGCGTTTTTATTTCTTTTTTCAAT 10140 
                                                                              
 
PyACC-ORF.       ----------------AATGAAGAAGAAATTTTAAGTGTAAAAAAGGAAATAGAAAAGAA 8558 
MALPY00458.      TTTTTATTTTTTTTAGAATGAAGAAGAAATTTTAAGTGTAAAAAAGGAAATAGAAAAGAA 10200 
                                 ******************************************** 
 
PyACC-ORF.       GGAAAAGGAAATGCTTCCATTTTATTTACAAGTGTGTCATAAATATGCAGATCTACATGA 8618 
MALPY00458.      GGAAAAGGAAATGCTTCCATTTTATTTACAAGTGTGTCATAAATATGCAGATCTACATGA 10260 
                 ************************************************************ 
 
PyACC-ORF.       TGTATCATCATGTATGAAGGAGAAAGGTGTTATTAGAAAAATTGTTCCATGGGAAAAATC 8678 
MALPY00458.      TGTATCATCATGTATGAAGGAGAAAGGTGTTATTAGAAAAATTGTTCCATGGGAAAAATC 10320 
                 ************************************************************ 
 
PyACC-ORF.       TAGATCCTTTTTCTATTATCGCTTATTAAGGAGATTGATATTACATACATTAAAGTAA-- 8736 
MALPY00458.      TAGATCCTTTTTCTATTATCGCTTATTAAGGAGATTGATATTACATACATTAAAGTAAGG 10380 
                 **********************************************************   
 
 
Figure 3.2 ClustalW™ alignment of MALPY00458 with PY01695 (PyACC-ORF) showing the 
position of PyACCctCxT-rev primer on the ORF.  The position of PyACCctCxT-rev primer is 
highlighted (yellow) and the intron sequence is in bold. Note that the reverse complement of the primer is 
indicated. MALPY0048 is the Plasmodb accession number of the chromosome where the PY01695 ORF 
is located. 
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Figure 3.3 Agarose gel electrophoregram of RT-PCR products from PY01695. (A) Reverse 
transcriptase first strand synthesis was carried out using random oligonucleotide hexamers (lanes 1 – 4) or 
oligodT primers (lanes 5 – 8) and PCR was carried out with primer set PyACCBC (Lane1/5), 
PyACCntCxT (lane 2/6) and PyACCctCxT (lane 3/7). No template control amplified with PyACCctCxT 
(lane 4/8). (B) RT-PCR amplification of PyLDH cDNA (850 bp) as a control. Amplification products were 
resolved on a 1% (w/v) agarose gel. 
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PY01695.          AAAAAATTATTAATTGCTAATAATGGTATGGCTGCATTAAAATGTATATTGTCATTAAAA 1320 
RT-PCR-PyBC.      ----------------------------------------------------------AA 2 
                                                                            ** 
 
PY01695.          GAATGGTTATTTAAAACATTTAATGATGAAAATTTGATACAAATAATAGTGTTAGCTACT 1380 
RT-PCR-PyBC.      GCATGGTTATTTAAA-CATTTAATGATGAGAATTTGATACAAATAATAGTATTAGCTACT 61 
                  * ************* ************* ******************** ********* 
 
PY01695.          GAAGATGATATAAAAAGTAATTCCAAATACATATCTTTATCAGATAAAGTTATTAAAGTT 1440 
RT-PCR-PyBC.      GATGATGATATAAAAAGTAATTCCAAGTACATATCTTTATCAGATAAAGTTATTAAAGTT 121 
                  ** *********************** ********************************* 
 
PY01695.          CCACCGGGAAAAAACAGTTATAATTATGCAAATGTTTCTTTAATTGTTGACATTGCAAAA 1500 
RT-PCR-PyBC.      CCCCCTGGAAAAAACTGTTATAATTATGCAAATGTTTCTTTAATTGTTGACATTGCAAAA 181 
                  ** ** ********* ******************************************** 
 
PY01695.          AAAGAAAATGTTGATGCAGTTTGGCCAGGTTGGGGACATTGCTCAGAAAATCCATTATTG 1560 
RT-PCR-PyBC.      AAAGAAAAGGTTGATGCAGTCTGGCCAGGTTGGGGACATTGCTCGGAAAATCCATTATTG 241 
                  ******** *********** *********************** *************** 
 
PY01695.          TCATCTATGCTAGAAAAGGAAAATATAATTTTTGTTGGACCGACTGATAATGTTATGGAA 1620 
RT-PCR-PyBC.      TCATCCATTCTAGAAAAGGAAAATATAATTTTTGTTGGGCCAACTGATACCGTTATGGAA 301 
                  ***** ** ***************************** ** *******  ********* 
 
PY01695.          GCATTAGGTGATAAAATATCAGCCAACATTTTAGCTCAAAGTGTTAATGTACCTGTTGTT 1680 
RT-PCR-PyBC.      GCATTAGGTGATAAAATATCAGCCAACATTTTAGCTCAAAGTGTTAATGTACCTGTTGTT 361 
                  ************************************************************ 
 
PY01695.          AAATGGAGTGGCGATAATTTAAAAATTAAAGATTTTGAAAATAATTCAATTAGTCAAGAT 1740 
RT-PCR-PyBC.      AAATGGAGTGGCGATAATTTAAAAATTAAAGATTTTGAAAATAATTCAATTAATCAAGAT 421 
                  **************************************************** ******* 
 
PY01695.          ATATATAATAAATCTACTATTCATTCGTTAGAAGAATGTATCAGAGAATGCAAAAGGATT 1800 
RT-PCR-PyBC.      ATATATAATAAATCTACTATTCATTCGTTAGAAGAATGTATCAGTGAATGCAAACGGATT 481 
                  ******************************************** ********* ***** 
 
PY01695.          GGCTATCCTGTTATGATAAAAGCGTCACAAGGTGGTGGTGGTAAAGGTATTCGAAAGGTA 1860 
RT-PCR-PyBC.      GGCTATCCCGTTATGATAAAAGCGTCGCAAGGTGGTGGTGGGAAAGGTATTCGAAAGGTA 541 
                  ******** ***************** ************** ****************** 
 
PY01695.          GAAAACGAAAATGAAATAAAAAAATATTATGAACAAGTTCAAAATGAATTACCAAATTCA 1920 
RT-PCR-PyBC.      GAAAACGAAAATGAAATAAAAAAATATTATGAACAAGTTCAAAATGAATTACCAAATTCA 601 
                  ************************************************************ 
 
PY01695.          CCAATATTTTTAATGAAAGTATGTAGCAATGTTAGACATATTGAAATACAAGTTGTTGGT 1980 
RT-PCR-PyBC.      CCAATATTTTTAATGAAATTATGTAGCAATGTTAGACATATTGAAATACAAGTTGTTGGT 661 
                  ****************** ***************************************** 
 
PY01695.          GATATGTATGG-AAATGTTTGTTCATTAAGTGGTAGAGATTGTACTACACAAAGACGATT 2039 
RT-PCR-PyBC.      GATATGTATGGGAAATGTTTGCTCATTAGTGGTAAGAGATTGTACTACCCAAAGACGATT 721 
                  *********** ********* ******   *  ************** *********** 
 
PY01695.          TCAAAAAATATTTGAAGAGGGACCACCTTCTATTGTTCCTCCACATACTTTTAGAGAAAT 2099 
RT-PCR-PyBC.      TCAAAAAATATTTGAAGAGGGGCCACCATCTATTGTTCCTCCACATACTTTTAGAGAAAT 781 
                  ********************* ***** ******************************** 
 
 
Figure 3.4 Alignment of PY01695 ORF with the product of biotin carboxylase RT-PCR 
amplification . RT-PCR-PyBC is the merged sequences corresponding to the forward and the reverse 
primer sequencing products. Approximately 700 bp were sequenced in both directions.* indicates 100% 
conserved nucleotide.  
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PY01695.          GGAAAAAGCATCTATACGTTTAACAAAAATGATCAAATATAGAGGTGCAGGAACCATTGA 2159 
RT-PCR-PyBC.      GGAAAAAGCATCTATACGTTTAACAAAAATGATCAAATATAGAGGTGCGGGAACCATTGA 841 
                  ************************************************ *********** 
 
PY01695.          ATATTTATATGATCAAGTTAATAACAAATATTATTTTTTAGAATTAAATACCCGTTTACA 2219 
RT-PCR-PyBC.      ATATTTATATGATCAAGTTAATAACAAATATTATTTTTTAGAATTAAATACTCGTTTACA 901 
                  *************************************************** ******** 
 
PY01695.          AGTAGAGCATCCTGTTTCAGAAGGAATAACAGATACCAATATTGTCGCTATTCAACTTCA 2279 
RT-PCR-PyBC.      AGTAGAGCATCCCGTTTCAGAAGGAATAACAGATACCAACATTGTTGCTATTCAGCTTCA 961 
                  ************ ************************** ***** ******** ***** 
 
PY01695.          AGTTGCTATGGGCATACCTCTTCAAAATATAGATGATATAAAAAAATTATATAAAATAGA 2339 
RT-PCR-PyBC.      AGTTGCTATGGGTATACCTCTTCAAAATATAGATGATATAAAAAAATTATATAAAATAGA 1021 
                  ************ *********************************************** 
 
PY01695.          AGAGAAAACAAAAAAAAACACATCGTCAAGCAGTGTTAGTATTGTAAATGATAAGTTAAA 2399 
RT-PCR-PyBC.      AGAGAAAACAAAAAAAAATACATCGTCAAGCAGTGTTAGTAGTGTAAATGATAAGTTAAG 1081 
                  ****************** ********************** *****************  
 
 
PY01695.          ACTTCCAATAAGCGAAAAAGATAATAATAAAACAGTGAAAACTAATTTGAGTGAACAACT 2459 
RT-PCR-PyBC.      ATTTCCAATAAGCGAAAAAGATAATAATAAAATAGTGAAAACTAATTTGAGTGAACAACT 1141 
                  * ****************************** *************************** 
 
PY01695.          TGGCATGTTTGATTTTTACAACAACATGCCCCACACTAAAAATCATGTTATTGCTGCTCG 2519 
RT-PCR-PyBC.      TGACATGTTTGATTTTTACAACAACATGCCACACACTAAAAATCATGTTATTGCTGCTCG 1201 
                  ** *************************** ***************************** 
 
PY01695.          AATAACAGCCGAAAACAGTAATGATAGTTTTAAACCAACGTCAGGCTTAGTAAAAAATGT 2579 
RT-PCR-PyBC.      AATAACAGCCGAAAACAGCAATGATAGTTTTAAACCGACGTCAGGCTTAGTAAAAAATGT 1261 
                  ****************** ***************** *********************** 
 
PY01695.          TAATTTTCAAAATTCGAAAGATGTATGGGGTTATTTCTCTATCAATAATGGGTTTGTTCA 2639 
RT-PCR-PyBC.      TAATTTTCAAAATTCGAAAGATGTATGGGGTTATTTTTCTATCAGCAATTGGAATGAGGA 1321 
                  ************************************ *******  *** **  **   * 
 
PY01695.          TGAATTTTCAGATTCACAAATTGGCCATATATTTGCAAAAGGGGAAACAAGAGAAATTGC 2699 
RT-PCR-PyBC.      CGAATATACAGAGACA-----TCGCCACAGA----------------------------- 1347 
                   **** * ****  **     * **** * *                              
 
                                                 
Figure 3.4 continued. 
 
 85 
PY01695.             AACTCTTTGGAAATAGGACAAAATAAAATGAGCGTAATCGGATTGTTAATGAATGTAAAG 6780 
RT-PCR-PyntCxT.      ----------------------------------------------TTATGTATGGTAAG 14 
                                                                   * *** ***  *** 
 
PY01695.             ACAGATGAATATAAAGAAGGAAGAGATATTGCTTTTATAATAAATGATATTACAACAAAT 6840 
RT-PCR-PyntCxT.      ACAGATGA-TATAAAGAAGGAAGAGATATTGCTTTTATAATAAATGATATTACAACCAAT 73 
                     ******** *********************************************** *** 
 
PY01695.             GGAGGTGCATTTAGTGTTTTAGAAGACGAACTATTTTATGGAGTATCATGTTATGCGAGA 6900 
RT-PCR-PyntCxT.      GGAGGTGCATTTAGTGTTTTAGAAGACGAACTATTTTATGGAGTATCATGCTATGCGAGA 133 
                     ************************************************** ********* 
 
PY01695.             GAAAAAAAAATACCACGTATATGTATATCTTGCAATTCCGGAGCAAAAATTGGATTATAT 6960 
RT-PCR-PyntCxT.      GAAAAAAAAATACCACGCATATACATATCTTGCAATTCCGGGGCTAAAATTGGATTATAT 193 
                     ***************** ****  ***************** ** *************** 
 
PY01695.             AATTATCTTATGGATAAAATTAAAGTATGCTGGAATGATGAAAACAAAAAAGAACTTGGA 7020 
RT-PCR-PyntCxT.      AATTATCTTATGGATAAAATTAAAGTATGCTGGAATGATGAAAATAAAAAAGAACTTGGA 253 
                     ******************************************** *************** 
 
PY01695.             TATAAATATATATATATAACAGAAGAAGTAAAAGAAACAATTCCTAAAAAAGATATTATT 7080 
RT-PCR-PyntCxT.      TATAAGTATATATATATAACAGAAGAAATAAAAGAAACAATTCCTAAAAAAGATATTATT 313 
                     ***** ********************* ******************************** 
 
PY01695.             TATTTAAGAGAAATTTATGAAAATGGAGAAAAAAGATATATAATTGATGCTATAGTAGGA 7140 
RT-PCR-PyntCxT.      TATTTAAGAGAAATTTATGAAAATGGAGAAAAAAGATATATAATTGATGCTATAGTAGGA 373 
                     ************************************************************ 
 
PY01695.             AATTTAAATAATCATATAGGAGTAGAAAATTTAAGAGGTAGTGGATTAATAGCAGGAGAA 7200 
RT-PCR-PyntCxT.      AATTTAAATAATCATATCGGGGTAGAAAATTTAAGAGGTAGTGGGTTAATAGCAGGAGAA 433 
                     ***************** ** *********************** *************** 
 
PY01695.             ACCTCAAAGGCTTATGATGAGATTTTTACTCTTTCATATGTCACTGGAAGAAGTGTTGGA 7260 
RT-PCR-PyntCxT.      ACCTCAAAGGCCTCCGATGAGACTTTTACTCTTTCATATGTCACTGGAAGAAGTGTTGGA 493 
                     *********** *  ******* ************************************* 
 
PY01695.             ATTGGTGCTTATTTAGTTAGATTAGGTAAACGAACTATTCAAAAAAAAGGATCGTCTCTT 7320 
RT-PCR-PyntCxT.      ATTGCTGCTTATTTCGTTAGATTAGGTAAACGAACTATTCAAAAAAAAGCATCCTCTCTT 553 
                     **** ********* ********************************** *** ****** 
 
PY01695.             TTACTAACTGGTTTTAATGCTTTAAATAAAATATTAGGTGAAAAGGTATATATAAGTAAT 7380 
RT-PCR-PyntCxT.      TTAA-AACCGGTTATAATGCAAGCAAAACTCTTCCGGCATAATAGTCATCTTCTAACATG 612 
                     ***  *** **** ******    ** *   *    *   ** **  ** *   *  *   
 
PY01695.             GAACAATTAGGAGGTGTAAATATTATGATGAAAAATGGAATATCTCAATTAGAAGCTGAA 7440 
RT-PCR-PyntCxT.      CATTAA------------------------------------------------------ 618 
                      *  ** 
 
 
Figure 3.5 Alignment of PY01695 ORF with the product of N-terminal carboxyl transferase RT-
PCR amplification. RT-PCR-PyntCxT is the merged sequences corresponding to the forward and the 
reverse primer sequencing products. * indicates 100% conserved nucleotide.  
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PyACC-ORF.           GACAATTATTTTGATGTTCTTGGGGAATCAACAAAATCATTTCACAATAAATTACAAGAA 7560 
RT-PCR-PyctCxT.      --------------------------------------------------ATTGCAAGAA 10 
                                                                       *** ****** 
 
PyACC-ORF.           GATAACAAATGTGATATTACCAAATCTAGAAACTTAAACAATTCAATTGATTCTGACCAA 7620 
RT-PCR-PyctCxT.      GATAGCAAATGTGATATTAGCAA-TCTAGAAACTTAAACAATTCAATTGGTTCTGATCAA 69 
                     **** ************** *** ************************* ****** *** 
 
PyACC-ORF.           CAATCCAATAATTATCCAAATGGATACATTAATGATCAAGACATACAAGAGTATGCAAAA 7680 
RT-PCR-PyctCxT.      GAATCCAATAATTATCCAACGGGATACACTAATGATCGAGGCATACAAGAGTATGTAAAA 129 
                      ******************  ******* ******** ** ************** **** 
 
PyACC-ORF.           AAGAACAGTTTGCACAGCAGTTCAGATAGTACTACTGTTGAACCAGAAAGTATCAAAGAA 7740 
RT-PCR-PyctCxT.      AAGAACAGTTTACACAGCAGTTCAGATAGTACTACTGTTGAACCAGAAAGTATCAAAGAA 189 
                     *********** ************************************************ 
 
PyACC-ORF.           TGTGATACTTCACTTATACACATCAATGGAAATAATGGTGATGAAGAATCAGGGAACGAA 7800 
RT-PCR-PyctCxT.      TGTGATACTTCACTTATGCACACCAATGAAAAAAATGGTGATGAAGAATCAGGGAACGAA 249 
                     ***************** **** ***** *** *************************** 
 
PyACC-ORF.           ATTAGTGATACGATTTCAGATAACTGGAACAAAATAAATGATGTAGATATGGACAATGTA 7860 
RT-PCR-PyctCxT.      ATTAGTGACATCATTCCAGATAACTGGAACAAAATAAATGATGTAGATATGGAAAATGTA 309 
                     ******** *  *** ************************************* ****** 
 
PyACC-ORF.           AATGAAGCAGATATTATCGAATTACTAAAAGGGTCAGATAAAAAACAAGGATTTTTAGAC 7920 
RT-PCR-PyctCxT.      AATGAAGCAGATATCATCGAATTACTAAAAGGGTCAGATAAAAAACAAGGATTTTTAGAT 369 
                     ************** ********************************************  
 
PyACC-ORF.           AAAAATAGTTACTTTGAATATATGAATGAATGGGGAAAAGGTATTATAACTGGAAGAGGA 7980 
RT-PCR-PyctCxT.      AAAAATAGTTACTTTGAATATATGAATGAATGGGGAAAAGGTATTATTACTGGAAGAGGA 429 
                     *********************************************** ************ 
 
PyACC-ORF.           AAA-TTAGGATCAATACCAATTGGTTTTATTGCTGTAA-ATAA--AAATTTAGTTACCCA 8036 
RT-PCR-PyctCxT.      AAAATTAGGATCAAAACCAATTGGTTTTTTTGTTGGGGGATGAGGAAATTTCCTCACCCG 489 
                     *** ********** ************* *** **    ** *  ******  * ****  
 
PyACC-ORF.           AACTGTTCCATGTGATCCAGCATTGAAAACTAAGGCTATAAAAACAACAAATGCCCCATG 8096 
RT-PCR-PyctCxT.      G-CGGAACCATGTGATCCAGTATCGAAAACTAAGGCTATAAGAATTAAAAATGCCCCATG 548 
                       * *  ************* ** ***************** **  * ************ 
 
PyACC-ORF.           TGTTTTTGTGCCTGATAATTCGTACAAAACTGCCCAATCTATTGAAGATTTTAATAAAGA 8156 
RT-PCR-PyctCxT.      ---TTTGTCGCCTAAGAAATCGGGAAAGCTTGCCCTTTCTATTGAAAGTTTTAATAAAGA 605 
                        ***   **** * ** ***   **   *****  *********  ************ 
 
PyACC-ORF.           AAATT-TACCTTTATTTGTCTTTGCAAATTGGAGAGGTTTTTCAGGAGGTACTATGGATA 8215 
RT-PCR-PyctCxT.      CACTCCTACCCCTTTCTTATTTTCCAACTGGACGAGGTTTTTCCGGAGGTACTAAGGATA 665 
                      * *  ****  * * *   *** *** * *  ********** ********** ***** 
 
PyACC-ORF.           TGTTTAACAGTAT-CTTAAAATTTGGATCAATGATAGTTAATCAATTAGTTAATTATAA- 8273 
RT-PCR-PyctCxT.      CCTTTACCCGTATTCTTACAGTTTGGATCAATGATAGTTAATCAATTAGTTAATTATAAA 725 
                       **** * **** **** * **************************************  
 
PyACC-ORF.           GCATCCCG--TTTTTGTATACATACCTATTTTGGGAGAACTTAGAGGTGGGTCTTGGGTA 8331 
RT-PCR-PyctCxT.      GCATCCCCGTTTTTTGTATACATACCTATCTTTGGAGAACTTAGAGGTGGATCTTGGGTA 785 
                     *******   ******************* ** ***************** ********* 
 
 
 
Figure 3.6 Alignment of PY01695 ORF with the product of C-terminal carboxyl transferase RT-
PCR amplification. RT-PCR-PyctCxT is the merged sequences corresponding to the forward and the 
reverse primer sequencing products. Approximately 500 bp were sequenced in both directions.* indicates 
100% conserved nucleotide. (▼) represents the splicing point of the exons.  
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PyACC-ORF.           GTAGTAGATGAAACATTGAACAGCCAAATAATAGAAATGTATGCAGATACTAATAGTAAA 8391 
RT-PCR-PyctCxT.      GTAGTAGATGAAACATTGAACAGCCAAATAATAGAAATGTATGCAGATAATAATAGTAAA 845 
                     ************************************************* ********** 
 
PyACC-ORF.           GGTGGAATATTAGAACCTCCAGGATTAGTAGAAGTCAAATTTAAGTTCGCAGAAATTAAG 8451 
RT-PCR-PyctCxT.      GGTGGAATATTAGAACCTCCAGGATTAGTAGAAGTCAAATTTAAGTTCGCAGAAATTAAG 905 
                     ************************************************************ 
 
PyACC-ORF.           AAATTAATGAATAACAGTGATCCATATATAATAGAACTAAATCAGAAACTCGCGACTCTT 8511 
RT-PCR-PyctCxT.      AAATTAATGAATAACAGTGATCCATATATAATAGAACTAAATCAGAAGCTCGCGACTCTT 965 
                     *********************************************** ************ 
                       ▼ 
PyACC-ORF.           CAGAATGAAGAAGAAATTTTAAGTGTAAAAAAGGAAATAGAAAAGAAGGAAAAGGAAATG 8571 
RT-PCR-PyctCxT.      CAGGATGACCAATAAATATTCATAATAAGAATTGAAATAAGATTAAAATCAACGAATATG 1025 
                     *** ****  ** **** ** *   *** **  ******  *   **   ** * * *** 
 
PyACC-ORF.           CTTCCATTTTATTTACAAGTGTGTCATAAATATGCAGATCTACATGATGTATCATCATGT 8631 
RT-PCR-PyctCxT.      CTTC-ATTTATTTAACAAATGAATAATAAAAGTATAGATCTACAAGATGCATGATACTCT 1084 
                     **** ****  ** **** **  * *****  *  ********* **** ** **  * * 
 
PyACC-ORF.           ATGAAGGAGAAAGGTGTTATTAGAAAAATTGTTCCATGGGAAAAATCTAGATCCTTTTTC 8691 
RT-PCR-PyctCxT.      ATGAAGGAAAAAGGTGTTATTAGCAAAGTTAATATATGT-ATATTTCTGAATTCATTTTA 1143 
                     ******** ************** *** **  *  ***  * *  ***  ** * ****  
 
PyACC-ORF.           TATTATCGCTTATTAAGGAGATTGATATTACATACATTAAAGTAA 8736 
RT-PCR-PyctCxT.      TGTGATCGCTTACTTAGGAAACT---------------------- 1166 
                     * * ******** * **** * *   
 
Figure 3.6 continued. 
 
 
3.2.2 Detection of acetyl-CoA carboxylase gene transcript by Northern blot analysis 
Total RNA isolated from P. yoelii, T. congolense and PyBCCP (Chapter 5) was resolved along 
side RNA standard markers by agarose gel electrophoesis. Figure 3.7A shows the 
electrophoregram prior to blotting onto a nitrocellulose membrane. P. yoelii total RNA (lane 1) 
consist of four bands; a band greater than 9 kb as well as three bands estimated at 2.8 kb, 2 kb 
and 0.7 kb. These three bands may correspond to P. yoelii large subunit ribosomal RNA (28S 
rRNA), small subunit ribosomal RNA (18S rRNA) and possibly the fragment of 28S rRNA 
(Dame and McCutchan, 1983; van Spaendonk et al., 2001). The band greater than 9 kb may be 
mRNA transcripts of large polypeptide of ± 500 kD.  Four major bands were observed in lane 2 
containing T. congolense total RNA control. These bands were estimated to be 2.2 kb, 1.4 kb, 
1 kb and 0.7 kb corresponding to 18S rRNA, 28S rRNA (α-fragment), 28S rRNA (β-fragment) 
and the cleavage product of 28S rRNA (Hasan et al., 1982; Urakawa and Majiwa, 2001). A band 
of approximately 3 kb corresponding to the P. yoelii biotinoyl domain cDNA was observed in 
lane 3; though the cDNA appeared to be partially degraded.  
 
 88 
The presence of P. yoelii acetyl-CoA carboxylase transcript in the total RNA preparation was 
confirmed by enhanced-chemiluminescence detection usi g avidin-peroxidase-p iodophenol 
system for detecting the presence of hybridized probes on the membrane (Figure 3.7B). Panel B 
and D was exposed to X-ray film for approximately 30 min while panel C was exposed for less 
than 5 min. A band greater than 9 kb was prominent in both lanes, however the size of the bands 
were different. This may be due to variation in exptression level of the enzyme at various stages 
of the parasite debelopment (Le Roch).  
 
 
 
Figure 3.7 Detection of P. yoelii acetyl-CoA carboxylase transcript by Northern blot analysis. (A) 
Agarose gel analysis of P. yoelii total RNA (lane 1) and T. congolense total RNA (lane 2). The molecular 
weight standards are shown (lane Mw). Agarose gel concentration was 1.2%. The arrow indicates a band 
above the 9 kb marker. Northern blot analysis of P. yoelii total RNA (B - C) and T. congolense total RNA 
(D). Lane 1 panel B contains 55.0 µg total RNA from predominantly trophzoites and schizonts; lane 2 
panel B contains 55.0 µg total RNA from ring stage. Lane 1 panel C contains 25 µg total RNA from 
mixed stage. RNA in panels B and D were hybridised with biotinylated probes prepared from P. yoelii 
biotin carboxylase-biotinoyl domain cDNA, while RNA in panel C was hybridised with biotinylated 
probes prepared from P. yoelii lactate dehydrogenase cDNA. Hybridization was detect d with the avidin-
peroxidase-p-iodophenol enhanced chemiluminescence detection system.  
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A band of size 1.25 kb was detected in panel C corresponding to P. yoelii lactate dehydrogenase 
as positive control. No RNA was detected in the negative control (panel D) even though a higher 
quantity of RNA product was resolved compared to panel B. 
 
3.3 Discussion  
This chapter describes the application of reverse transcriptase-PCR (RT-PCR) and Northern blot 
analysis to investigate the expression of the gene that codes for acetyl-CoA carboxylase by P. 
yoelii strain 17XL. Primers were designed to amplify portions of the biotin carboxylase, N-
terminal and C-terminal carboxyl transferase domains of what is believed to be a gene encoding 
the P. yoelii multi-domain polypeptide acetyl-CoA carboxylase. Primers were designed based on 
the Plasmodb-published P. yoelii 17XNL PY01695 ORF sequence. The PCR products were 
sequenced to verify the RT-PCR results. Biotinylated probes prepared to hybridise with the 
region of the transcript encoding the biotinoyl domain were used to detect the presence and size 
of the transcript.  
There is no available information on the size of the large subunit ribosomal RNA (LSU rRNA) 
and small subunit ribosomal RNA (SSU rRNA) transcripts in P. yoelii. Only partial sequences 
are available on the NCBI and Plasmodb (Bahl et al., 2003) databases. Although the pattern of 
resolution on an agarose gel appeared to be consiste t with reports on P. berghei ribosomal RNA 
transcripts (Dame and McCutchan, 1983; van Spaendonk et al., 2001). Unlike in other organisms, 
some apicomplexan parasites produce ribosomes with structurally distinct rRNA molecules that 
are encoded on a single copy gene and expressed at different stages of the parasite development 
(Dame and McCutchan, 1983; McCutchan et al., 1988; McCutchan et al., 1995). In Plasmodium, 
the A-type ribosome is expressed at the liver and blood stages, while the O-type and S-type 
ribosomes are expressed at the insect stage (McCutchan et al., 1988; McCutchan et al., 1995). 
The transcript for the LSU rRNA in Plasmodium is cleaved to produce two subunits. In P. 
berghei, the sizes are 3 kb and 0.8 kb (Dame and McCutchan, 1983; van Spaendonk et al., 2001). 
The SSU rRNA is not cleaved. The results therefore suggest that P. yoelii strain 17XL may have 
a similar mechanism of post-transcriptional modification of the LSU rRNA. Thus the size of the 
LSU rRNA and the SSU rRNA in P. yoelii strain 17XL is approximately 3.5 kb (cleaved into 
2.8 kb and 0.7 kb fragments) and 2 kb, respectively. 
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Acetyl-CoA carboxylase in P. yoelii strain 17XNL is encoded by a single copy gene thatis 
located on chromosome 13 (Plasmodb database). First strand cDNA synthesis was carried out 
using either oligo-dT primers that annealed on the poly-A tail on the 3’untranslated region (UTR) 
of the transcript or random hexameric oligonucleotides. The two methods of first strand cDNA 
synthesis appeared to produce cDNA that was subsequently amplified by the primers positioned 
as illustrated on Figure 3.1. The PyACCctCxT primer pair was positioned to amplify the mRNA 
without the 235 bp intron at 3, end of the ORF (Figure 3.6). A proper negative control for this 
analysis would have involved using a reverse primer designed to anneal on the intron. However, 
the RNA samples were treated with DNase I to digest any residual genomic DNA before reverse 
transcriptase reaction. The size of the PCR products (Figure 3.3) and the sequencing data 
(Figures 3.4 – 3.6) clearly showed that the products were from an RNA transcript instead of 
genomic DNA. This therefore suggests that the blood stage P. yoelii transcribes the gene that 
encodes acetyl-CoA carboxylase. The copy number of the gene was not deduced in the study. 
Real time PCR could be used to quantify the amount f mRNA transcript, precisely at the various 
stages of the parasite life cycle. The blood samples used for the study contained a mixed stage P. 
yoelii infection; therefore stage-specific expression of the gene was not established. Previous 
studies (Le Roch et al., 2003) using P. falciparum as model showed that the gene is highly 
expressed at the gametocyte and sporozoite stages and minimally expressed at the 
intraerythrocytic stage of the parasite life cycle. P. yoelii is likely to have a similar expression 
profile. 
The details of the synthesis of fatty acids for membrane biogenesis at the intraerythrocytic stage 
of the parasite still remain to be evaluated. The high rate of morphological changes within the 
intraerythrocytic stage of the parasite is expected to be synonymous with increased membrane 
biogenesis (Mitamura and Palacpac, 2003; Palacpac et al., 2004), therefore suggesting high 
expression levels of the acetyl-CoA carboxylase gene (Davis et al., 2000; Hasslacher et al., 
1993). Does the expression level of acetyl-CoA carboxylase gene correlate with the expression 
levels of the genes encoding the enzymes of the Typ II fatty acid synthase complex? Using the 
expression pattern derived from an array experiment (Le Roch et al., 2003) it was observed that a 
similar pattern does exist between the expression pr file of acetyl-CoA carboxylase and the genes 
encoding enzymes of the fatty acid synthase complex (Figure 3.5) in P. falciparum; namely: 
malonyl-CoA-acyl carrier protein transacylase (FabD), beta-ketoacyl-acyl carrier protein 
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synthase III (FabH), 3-oxoacyl-(acyl-carrier protein) reductase (FabG) and beta-hydroxyacyl-
ACP dehydratase (FabA/Z). Beta-ketoacyl-acyl carrier protein synthase III precursor is yet to be 
identified in P. yoelii and P. vivax, and 3-oxoacyl-(acyl-carrier protein) reductase is yet to be 
identified in other Plasmodium species. There was no data on the expression profiles of enoyl-
ACP reductase (FabI) and FabB/F (Le Roch et al., 2003). 
The pattern of expression of the genes for Type II FAS clearly suggests that the rate of de novo 
fatty acid biosynthesis is lower at the blood stage nd higher at the gametocyte and sporozoite 
stages. Acetyl-CoA carboxylase and FabD mRNA transcripts were not detected at the ring and 
merozoite stages (Le Roch et al., 2003).  Perhaps this information validates previous postulates 
that the parasite scavenges lipid precursors from the hosts at the intraerythrocytic stage without 
the need for de novo fatty acid biosynthesis (Beaumelle and Vial, 1988a; Beaumelle and Vial, 
1988b; Beaumelle t al., 1988; Paula Simões et al., 1993; Simões et al., 1990; Van der Schaft et 
al., 1987). To add to this, the pattern of expression of genes involved in the Type II fatty acid 
synthesis strongly suggests that the parasite increases de novo fatty acid biosynthesis at the 
gametocyte and sporozoite stages. These stages occur predominantly at the insect stage and thus 
fatty acid synthesis may be increased at these stags probably due to lack of lipid precursors in 
the mosquito vector. Could this be an energy saving mechanism the parasite employs at the blood 
stage? This question could be answered by analysing the expression levels of the genes involved 
in the Type II fatty acid synthase and the acetyl-CoA carboxylase gene in a lipid-free culture of 
synchronised Plasmodium parasites. The low level of expression of acetyl-CoA carboxylase at 
the trophozoite (blood) stage is to perhaps make up the fatty acids that the parasite may have been 
unable to obtain from the host. This can be explored by knocking out the acetyl-CoA carboxylase 
gene in the parasite and monitoring parasite survival. 
Phospholipase C, glycerophosphodiester phosphodiesterase, diacylglycrol kinase, acyl-CoA 
synthase and diacylglycerol-O-acyltransferase are some key enzymes involved in the metabolism 
of imported lipid precursors (Mitamura and Palacpac, 2003; Palacpac et al., 2004) such as 
phosphatidylserine, phosphatidylcholine, diacylglycerol and fatty acids in P. falciparum 
(http://sites.huji.ac.il/malaria/maps/phserine). 
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These metabolites are involved in the biosynthesis of phospholipids used in membrane biogenesis 
(Holtz, 1977; Ke et al., 2000b; Mitamura and Palacpac, 2003). The transcription profiles (data 
not shown) of the genes encoding these enzymes show that they are more highly expressed at the 
intraerythrocytic stage, than in the gametocyte and the sporozoite stages of the parasite (Le Roch 
et al., 2003). This is in contrast to the expression profiles of the acetyl-CoA carboxylase and 
Type II fatty acid synthase genes. As a result membrane biogenesis at the intraerythrocytic stage, 
which has been shown to be high at this stage (Moll et al., 1988; Moll et al., 1990; Van der 
Schaft et al., 1987; Vial et al., 1988), may utilize imported lipid precursors instead of those 
produced by a de novo acetyl-CoA carboxylase-Type II fatty acid synthase pathway. 
The RT-PCR results were further supported by the Northern blot analysis. Biotinylated (“cold”) 
probes were prepared with Klenow fragment (Feinberg and Vogelstein, 1983) using 
decanucleotide primers supplied by the manufacturer to the enhance specificity of hybridisation 
Figure 3.8 Expression profile of five genes involved in fatty acid synthesis in P. falicparum. 
The expression levels of acetyl-CoA carboxylase (    ), FabD (    ), FabH (    ), FabG (     ) and 
FabA/Z (    ) obtained by LeRoch et al. (2003). * represents average of the early and late st ges 
of the parasite. 
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between the target mRNA transcript and its corresponding probes. Enhanced chemiluminescence 
(ECL) used to detect presence of hybridisation using avidin-peroxidase-p iodophenol-luminol 
system due to the high affinity between avidin and biotin; thus eliminating the need for 
autoradiography. ECL is a highly sensitive technique and can detect targets at femtomole (10−15 
mole) quantity (Kricka and Thorpe, 1986a; Kricka and Thorpe, 1986b; Thorpe t al., 1985).   
The size of the published (Plasmodb) ORF of PY10695 gene is 8.7 kb. The size detected by 
Northern blot was above 9 kb. The presence of 5’ and 3’ untranslated regions (UTR) on the 
transcript may account for the size observed on the luminograph. Acetyl-CoA carboxylase has 
been shown to be regulated at the transcription level (Barber et al., 2003; Mao et al., 2003; 
Thampy and Wakil, 1988a; Wakil et al., 1983). The expression profile of acetyl-CoA carboxylase 
gene suggests that the Plasmodium acetyl-CoA carboxylase gene is inducible, depending o  the 
stage of the parasite development. Being an inducible gene, it is expected that the gene may 
contain regulatory regions upstream from the start codon or down stream from the stop codon 
that regulates the transcription of the gene. The presence of UTR in transcripts is not uncommon 
in Plasmodium. Several Plasmodium transcripts such as rif gene, heat shock proteins and DNA 
polymerase have 5’UTR ranging between 0.5 kb and 2 kb, which are transcriptionally or post-
transcriptionally regulated (Militello et al., 2004; Porter, 2001; Tham et al., 2007; Watanabe t 
al., 2002).  
In mammals, transcription of acetyl-CoA carboxylase genes are controlled by two to three sets of 
promoters upstream of the coding sequence (Barber et al., 2003; Mao et al., 2003). This results in 
heterogeneous populations of acetyl-CoA carboxylase transcripts in various tissues such as 
mammary gland, liver, adipose tissue and heart (Barber et al., 2003; Lopez-Casillas et al., 1989; 
Luo et al., 1989). This heterogeneity mostly occurs at the 5’ UTR region of the transcript (Lopez-
Casillas et al., 1989; Luo et al., 1989). Perhaps, the smearing effect observed on the Northern 
blot (Figure 3.7B) may be as a result of the presence of a heterogene us population of acetyl-CoA 
carboxylase transcripts; though there is no other evidence to support this. However, the 
heterogeneity in mRNA population due to differential processing of the 5’UTR region is also 
observed in Plasmodium (Pace et al., 1998). The size of the 5’ and 3’ flanking regions of the 
acetyl-CoA carboxylase gene was deduced from the Plasmodb database (Figure 3.9). It was 
observed that the 5’ flanking region between the initiation codon of the acetyl-CoA carboxylase 
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coding sequence and the adjacent coding sequence was consistent (~ 2.9 kb) in P. falciparum, 
vivax and knowlesi. The 5’ flanking region of P. yoelii was spread between two unassembled 
contiguous fragments of Chromosome 13, therefore the complete sequence was not obtained. The 
consistent length on the 5’ flanking region may suggest an organized structure containing 
transcription promoters and other regulatory elements. The AT-content 5’ flanking region of 
acetyl-CoA carboxylase gene in P. falciparum and yoelii (partial) is ~ 76%. Whereas the AT-
content of the 5’UTR flanking region of acetyl-CoA carboxylase gene in P. vivax and knowlesi is 
51% and 60%, respectively, with 77% sequence identity. The 5’ flanking regions of the acetyl-
CoA carboxylase gene in the four Plasmodium species contain very long streteches of A and T 
nucleotides. The size of the 3’ flanking regions was not consistent. Mapping of the 5’ and 3’ 
UTRs of acetyl-CoA carboxylase transcripts in Plasmodium by PCR may reveal the 
configuration of the promoter regions and possible mechanism of transcription of the gene at the 
various stages of the parasite development.  
 
 
Figure 3.9 The size of the 5’ and 3’ flanking regions of acetyl-CoA carboxylase gene locus in four 
Plasmodium species. Arrows represent gene coding regions pointing from 5’ to 3’ direction. Filled arrows 
represent acetyl-CoA carboxylase gene coding region, open arrows represent coding regions for 
hypothetical proteins and stripped arrow represents coding region for TATA modulatory element in the P. 
yoelii gene sequence. The 5’ and 3’ acetyl-CoA carboxylase flanking regions are represented by solid 
lines (adapted from Plasmodb database). 
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CHAPTER 4 
PLASMODIUM YOELII ACETYL-COA CARBOXYLASE: ANTIBODY PRODUCTION 
AND IMMUNODETECTION  
 
4.1 Introduction 
The P. yoelii acetyl-CoA carboxylase gene of strain 17XNL was identified in Plasmodb (ID: 
PY01695) and this study showed that the strain 17XL P. yoelii parasite produces an mRNA 
transcript that codes for the enzyme (Chapter 3). The enzyme can be detected by the presence of 
the biotin moiety using streptavidin or avidin-mediated detection, anti-biotin antibodies or an 
antibody directed against an immunogenic peptide within the enzyme. This may reveal the 
subcellular localisation of the enzyme that is believed to be targeted to the apicoplast.  
 
The challenge for designing a suitable peptide for antibody production in chickens as well as 
other hosts is to select a region of a protein sequence that fulfils the following criteria: (i) high 
surface probability (ii) hydrophilicity and (iii) the region must be flexible to assume a spatial 
orientation that is found in the native protein. Avoiding potential N-glycosylation sites of the 
protein may be useful in designing effective peptides for antibody production because of possible 
masking of the selected region on the native protein by the polysaccharide moiety. Anti-peptide 
antibodies produced in chickens against Plasmodium protein kinases have been shown to be 
effective tools in characterising several malaria parasite proteins (Dorin et al., 2005; Nunes et al., 
2007). A major obstacle faced in designing peptides from Plasmodium proteins for antibody 
production is the presence of multiple lysine residues in many Plasmodium proteins. Lysine-rich 
regions contribute to the high scores in the surface probability, hydrophilicity and flexibility 
algorithms. Antibodies made against such region may cross-react with several Plasmodium 
proteins and thus are avoided in peptide design. 
 
By use of the Predict7™ epitope prediction algorithm (Cármenes t al., 1989), a peptide from an 
immunogenic region of PyACC was designed and synthesised to generate anti-PyACC-peptide 
antibodies in chickens. It was necessary to avoid choosing a peptide from conserved regions of 
the enzyme to prevent possible cross-reactivity with mouse acetyl-CoA carboxylase. In a similar 
manner, anti-peptide antibody was produced in chickens against P. yoelii lactate dehydrogenase 
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(PyLDH). PyLDH is a metabolic protein (Zhou et al., 2004) expressed at high levels by the 
parasite (Le Roch et al., 2003).  These antibodies were used for the detection of acetyl-CoA 
carboxylase and lactate dehydrogenase in P. yoelii lysate resolved by SDS-PAGE and blotted 
onto nitrocellulose membrane and P. yoelii-infected mouse red blood cells by 
immunofluorescence microscopy.  
 
 
4.2 Results 
4.2.1 Selection of immunogenic peptide for anti-P. yoelii acetyl-CoA carboxylase antibody 
production in chickens 
Following sequence alignment, a peptide from the P. yoelii acetyl-CoA carboxylase that appeared 
to be unique to P. yoelii and absent in chicken and mammalian acetyl-CoA carboxylases was 
chosen by epitope prediction analysis using the Predict7™ software . The P. yoelii lactate 
dehydrogenase (PyLDH) peptide was selected as a comparison for this experiment using the 
same epitope prediction software. This LDH peptide appeared to be conserved across all 
Plasmodium lactate dehydrogenase orthologues examined and not present in chicken and mouse 
lactate dehydrogenase amino acid sequences.  
 
Figure 4.1A shows the ClustalW™ alignment of lactate dehydrogenas  sequences from 
Plasmodium, chicken and mouse. A region (residue 55 – 135) was plotted (Figure 4.1B) to show 
the surface probability, hydrophilicity and flexibil ty scores of the selected peptide (residues 85 – 
100) of P. yoelii lactate dehydrogenase. The region in the box was cho en for peptide synthesis. 
A cysteine residue was added at the C-terminal of the peptide to allow the conjugation to a rabbit 
albumin carrier owing to the higher score of surface probability and hydrophilicity towards the 
N-terminal compared to the C-terminal. Figure 4.2 illustrates the ClustalW™ sequence alignment 
data and the plot of surface probability, hydrophilicity and flexibility of residues 1460 – 1545 
containing the selected region (residue 1500 – 1517) of P. yoelii acetyl-CoA carboxylase. This 
region is located between the biotin carboxyl carrier protein and the carboxyl transferase domains 
(Figure 4.2A). The region in the box was chosen for peptide synthesis. The higher score of 
hydrophilicity and surface probability towards the N-terminal suggested that the conjugation of 
the peptide to the carrier should be at the N-terminal for maximum exposure of that region. A 
cysteine residue was incorporated at the N-terminal of the peptide to enable the conjugation to 
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rabbit albumin carrier. The two peaks flanking the chosen peptide region appeared to be more 
attractive options. However, those regions have a number of lysine residues and therefore were 
avoided. Table 4.1 summarises the features of the peptides used in this study to produce anti-
peptide antibodies in chickens against P. yoelii lactate dehydrogenase and P. yoelii acetyl-CoA 
carboxylase.  
 
Table 4.1 Characteristics of the P. yoelii acetyl-CoA carboxylase and lactate dehydrogenase peptides 
selected for antibody production 
 
 Anti-pLDH-IgY Anti-PyACC-IgY 
Name APG ( or pLDH) TNT (or PyACC) 
Sequence APGKSDKEWNRDDLC CRSNDDNSQSSRNRTNT 
Length (amino acid residues) 15 17 
Modification C-terminal Cys N-terminal Cys 
Molecular weight 1731.9 1954 
Region on parent protein Residue 85 – 98  Residue 1500 – 1516  
NCBI access number XP_724101 XP_729490 
Linker MBS MBS 
Carrier Rabbit albumin Rabbit albumin 
 
 
4.2.2 Anti-P. yoelii acetyl-CoA carboxylase  peptide antibody production in chickens 
Chickens were immunised with the peptide-carrier complex emulsified in FCA (week 0) or FIA 
(weeks 2, 4 and 6). Eggs were collected from immunised chickens daily and IgY isolated from a 
weekly pool of eggs per chicken. IgY isolated from eggs collected prior to immunisation (pre-
immune IgY) was used as the internal control. Weekly anti-peptide-IgY titres were assessed by 
ELISA against the peptides in both chickens in order to monitor the progress of anti-peptide 
antibody levels in each chicken (Figure 4.3). The profiles show that levels of anti-peptide-IgY 
increased after the second immunisation at week 2 and peaked between week 7 and week 8. The 
anti-peptide antibody levels started falling after week 8.  
 
Crude IgY isolated from weeks 4 – 8 and weeks 9 – 12 from each chicken was pooled and an 
aliquot of the pooled antibody was kept. The pooled antibody was passed over the peptide-
immobilised affinity matrix as described in Section 2.3.7. 
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M. musculus-A.  KLVIITAGARQQEGES-----RLNLVQRNVNIFKFIIP----------------NIVKYSPHCKLLIVSNPVDILTYVAW  
M. musculus-B.  KIVVVTAGVRQQEGES-----RLNLVQRNVNVFKFIIP----------------QIVKYSPDCTIIVVSNPVDILTYVTW  
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P. berghei.     DVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGG----------------HIKNNCPNAFIIVVTNPVDVMVQLLH  
P. chabaudi.    DVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGG----------------HIKKHCPHAFIIVVTNPVDVMVQLLH  
P. falciparum   DVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGG----------------HIKKNCPNAFIIVVTNPVDVMVQLLH  
P. knowlesi.    DVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGG----------------HIKKLCPNAFIIVVTNPVDVMVQLLF  
P. vivax.       DVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGG----------------HIKNLCPNAFIIVVTNPVDVMVQLLF  
P. yoelii.      DVVIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGG----------------HIKNNCPNAFIIVVTNPVDVMVQLLH  
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Figure 4.1 ClustalW™ alignment and selection of the P. yoelii lactate dehydrogenase peptide for antibody production in chickens. (A) 
ClustalW alignment showing highly conserved peptide regions of six Plasmodium LDH amino acid sequences (P. berghei, chabaudi, 
falciparum, knowlesi, vivax and yoelii) that was chosen for the production of Plasmodium LDH (blue underline) anti-peptide antibody. (B) The 
Predict7™ prediction plots of surface probability (—), hydrophilicity (▬), and flexibility (---) of P. yoelii LDH residue of the chosen peptide 
(55 – 135). The box represents the profile of the underlined peptide sequence in panel A.  
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Figure 4.2 ClustalW™ alignment and selection of the anti-P. yoelii acetyl-CoA carboxylase peptide for antibody production in chickens. 
(A) ClustalW™ alignment showing a non-conserved peptid  (blue underline) region between P. yoelii acetyl-CoA carboxylase and acetyl-CoA 
carboxylase from mouse and chicken that was chosen f r the production of P. yoelii acetyl-CoA carboxylase anti-peptide antibodies. Thedegree of 
conservation is indicated by the shading, with black shading indication 100% conservation of the amino acid. (B) The Predict7TM epitope prediction 
plots of surface probability (—), hydrophilicity (▬) and flexibility (---) of the P. yoelii acetyl-CoA carboxylase amino acid residues of the chosen 
peptide (1465 – 1545) are indicated. The box represnts the profile of the underlined peptide sequence i  panel A. The arrows indicate other 
regions with high epitope prediction scores but containing tandem lysine repeats.  
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Figure 4.4 shows the elution profiles of anti-pLDH antibody and anti-PyACC antibody. The 
profile showed a similar trend for both chickens. The peak fraction for anti-pLDH eluted at 10 
ml with A280 nm of > 3.0 for both chickens (Figure 4.4A), while the peak fraction for anti-
PyACC eluted at 5 ml with A280 nm of 2.4 for both chickens. Fractions from the affinity matrix 
with A280 nm between 0.3 and > 3.0 were pooled. The total yield of pooled affinity-purified 
anti-pLDH peptide and anti-PyACC peptide antibody was 23 mg and 25 mg respectively.  
 
4.2.3 Detecting P. yoelii acetyl-CoA carboxylase in P. yoelii-infected mouse erythrocyte 
lysate with anti-peptide antibody directed against P. yoelii acetyl-CoA carboxylase 
The anti-PyACC antibody was used to establish the in vivo expression of acetyl-CoA 
carboxylase in P. yoelii-infected mouse-blood cells lysate from a mixed stage infection. Anti-
pLDH peptide IgY was used as a control. The antibody detected two major proteins at 35 kD 
and 56 kD and minor bands at 44 kD and above 116 kD (Figure 4.5). The antibody did not 
detect any protein in non-parasitised-mouse blood cells. The preimmune control did not detect 
any protein on both lanes. The anti-PyACC antibody recognised a diffuse band extending 
from approximately 440 kD to about 220 kD on parasitised-blood cells lysate (Figure 4.5B). 
No detectable protein was observed in non infected mouse red blood cell lysate negative 
control containing approximately equal amounts of bl od cells as in the infected blood cells. 
The pre-immune IgY control did not detect any protein.  
 
4.2.4 Detection of acetyl-CoA carboxylase in P. yoelii-infected red blood cells by 
immunofluorescence microscopy 
The anti-PyLDH and anti-PyACC antibodies were used to detect the presence of lactate 
dehydrogenase (positive control) and acetyl-CoA carboxylase in situ in parasitized mouse red 
blood cells by immunofluorescence microscopy. The secondary antibody was FITC-
conjugated donkey anti-chicken IgY. 4’,6-diamidino-2-phenyl dihydrochloride (DAPI) was 
used as the nuclear stain to confirm the presence of parasites in a red blood cell. DAPI is a 
cell permeable dye that binds to minor groove of DNA double helix, preferably on the AT-rich 
region (Naimski et al., 1980). The excitation and emission wavelength for FITC is 492 nm 
and 518 nm, respectively (Harlow and Lane, 1988), while the excitation and emission 
wavelength for DAPI-DNA complex is 364 nm and 458 nm, respectively (Naimski et al., 
1980).  
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Figure 4.3 Evaluation of anti-peptide antibody production in chicken. Laying chickens were 
immunised at weeks 0, 2, 4 and 6 (arrows) with synthetic peptides-rabbit albumin (carrier) complex in 
Freund’s adjuvant. IgY isolated from chickens immunised with pLDH peptide (A) and PyACC peptide 
(B) was evaluated by ELISA (described in Section 2.3.8) for response against the peptide antigens. 
Peptide concentration was 1 µg/ml (0.15 µg/well) and primary antibody (crude IgY) was 100 µg/ml 
(0.1 µg/well). (▬▬) chicken 1 and (──) chicken 2. Antibodies were detected with rabbit-anti chicken 
IgY antibody conjugated to HRPO. 
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Figure 4.4 Elution profile of anti-peptide antibody from affinity matrices . Pooled weeks 4 – 8 
anti-peptide antibody was passed over pLDH peptide (A) and PyACC-peptide (B) immobilised-affinity 
matrices, eluted with 0.1M glycine-HCl (pH 2.8). (▬▬) chicken 1 and (──) chicken 2. 
 
 
The sample used was from a mixed infection. Green fluorescence was detected in parasitized 
RBC incubated with the anti-PyACC peptide antibodies indicating the presence of 
Plasmodium acetyl-CoA carboxylase. The green fluorescence appeared to be distributed 
within a specific organelle in the parasite cells at trophozoite and gametocyte ateges, sightly 
in the cytoplasm but absent from the RBC cytoplasm. The blue fluorescence showed that the 
green FITC fluorescent signal is from a parasitized RBC. No signal was detected in non-
parasitised RBC. A diffrent trend was observed with the anti-PyLDH antibodies positive 
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control. The FITC signal was more evenly distributed in the cytoplasm of the parasite. The 
preimmune IgY was negative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Anti-peptide antibody detection of acetyl-CoA carboxylase and lactate dehydrogenase 
in P. yoelii-infected mouse blood cell lysate by Western blot. Immuno-blotting of P. yoelii-infected 
mouse blood cells lysate (lane 2) from a mixed stage parasite infection or non-infected mouse blood 
cells (lane 1) with antibodies directed against peptides P. yoelii acetyl-CoA carboxylase and lactate 
dehydrogenase peptides. The lysate was resolved by SDS-PAGE on a 10% (A) and a 5.5% (B) 
acrylamide gel, transferred to nitrocellulose membrane and probed with 2.5 µg/ml of immune or pre-
immune (negative control) antibody. Antibodies were detected with rabbit-anti-chicken IgY antibody 
conjugated to HRPO. Both lanes were loaded with approximately equal amounts of RBC. The position 
of molecular weight standards are indicated on the left hand panels. The arrow indicates the estimated 
position of 330 kD. 
 
 
A similar study to detect the presence of acetyl-CoA carboxylase in P. yoelii-infected mouse 
RBC was carried out with FITC-conjugated avidin. The signal FITC signal was low (data not 
shown) but a pattern similar to anti-PyACC antibodies was observed. Avidin alone was used 
as a negative control, and no fluorescent signal was observed in cells incubated with avidin 
alone. 
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Figure 4.6 Detection of acetyl-CoA carboxylase and lactate dehydrogenase using anti-peptide antibodies. P. yoelii-infected mouse red blood cells 
(unsynchronised) were incubated with 10 µg of anti-PyLDH peptide IgY or anti-PyACC IgY or pre-immune IgY. Antibodies were detected with FITC-
conjugated donkey anti-IgY IgG and cells were conterstained with DAPI. Cells were viewed at 1000× magnification with a fluorescent microscope 
mounted with a digital camera. Flourescent images wre captured under UV and green filters, and processed with the analySIS™ software. Arrows indicate 
uninfected RBC.  
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4.3 Discussion 
Having shown that the parasite transcribes the mRNA encoding P. yoelii acetyl-CoA 
carboxylase, the next step was to confirm the presence of the enzyme in parasite lysates. An 
immunogenic peptide was chosen from the published sequence of P. yoelii 17XNL acetyl-
CoA carboxylase as well as lactate dehydrogenase; an “in house” protein used as a control in 
immunochemical assays. Several regions of the protein exhibiting high predicted surface 
probability, hydrophilicity, antigenicity and flexibility (Cármenes et al., 1989) were 
identified. Rabbit albumin was chosen as the carrier b cause it has been shown in our 
laboratory to induce strong immune responses in chickens resulting in the production of high 
antibody titre.  
 
The use of chickens in antibody production is very convenient because chickens naturally 
package antibodies against an immunogen in to theireggs to protect their unhatched chicks 
(Erhard and Schade, 2001; Larsson and Sjöquist, 1990). Therefore antibodies are extracted 
from the chicken egg yolk, which is less traumatic for the birds than having to bleed them to 
isolate antibodies from the serum. Chicken egg yolks have higher antibody titre than chicken 
serum as a result of active transport of IgY from serum into egg yolk (Larsson and Sjöquist, 
1988; Larsson and Sjöquist, 1990). Chicken egg yolkIgY can retain biological activities for 
several years when stored at 4ºC in the presence of anti-bacterial against such as sodium azide 
(Goldring and Coetzer, 2003). Sometimes due to persist nt freeze-thaw cycles, IgY forms 
insoluble precipitates. This can be avoided by storing the antibody at –20ºC in the presence of 
50% glycerol (Personal observation). Antibodies directed against plasmodial proteins have 
been shown to be useful tools in characterising plasmodial kinases (Dorin et al., 2005; 
Merckx et al., 2003; Nunes et al., 2007).  
 
Both peptides produced peak immunogenic responses i chickens between week 6 and 8 post 
immunization. The free peptide was used as antigen in ELISA because antibodies directed 
against the carrier may produce erroneous results in the monitoring of the anti-peptide 
antibody titres. The length of the peptides is thought to contribute to the degree of binding. 
While some studies have shown that 6 – 15-mer peptid s bind poorly to plastic (Muller, 
1988), other studies have shown that 10 – 20-mer peptides binds effectively to plastic (Davies 
et al., 1987). 
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Both affinity-purified anti-peptide antibodies recognised the native enzyme resolved by SDS-
PAGE and in situ by immunofluorescence microscopy.  This demonstrated that the anti-
peptide antibodies could recognise non-conformationl forms of the native protein (Davies t 
al., 1987; Dyson and Wright, 1995). The theoretical mo ecular weight of PyLDH is 34 kD but 
the enzyme may form homotetrameric complexes of approximately 120 kD (Menting et al., 
1997; Turgut-Balik et al., 2004). The size of the protein was estimated (Figure 4.5B) 
corresponds to the size of the theoretical mass of the P. yoelii acetyl-CoA carboxylase. 
Northern blot analysis showed similar pattern (Figure 3.7), suggesting that there might be a 
relationship between the the proteins produced from the transcripts. Previous studies have 
shown that this diffused pattern in resolution of native Plasmodium proteins on SDS-PAGE 
gel is probably due to the size and presence of highly charged amino acid residues common in 
the Plasmodium proteome (Mattei and Scherf, 1992a; Mattei and Scherf, 1992b; Tebele t al., 
2000).  
 
The apicomplexa plastid is believed to be the organelle responsible for fatty acid biosynthesis 
since most enzymes of the Type II fatty acid synthase have apicoplast target sequences 
(Gornicki, 2003; Prigge t al., 2003; Ralph et al., 2004a), thus may be targeted to the plastid. 
The patterns of FITC signal obatained for acetyl-CoA carboxylase (Figure 4.6) suggest that 
the enzyme is distributed within the plastid. This was diffrent to lactate dehydrogenase, a 
cytoplasmic enzyme involved in the glycolytic pathway (Tomar et al., 2006; Winter et al., 
2003). Using antibodies directed against a known apicoplast-targeted protein such as acyl 
carrier protein for co-localisation studies (Jelenska et al., 2001) may be useful in discerning 
the localisation of the enzyme in a Plasmodium parasite. The result of FITC-conjugated 
avidin was expected to show a similar trend to anti-PyACC antibody. This reagent will detect 
other biotinylated proteins in parasite cells. Immuno-precipitation of the native acetyl-CoA 
carboxylase from a parasite lysate using anti-PyACC antibodies for activity assays was not 
successful. Perhaps, using metabolically labelled proteins would yield a better result 
(McCarthy et al., 1983). 
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CHAPTER 5 
PLASMODIUM YOELII ACETYL-COA CARBOXYLASE: CLONING, EXPRESSION 
AND CHARACTERISATION OF THE BIOTINOYL DOMAIN 
 
5.1 Introduction 
One major benefit of the sequencing of the Plasmodium genome is that several genes with or 
without any annotated function can be studied by cloning and expression of the protein 
encoded by such a gene. Escherichia coli has proved to be a valuable tool for the cloning ad
expression of recombinant proteins for structure and function studies aimed at novel drug 
design (Makrides, 1996). Plasmodium protein kinases (Dorin et al., 2005; Merckx et al., 
2003; Nunes et al., 2007), glycolytic enzymes (Brady and Cameron, 2004; Turgut-Balik et 
al., 2004; Winter et al., 2003) and surface-related proteins (Narum et al., 2001; Rodrigues et 
al., 2003; Wang et al., 2008) have been successfully cloned and expressed using the E. coli 
expression system. In 2003, about 80% of the proteins deposited in the Protein Data Bank 
with resolved crystal structures were expressed in E. coli due to the robustness and the 
relative cost of using the E. coli expression system (Sorensen and Mortensen, 2005b). 
However, not every protein has been successfully expressed in E. coli even when correctly 
cloned in frame with the expression plasmid promoters and other genetic information needed 
for high level expression of the cloned gene (Flick et al., 2004; Mehlin et al., 2006; Narum et 
al., 2001; Withers-Martinez et al., 1999; Zhou et al., 2004). This shortcoming is often 
attributed to distinctive structural features of the gene to be expressed and instability and 
inefficiency of translation of the mRNA in E. coli. Susceptibility of the expressed protein to 
proteolytic degradation by endogenous proteases and improper folding of the expressed 
protein also results in insoluble recombinant proteins. The uniqueness of the AT-rich malaria 
genome is thought to contribute to problems expressing Plasmodium proteins (Flick et al., 
2004; Mehlin et al., 2006; Withers-Martinez et al., 1999; Zhou et al., 2004). 
 
There is a concerted effort to study acetyl-CoA carboxylase in organisms ranging from higher 
eukaryotes such as humans (Abu-Elheiga et l., 1995; Boone et al., 2000; Boone et al., 1999; 
Munday, 2002) to lower eukaryotes such as protozoan parasites (Gornicki, 2003; Zuther t
al., 1999) due to the implication of this enzyme in obesity and a possible target for anti-
parasitic drugs (Blanchard and Waldrop, 1998; Thampy and Wakil, 1988a; Thampy and 
Wakil, 1988b). However, only the E. coli and yeast acetyl-CoA carboxylase crystal structures 
of various domains and subunits  of the enzyme (Al-Feel et al., 2003; Athappilly and 
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Hendrickson, 1995; Cronan, 2002; Cronan and Waldrop, 2002; Shen et al., 2004; Zhang et 
al., 2004) have been resolved. Human acetyl-CoA carboxylase has been recently cloned, 
expressed and characterised (Kim et al., 2007). Lee et al. (Lee et al., 2008) published the 
structural and functional organisation of the human acetyl-CoA carboxyalse-2 biotinoyl 
domain and it is the only eukaryotic biotinoyl domain of a multi-enzyme-domain type acetyl-
CoA carboxylase to be structurally elucidated. 
 
The importance of carbon in energy metabolism emphasises the essential function of biotin in 
living systems. Biotin, also known as vitamin H, is an important cofactor for several proteins 
that possess diversified metabolic functions in the living system (Beckett, 2005; Chapman-
Smith and Cronan, 1999b; Chapman-Smith and Cronan, 1999c; Reche and Perham, 1999). It 
is required by all organisms and synthesised by plants and most prokaryotes. Biotin-
dependent enzymes play crucial roles in energy metabolism by mediating catalytic functions 
in pathways such as lipogenesis, gluconeogenesis and amino-acid metabolism (Goss and 
Wood, 1984). Primarily, biotin functions as an acceptor of a carboxyl group in the carbon 
fixation pathways of fatty acid synthesis and oxidation. Enzymes such as acetyl-CoA 
carboxylase, pyruvate carboxylase and transcarboxylases have covalently bound biotin in 
their biotin binding domains which is often referred to as the biotin carboxyl carrier protein 
(BCCP) or biotinoyl domain. A biotin ligase (EC 6.3.4.15) attaches the biotin molecule to an 
ε-amine of a lysine residue within a highly conserved biotin binding motif (Chapman-Smith et
al., 1999). The process of covalent attachment of a biotin molecule to a biotin-dependent 
enzyme is called biotinylation. This reaction is a highly conserved and a specific post/co-
translational modification (Chapman-Smith et al., 1999; Reche t al., 1998). The Plasmodium 
genome has been shown to contain biotin-dependent enzymes (Plasmodb database). These 
inferences were made by gene annotation using comparative analysis with well established 
biotin-bound enzymes in organisms such as human, S. cerevisiae, E. coli and A. thaliana. The 
genomes of S. cerevisiae (Piskur, 2001) and A. thaliana (Walbot, 2000) have been sequenced, 
published and are well characterised.  
 
There is little understanding of the fate of biotin in the Plasmodium parasite, though the 
importance of this cofactor in glucose and amino-acid metabolism is evident. The biotin 
carboxylase and the carboxyl transferase domains (as well as subunits) of acetyl-CoA 
carboxylase are entirely dependent on the biotinylated biotin carboxyl carrier protein domain 
for their activities (Cronan, 2001; Goss and Wood, 1984; Lee et al., 2008; Solbiati et al., 
 109 
2002). Thus, it is essential to embark on the study of acetyl-CoA carboxylase by empirically 
characterising the biotin carboxyl carrier protein domain which is conserved in evolutionary 
divergent organisms. The aim of this study was to recombinantly express the regions spanning 
the biotin carboxyl carrier protein domain of P. yoelii 17XL acetyl-CoA carboxylase. Primers 
were designed based upon the PY01695 (Plasmodb™ ID) ORF of P. yoelii yoelii 17XNL 
annotated as “acetyl-CoA carboxylase 1 precursor-related”. The recombinant protein was 
analysed for its potential to be biotinylated in vivo by the expression host, E. coli. Figure 5.1 
is a flowchart illustrating the experimental plan used to recombinantly express and 
characterise P. yoelii 17XL acetyl-CoA carboxylase biotinoyl domain.  
 
5.2 Results 
5.2.1 PCR amplification of a 1041 bp cDNA containing the biotinoyl domain of acetyl-
CoA carboxylase from P. yoelii 17XL genomic DNA 
The High Fidelity™ PCR system was used to amplify the 1041 bp DNA fragment which 
includes the acetyl-CoA carboxylase biotin carboxyl carrier  protein domain (PyBCCP) from 
P. yoelii 17XL genomic DNA. The PyBCCP-fwd and PyBCCP-rev primers with added EcoRI 
and NotI restriction sites (Table 2.2) were used for this process. The nucleotid  sequence and 
the coding amino-acid sequence from the published PY01695 corresponding to the region 
intended to be amplified from the 17XL strain are shown in Figure 5.2. The nucleotide 
sequence is approximately 1041 bp, which excludes th  additional nucleotides corresponding 
to the restriction sites. The entire sequence spans the biotin carboxyl carrier protein domain of 
P. yoelii acetyl-CoA carboxylase with 108 and 169 amino acid residues before and after the 
first and last amino acid residues of the biotin carboxyl carrier protein domain respectively. 
The VEAMKM biotin binding motif was intended to be in the centre of the 1041 bp sequence 
to (i) be as far removed as possible from the His-tag and GST-tag sequence on the N terminals 
of the recombinant proteins and (ii) include other possible residues out side the domain that 
may be vital for interaction with the biotin protein l gase and correct protein folding. 
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(bp 2940)
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~ 45 kD His-tagged fusion protein
+++++
His6-PyBCCP
pGX-PyBCCP
       5991 bp
In vivo biotinylation study
Carboxyl transferase
EcoRI NotI
EcoRIEcoRI NotI NotI
+++++
5' 3'
18.8 kb partially sequenced 
MALPY00458 (Chromosome 13)
PyBCCP
1041 bp cDNA
 
 
Figure 5.1 Flow chart depicting the experimental plan to clone and express P. yoelii 17XL biotin 
carboxyl carrier protein domain . A region spanning the 73 amino-acid biotin carboxyl carrier 
protein domain of the multi-domain gene (PY01695) encoding P. yoelii acetyl-CoA carboxylase was 
amplified, cloned into pJET1and subcloned into pET-28a and pGEX-4T-1 expression vectors using 
the EcoRI and NotI restriction sites. The numbers 2940 bp and 3982 bp indicate the region of the ORF 
amplified for the study. The entire fragment to be cloned was 1041 bp. 
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Figure 5.2 Nucleotide and predicted amino acid sequences of PY01695 region 2940 bp – 2982 bp. 
The entire region spanning the biotin carboxyl carrier protein domain (in blue) with the biotin binding 
motif (highlighted) of PY01695 ORF of MAL00458 of P. yoelii. The theoretical molecular weight of 
the polypeptide was deduced to be 40.6 kD. The double underlined sequences were used to design the 
primers. The bold nucleotide sequences are the added EcoRI and NotI restriction sites. The arrows 
points to the position where the restriction site sequences were added. The lower case italics are 
additional bases.  
 
 
The PCR product was analysed by agarose gel electropho esis (Figure 5.3A). A DNA band 
corresponding to the expected size of 1041 bp was observed. The 850 bp DNA band in lane 2 
codes for P. yoelii 17XL lactate dehydrogenase (PyLDH) positive control amplified from the 
same sample of P. yoelii genomic DNA. Prior to ligation into the pJET1 plasmid, the PCR 
5’gaGAATTC  
               EcoRI 
ACGGAAGATAGCCTAAATAGGGAAGACATTGCTATAAAATCAGAAAATAATATCAATGAC 
T  E  D  S  L  N  R  E  D  I  A  I  K  S  E  N  N  I  N  D 
ATAAGTTTAAATGGAAAAATGAAAAGAGCACACATTTTTGATATAATTTTTCAAAATGTA 
I  S  L  N  G  K  M  K  R  A  H  I  F  D  I  I  F  Q  N  V 
AAATATAAGTTTAAAGGATATAATACTGGTGAAGATTTATACAAATTGAATATAAATGAT 
K  Y  K  F  K  G  Y  N  T  G  E  D  L  Y  K  L  N  I  N  D 
CAAGAAATAGAAATATTAGCAAAATATGATAAAGAAAATAATAAAATATTTGCATCATTC 
Q  E  I  E  I  L  A  K  Y  D  K  E  N  N  K  I  F  A  S  F 
CATAATCAAACATATATATATACATGTATAGAAGATTCCTTAGGAACACATATGAATTTA 
H  N  Q  T  Y  I  Y  T  C  I  E  D  S  L  G  T  H  M  N  L 
GGGAAAGATAATGTATTTATTCCTGTTATTACTAATCCATATCATTTAATATCAAATACA 
G  K  D  N  V  F  I  P  V  I  T  N  P  Y  H  L  I  S  N  T 
AATGGAAAAATTGTAAAATATTTAATAAAAGATGGTGAAAAAATTAACAAATTTGATGAT 
N  G  K  I  V  K  Y  L  I  K  D  G  E  K  I  N  K  F  D  D 
TACATAGAAGTAGAAGCGATGAAAATGATTATGACTTTTAAATCTACTGAAACTGGTATA 
Y  I  E  V  E  A  M  K  M  I  M  T  F  K  S  T  E  T  G  I 
TTAAAGCATAAGATGTCAGAAGGTGCTATGATAAAAATTGGTGATTTATTAGGAGTTATA 
L  K  H  K  M  S  E  G  A  M  I  K  I  G  D  L  L  G  V  I 
GAAAAGGAAAAGGATAATCAAAATTACCAAAATGATGATAATAATAACAAAATTATTGAT 
E  K  E  K  D  N  Q  N  Y  Q  N  D  D  N  N  N  K  I  I  D 
TTTATTGGGCATCTAAATTTGTCAAACAAAAATGCATATGAATTAAACGGAACATTTGTT 
F  I  G  H  L  N  L  S  N  K  N  A  Y  E  L  N  G  T  F  V 
CCAGACTTAGCAGAAGAGTCACATAATAACGAAGTATGCTGTAAAAACATTGAAAAAGAA 
P  D  L  A  E  E  S  H  N  N  E  V  C  C  K  N  I  E  K  E 
AAAATGGAAAACCTCAGAAAAATTGAAGATCCGAAAAATAATAAAATTTATCCCACAAAA 
K  M  E  N  L  R  K  I  E  D  P  K  N  N  K  I  Y  P  T  K 
CACACCAATAGAAATTCACAGGTTAATACAACAAATGAATCAGTGTCTGTTCAAGATATA 
H  T  N  R  N  S  Q  V  N  T  T  N  E  S  V  S  V  Q  D  I 
AAAACGGAAAATATGAAAAAAGATGAAAGCCAATTTTGCACAGAAGATAAACAAATACAA 
K  T  E  N  M  K  K  D  E  S  Q  F  C  T  E  D  K  Q  I  Q 
AATAACCAAGTAAATAGACGGAATAAATTGTTTTTGAAAAAAAATAATGGAAAAAATAAC 
N  N  Q  V  N  R  R  N  K  L  F  L  K  K  N  N  G  K  N  N 
AAAAATAATATGTTTCGTTTATTTTCCCAGAAAAATGATAATGACAGTAAAATAATAGAT 
K  N  N  M  F  R  L  F  S  Q  K  N  D  N  D  S  K  I  I  D 
TCGAATATAGAAAGTAACTCCAGAGATGATACTTTAAGTTATGATAAGATAAATAAAAAA 
S  N  I  E  S  N  S  R  D  D  T  L  S  Y  D  K  I  N  K  K 
CGCCGGCGtc3’ 
    NotI 
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product was purified from the agarose gel and analysed by agarose gel electrophoresis to 
ascertain the level of purity. A distinct band of the expected size is seen (Figure 5.3). The 
yield of the purified product was approximately 5 µg. 
 
 
  
  
 
 
Figure 5.3 PCR amplification of the PyBCCP cDNA from P. yoelii genomic DNA and 
purification of the PCR product. (A) Agarose gel (0.5%) analysis of PyBCCP (lane1) and PyLDH 
DNA positive control (lane 2) PCR products. (B) Lane 1 is unpurified PCR product and lane 2 is 
purified PCR product. The approximate amount of purified PCR product was estimated using the 
Fermentas MassRuler™ DNA ladder (Mw in panel A). 
 
 
 
5.2.2 Cloning of the PyBCCP PCR product into pJET1™ blunt end cloning plasmid 
The PCR product was ligated into pJET1™ blunt end cloning vector to form pJ-PyBCCP. A 
blunt end cloning vector was used because the PCR fragment lacked T-overhangs due to the 
activity of a proof reading enzyme present in the High Fidelity™ PCR system. The ligation 
reaction product was used to transform competent E. coli JM109 cells and 75 colony forming 
units were obtained. The presence of the PyBCCP insert was established by colony PCR 
using the insert primers (PyBCCP-fwd and PyBCCP-rev), as well as by restriction digestion 
of the plasmid isolated from a colony forming unit using EcoRI and NotI restriction 
endonucleases (Figure 5.4A)  
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Plasmids isolated from the first colony (Figure 5.4A, lane 1) were digested with EcoRI and 
NotI either sequentially or concurrently (double digest). The restriction digestion products 
were analysed by agarose gel electrophoresis (Figure 5.4B). Two distinct DNA bands, one at 
3 kb corresponding to the pJET1 plasmid and another at 1 kb fragment corresponding to 
PyBCCP insert were obtained. The EcoRI and NotI-restricted PyBCCP (PyBCCP Eco-Not) 
fragment was purified from the agarose gel and usedfor subcloning. 
  
 
 
 
 
 
 
  
 
 
 
 
Figure 5.4 Confirmation of the presence of the PyBCCP insert in the plasmid of transformed E. 
coli JM109 cells. (A) DNA from five colonies (lanes 1 – 5) was amplified by PCR using the PyBCCP 
specific primers (PyBCCP-fwd and PyBCCP-rev). The 1 kb DNA band in each of the lanes 
corresponds to the amplified PyBCCP insert. (B) Analysis of restriction endonuclease digestion of 
plasmid isolated from a colony. Lane 1 is the circular recombinant pJ-PyBCCP plasmid, lane 2 is pJ-
PyBCCP digested sequentially with EcoRI and NotI, respectively and lane 3 is pJ-PyBCCP digested 
simultaneously with EcoRI and NotI. Liner pJET1 plasmid is 3 kb in size (open arrow) and 
PyBCCPEco-Not fragment is 1041 bp in size (striped arrow). Agarose concentration was 0.5% (w/v). 
 
 
5.2.3 Subcloning of the PyBCCPEco-Not cDNA into pET-28a and pGEX-4T-1  
The pET-28a and the pGEX-4T-1 plasmids were isolated from E. coli cells, digested with 
EcoRI and NotI restriction enzymes, and dephosphorylated with shrimp alkaline phosphatase. 
Figure 5.5A shows a single distinct band of ~ 5.5 kb (lane 2) corresponding to the size of the 
linear pET-28a plasmid (5.4 kb) and Figure 5.5B shows a single band of ~ 5 kb (lane 2) 
matching the size of the linear pGEX-4T-1 plasmid (4.9 kb). The three bands observed in the 
lane resolving the circular plasmids (lane 1) are th coiled, super coiled and nicked 
conformations. Approximately 1 µg/ml of pET-28a and 0.75 µg/ml of pGEX-4T-1 were 
obtained. 
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Figure 5.5 Isolation, restriction digestion and purification of expression plasmids. pET-28a (A) 
and pGEX-4T-1 (B) before (lane 1) and after (lane 2) double restriction digestion with EcoRI and 
NotI.  
 
 
PyBCCPEco-Not was ligated into pET-28a and pGEX-4T-1 to produce pT-PyBCCP and pGX-
PyBCCP correspondingly. The recombinant pT-PyBCCP and pGX-PyBCCP plasmids were 
transformed into E. coli JM109 cells for propagation of the plasmid. Although JM109 is an 
expression host for pGEX-4T-1, the protease-deficient E. coli BL21 was subsequently used as 
the expression host. Approximately 100 colony forming units were obtained after 
transformation. A few of the colonies were screened for the presence of the PyBCCP Eco-Not 
insert by restriction digestion as well as by PCR using the PyBCCP-fwd and PyBCCP-rev 
primers and analysed by agarose gel electrophoresis (Figure 5.6). In Figure 5.6A, the 
restriction digestion with EcoRI yielded an intense DNA band with an estimated size of 6.5 
kb (lane 2). This size corresponds to the sum of the sizes of pET-28a (5.3 kb) and the size of 
the cloned PyBCCPEco-Not (~1 kb). Double digestion with EcoRI and NotI yielded two DNA 
bands at 5.5 kb and 1 kb (lane 3), thus confirming the presence of the cloned PyBCCPEco-Not. 
The PCR amplification confirmed the presence of the 1 kb PyBCCPEco-Not (lane 4). 
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Similar results were obtained when plasmids isolated from an E. coli colony transformed with 
pGX-PyBCCP were analysed for the presence of the cloned PyBCCPEco-Not (Figure 5.6B). 
Digestion of the plasmid with EcoRI resulted in a single DNA band with an approximate size 
of 6 kb being the sum of 1 kb cloned PyBCCP and 4.9 kb plasmid (lane 2). Double digestion 
with EcoRI and NotI produced a 1 kb insert and the plasmid that migrated at 5 kb (lane 3). 
The amplified PCR product also migrated at 1 kb (lane 4). The results indicated that the 
recombinant plasmids contained the cloned PyBCCPEco-Not insert.  
 
 
 
 
Figure 5.6 Agarose gel analysis of the subcloned of PyBCCPEco-Not insert in pET-28a and pGEX-
4T-1 vectors. E. coli transformed with pT-PyBCCP (A) and pGX-PyBCCP (B) were cultured and 
plasmids isolated. Lane 1, circular recombinant plasmid; lane 2, EcoRI-restricted plasmid; lane 3, 
EcoRI and NotI-double restricted plasmid; lane 4, PCR product of the plasmid amplified with 
PyBCCP sequence primers. 
 
 
5.2.4 Sequencing of the pT-PyBCCP and the pGX-PyBCCP expression plasmids 
To establish that the PyBCCPEco-Not insert cloned into the expression vector was in the proper 
reading frame, the recombinant plasmids were sequenced using vector-specific primers (Table 
2.2). Figure 5.7 illustrates the expression plasmid constructs showing details of the 
positioning of the sequencing primers with respect to the cloned PyBCCPEco-Not. The priming 
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positions of the pET-28a sequencing primers (~ 197 bp and ~ 98 bp from the EcoRI site and 
the NotI site, respectively) resulted in sequence data that included the start codon, stop codon, 
the N- and C-terminal poly-His tag, the T7 tag and the cloned PyBCCP as shown in Figure 
5.7A. There was a small overlap in the sequences obtained from both primers as ~ 800 bp was 
sequenced from both directions. The priming positions f the pGEX-4T-1 sequencing primers 
(~ 188 bp and ~ 81 bp from the EcoRI site and the NotI site, respectively) resulted in 
sequence data that included a portion of the GST tag sequence and the stop codon as shown in 
Figure 5.7B. There was greater overlap between the two sequences (forward and reverse) than 
that obtained for the pT-PyBCCP construct. 
 
The nucleotide sequences corresponding to the forward and the reverse directions of the 
sequencing data were merged into a single sequence that was translated into the coding amino 
acid sequence and aligned with the theoretical sequence (Figure 5.2) using the ClustalW™ 
algorithm (Figure 5.8). The sequencing data showed that the VEAMKM biotin attachment 
motif in the 17XL strain of P. yoelii was 100% identical in all published Plasmodium acetyl-
CoA carboxylase biotinoyl domain biotin binding motifs as well as the E. coli BCCP biotin 
binding motif. Eight amino acids outside the biotinyl domain were consistent in both 
constructs and different from the published sequence. These differences may be due to the 
different strain used for sequencing.  
 
5.2.5 In vitro biotinylation of rabbit albumin as a positive control in avidin-biotin assays 
Rabbit albumin was biotinylated for use as a control. N-Hydroxysuccinimide-biotin (NHS-
biotin) was reacted with rabbit albumin, to form a st ble amide bond between the ε-lysine 
residues on the rabbit albumin and the carboxylic acid functional group on the biotin 
molecule. The biotin-rabbit albumin complex was separated from unreacted NHS-biotin and 
NHS ester reaction product by size exclusion chromat gr phy. Figure 5.9A shows the elution 
profile of the purification of biotin-rabbit albumin complex. Two distinct peaks were 
observed; the first peak corresponds to the biotin-rabbit albumin complex and the second peak 
corresponds to the unreacted NHS-biotin.  Proteins luting in Peak 1 (Figure 5.9A) were 
resolved along side unbiotinylated rabbit albumin o a 10% acrylamide gel. Following 
transfer of the protein to a nitrocellulose membrane, the presence of biotin bound to the rabbit 
albumin was confirmed by avidin-peroxidase and by an anti-biotin monoclonal antibody. 
Figures 5.9B and C illustrate the results of the SDS-PAGE of the proteins that eluted in Peak 
1 and the Western blot analysis using the avidin-peroxidase detection system. The protein 
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band in lane 2 corresponding to the eluted proteins migrated the same distance as the 
unbiotinylated rabbit albumin (~ 57.7 kD). The theor tical mass of rabbit albumin used for 
this study is 62.8 kD. However, in a non-reducing SDS-PAGE gel, the biotin-rabbit albumin 
complex resolved at 66.2 kD while the unbiotinylated rabbit albumin resolved at 63.1 kD 
(results not shown), closer to the theoretical mass. The Western blot using avidin-peroxidase 
showed the presence of biotin bound to rabbit albumin olecule by detecting a band of 
approximately 57.7 kD in lane 2, which contains proteins eluting in Peak 1.  
 
 
 
 
 
Figure 5.7 Schematic illustration of the sequencing primer positions with respect to the cloned 
PyBCCPEco-Not. (A) pT-PyBCCP construct showing the ORF (bp 124 – 1314), the cloned PyBCCP 
(striped box), the N- and C-terminal poly-His tag position (H), the T7 tag position (T) and the position 
of the sequencing primers (bold arrows). (B) pGX-PyBCCP construct showing the ORF (bp 258 – 
1991), the cloned PyBCCP (striped box), GST gene (open box) and the position of the sequencing 
primers (bold arrows). The two sequencing directions (broken arrows) illustrate the degree of overlap 
in the sequencing data.   
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Figure 5.8 ClustalW™ alignments of the sequenced pT-PyBCCP and pGX-PyBCCP with the 
amino acid sequence from P. yoelii 17XNL obtained from the Plasmodb database. (A) pT-
PyBCCP expression construct. The poly-His-tag on the pT-PyBCCP is double underlined (B) pGX-
PyBCCP expression construct. For both panels, the biotinylation motif is highlighted and the biotin 
carboxyl carrier protein domain is in bold case. * indicates 100% conserved amino acid residue. 
Biotinylation motif 
A pT-PyBCCP.    LRRRYTMGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFTEDSLNREDIAIKSENNI 60 
PyBCCP.       ------------------------------------------TEDSLNREDIAIKSENNI 18 
                                                        ****************** 
 
pT-PyBCCP.    NDISLNGKMKRAHIFDIIFQNVKYKFKGYNTGEDLYKLNINDQEIEILAKYDKENNKIFA 120 
PyBCCP.       NDISLNGKMKRAHIFDIIFQNVKYKFKGYNTGEDLYKLNINDQEIEILAKYDKENNKIFA 78 
              ************************************************************ 
 
pT-PyBCCP.    SFHNQTYIYTCIEDSLGMHMNLGKDNVFIPVITNPYHLISNTNGKIVKYLIKDGEKINKF 180 
PyBCCP.       SFHNQTYIYTCIEDSLGTHMNLGKDNVFIPVITNPYHLISNTNGKIVKYLIKDGEKINKF 138 
              ***************** ****************************************** 
 
 
 
pT-PyBCCP.    DDYIEVEAMKMIMTFKSTETGILKHKMSEGAMIKIGDLLGVIEKEKDNQNYQNDDNN-KI 239 
PyBCCP.       DDYIEVEAMKMIMTFKSTETGILKHKMSEGAMIKIGDLLGVIEKEKDNQNYQNDDNNNKI 198 
              ********************************************************* ** 
 
pT-PyBCCP.    IDFIGHLNLSNKNAYELNGTFVPDLAEVSHNNEVCCNNIEKEKMENLRKIENPKNNKIYP 299 
PyBCCP.       IDFIGHLNLSNKNAYELNGTFVPDLAEESHNNEVCCKNIEKEKMENLRKIEDPKNNKIYP 258 
              *************************** ********:**************:******** 
 
pT-PyBCCP.    TKHINRNSQVNTTNESVSVQDIKTENMKKDESQFCTEDKQIQNNQVNRRNKLFGKKNNGK 359 
PyBCCP.       TKHTNRNSQVNTTNESVSVQDIKTENMKKDESQFCTEDKQIQNNQVNRRNKLFLKKNNGK 318 
              *** ************************************************* ****** 
 
pT-PyBCCP.    KNKNNMFRLFSQKNDNDSKIIDSNIESNSRDATALEHHHHHHDPA         404 
PyBCCP.       NNKNNMFRLFSQKNDNDSKIIDSNIESNSRD--------------         349 
              :******************************               
pGX-PyBCCP.    WIPGFTEDSLNREDIAIKSENNINDISLNGKMKRAHIFDIIFQNVKYKFKGYNTGEDLYK 60 
PyBCCP.        -----TEDSLNREDIAIKSENNINDISLNGKMKRAHIFDIIFQNVKYKFKGYNTGEDLYK 55 
                    ******************************************************* 
 
pGX-PyBCCP.    LNINDQEIEILAKYDKENNKIFASFHNQTYIYTCIEDSLGMHMNLGKDNVFIPVITNPYH 120 
PyBCCP.        LNINDQEIEILAKYDKENNKIFASFHNQTYIYTCIEDSLGTHMNLGKDNVFIPVITNPYH 115 
               **************************************** ******************* 
 
 
 
pGX-PyBCCP.    LISNTNGKIVKYLIKDGEKINKFDDYIEVEAMKMIMTFKSTETGILKHKMSEGAMIKIGD 180 
PyBCCP.        LISNTNGKIVKYLIKDGEKINKFDDYIEVEAMKMIMTFKSTETGILKHKMSEGAMIKIGD 175 
               ************************************************************ 
 
pGX-PyBCCP.    LLGVIEKEKDNQNYQNDDNN-KIIDFIGHLNLSNKNAYELNGTFVPDLAEVSHNNEVCCN 239 
PyBCCP.        LLGVIEKEKDNQNYQNDDNNNKIIDFIGHLNLSNKNAYELNGTFVPDLAEESHNNEVCCK 235 
               ******************** ***************************** ********: 
 
pGX-PyBCCP.    NIEKEKMENLRKIENPKNNKIYPTKHINRNSQVNTTNESVSVQDIKTENMKKDESQFCTE 299 
PyBCCP.        NIEKEKMENLRKIEDPKNNKIYPTKHTNRNSQVNTTNESVSVQDIKTENMKKDESQFCTE 295 
               **************:*********** ********************************* 
 
pGX-PyBCCP.    DKQIQNNQVNRRNKLFLKKNNGKKNKNNMFRLFSQKNDNDSKIIDSNIESNSRDAAASLT 359 
PyBCCP.        DKQIQNNQVNRRNKLFLKKNNGKNNKNNMFRLFSQKNDNDSKIIDSNIESNSRD------ 349 
               ***********************:******************************       
 
B 
Biotinylation motif 
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5.2.6 Expression of recombinant His6-PyBCCP and GST-PyBCCP  
Recombinant P. yoelii biotinoyl protein (PyBCCP) was expressed at 37°C for 5 h by 
induction with 0.5 mM IPTG as a His-tagged (His6-PyBCCP) or GST-tagged (GST-PyBCCP) 
fusion protein in E. coli in the presence or absence of 0.2 mM D-biotin. The expression media 
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Figure 5.9 In vitro biotinylation of rabbit albumin using NHS-biotin. Rabbit albumin was 
reacted with NHS-biotin and the reaction product was purified over a Sephadex-G25 size exclusion 
chromatography matrix. (A) The elution profile of the purification process. The arrows indicate 
peaks corresponding to the region of the profile with s gnificantly high absorbance at 280 nm. (B)
Proteins eluting at peak 1 were resolved by reducing 10% SDS-PAGE; lane 1 is unbiotinylated 
rabbit albumin and lane 2 is biotinylated rabbit albumin that eluted in peak 1. (C) The resolved 
proteins were transferred onto a nitrocellulose membrane and probed for the presence on biotin 
with avidin-peroxidase conjugate. Lanes 1 and 2 in Panel C correspond to those in Panel B. 
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was supplemented with biotin to establish whether external biotin is needed for the in vivo 
biotinylation of the expressed protein by the E. coli host. The total cell protein was analysed 
for the presence of recombinantly expressed proteins by SDS-PAGE as well as by Western 
blot using anti-His-tag antibody to detect His6-PyBCCP and biotinylated-anti-GST antibody 
to detect GST-PyBCCP.  
 
His6PyBCCP was expressed as a 50 kD protein in E. coli cells induced with IPTG and was 
not prominent in lanes containing cell proteins from uninduced cells or cells expressing the 
parent plasmid (Figure 5.10). The supplementation of the expression medium with biotin did 
not appear to alter the expression of His6PyBCCP. The size of the expressed His6PyBCCP 
was 5 kD more than the theoretical mass (~ 45 kD) deduced using the ProtParam™ online 
tool (www.expasy.org). The 50 kD protein band contained poly-His tag as it was detected by 
anti-His tag antibody (Figure 5.10B). The anti-His-tag antibody also detected some minor 
protein bands below the 50 kD protein band in lanes for induced cells. These minor protein 
bands may be degraded or truncated products of the His6PyBCCP. No His-tagged proteins 
were detected in lanes containing proteins from uninduced cells or cells expressing the parent 
plasmid (lanes 1 and 2).   
 
Figure 5.11 illustrates the results of GST-PyBCCP expr ssion in IPTG-induced/uninduced 
cells with or without D-biotin supplementation. GST-PyBCCP migrated as a 66 kD protein 
band that appears to have co-migrated with an E. coli protein. It is more prominent in lysates 
from cells induced with IPTG than in uninduced cells. The mass of the band corresponds to 
the sum of mass of the GST tag (26 kD) and the theoretical mass of the PyBCCP (40.5 kD) 
using ProParam™ (www.expasy.org). A 26 kD protein ba d, which is prominent in induced 
cells expressing the parent vector (pGEX-4T-1), which corresponds to the GST-tag. This 
26 kD band was also observed in uninduced cells suggesting basal expression of GST due to a 
possible leaky Ptac promoter (Makrides, 1996). 
 
The expression of GST-PyBCCP was further confirmed by Western blot analysis using 
biotinylated anti-GST-antibody.  A band at 66 kD was prominent in lanes containing proteins 
from IPTG-induced cells as well as some minor bands below the 66 kD band, synonymous 
with His6-PyBCCP expression. These minor bands may be degradd GST-PyBCCP in view 
of the fact that they were detected by the biotinylated anti-GST antibody. 
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Figure 5.10 Analysis of His6-PyBCCP expression. (A) SDS-PAGE (10%) analysis of total cell 
lysate from E. coli Rosetta (DE3) PLysS cells induced with IPTG (+) or uninduced (−), with (+) or 
without (−) biotin supplementation. Lanes 1 and 2 contain proteins from cells expressing the parent 
pET-28a plasmid and lanes 3 – 6 contain proteins from cells expressing the recombinant pT-
PyBCCP plasmid. (B) Western blot analysis of the resolved proteins corresponding to Panel A, 
probed with anti-His-tag antibody, followed by goat anti-mouse-IgG-peroxidase. Filled arrows 
indicate the expressed recombinant protein while a striped arrow indicates a minor protein band 
detected by the anti-His-tag antibody.  
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Figure 5.11 Analysis of GST-PyBCCP expression. (A) SDS-PAGE (10%) analysis of total cell 
lysate from E. coli BL21 cells induced with IPTG (+) or uninduced (−), with (+) or without (−) 
biotin supplementation. Lanes 1 and 2 contain proteins from cells expressing the parent pGEX-4T-
1 plasmid and lanes 3 – 6 contain proteins from cells expressing the recombinant pGX-PyBCCP 
plasmid. (B) Western blot analysis of the resolved proteins corresponding to Panel A, probed with 
biotinylated anti-GST antibody, followed by avidin-peroxidase. Filled arrows indicate the 
expressed recombinant protein, open arrows indicate GST-tag and striped arrows indicate minor 
protein bands detected by the biotinylated anti-GST antibody. 
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The 26 kD GST was also detected in cells expressing the parent plasmid. There were 
conspicuous 22 kD protein bands detected in all the lan s by the avidin-peroxidase probe. 
These bands may be a biotinylated E. coli protein, possibly the biotin carboxyl carrier protein 
subunit of the E. coli acetyl-CoA carboxylase, which has a theoretical mass of 18.8 kD but 
due to its high alanine content, the protein has been shown to migrate higher than its actual 
mass in an acrylamide gel (Cronan, 2001; Cronan, 2002). The band slightly below 18.4 kD is 
the dye front. 
 
5.2.7 Expression of the N-terminal region of putative P. yoelii copper transporter 
The N-terminal region of a hypothetical P. yoelii surface related protein (PY00413) was 
expressed as a GST-fusion protein (GST-PyCTRNt) in E. coli BL21 strain (Choveaux and 
Goldring, unpublished). This was carried out as a negative control in the study of the in vivo 
biotinylation to establish that the biotinylation of PyBCCP by E. coli was specific owing to 
the presence of the biotinylation motif (VEAMKM) whic  is absent in the hypothetical P.
yoelii surface related protein. This protein was preferred b cause it originates from P. yoelii 
and contains 14 lysine residues. The amino-acid sequence of the expressed region of the 
protein is shown in Figure 5.12 (lysine residues in bold). The total cell protein was analysed 
for the expression of GST-PyCTRNt by SDS-PAGE as well as by Western blot using 
biotinylated anti-GST antibody.  
 
 
 
 
Figure 5.12 Predicted amino as sequence of PyCTRNt 
 
 
Figure 5.13 shows SDS-PAGE and Western blot analysis of GST-PyCTRNt expression in 
induced/uninduced cells in the presence or absence of D-biotin. GST-PyCTRNt migrated as a 
40 kD protein band, which was prominent in the lanes containing proteins from induced cells. 
The 40 kD protein is equivalent to the sum of the GST-tag (26 kD) and the PyCTRNt (17 kD) 
sequence.  
 
 
MNIWKIIYIVLIINSLFVVNVNCESNDQNDGTTSNKKNTGCCGGTNKPLP 
SVNKPLKSCCSDKQSGDDECKPILDLNHIGSKGKNKIPFIYKCCINHDIY 
ESIINEHFSEENQSNTTGGPEKLNMMMGNLSMPMSFQNTTHTIILFKFWE 
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Figure 5.13 Analysis of GST-PyCTRNt expression in BL21 cells. (A) SDS-PAGE (10%) 
analysis of total cell lysate from E. coli BL21 cells induced with IPTG (+) or uninduced (−), with 
(+) or without (−) biotin supplementation. Lanes 1 and 2 contain proteins from cells expressing the 
parent pGEX-4T-1 plasmid and lanes 3 – 6 contain proteins from cells expressing the recombinant 
PyCTRNt-pGEX-4T-1plasmid. (B) Western blot analysis of the resolved proteins corresponding to 
Panel A, probed with biotinylated anti-GST antibody, followed by avidin-peroxidase. Filled arrows 
indicate the expressed recombinant protein and openarrows indicate GST-tag.  
 
 Mw 1 2 3 4 5 6 
IPTG  + –      –    +        –    +        
Biotin  –    –   –    –   +        +        
 kD 
116.0 
 
 
 
 
 
 
 
 
66.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
45.0 
 
 
 
 
 
 
 
35.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
18.4 
 
A 
 Mw 1 2 3 4 5 6 
IPTG  + –      –    +        –    +        
Biotin  –    –    –    –    +        +        
 kD 
 
 
 
 
 
 
116.0 
 
 
 
 
 
 
 
 
66.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45.0 
 
 
 
 
 
 
 
35.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25.0 
 
 
 
 
 
 
 
 
 
 
18.4 
 
B 
 125 
In cells expressing the parent vector (pGEX-4T-1), a prominent 26 kD protein band was 
observed in the induced cells, which corresponds to the GST tag. Basal expression of GST 
was also observed in uninduced cells. Expression of GST-PyCTRNt was confirmed by 
Western blot analysis using biotinylated anti-GST antibody.  A band at 40 kD was prominent 
in lanes containing proteins from IPTG-induced cells. The 26 kD GST was detected in lysates 
of cells expressing the parent plasmid. Similar to Figure 5.11B, 22 kD bands were detected in 
all lanes by the avidin-peroxidase secondary probe.  
 
5.2.8 Analysis of in vivo biotinylation of recombinant P. yoelii biotinoyl  
To confirm that the expressed recombinant GST-PyBCCP and His6-PyBCCP were 
biotinylated by the host cell, the total protein of cells induced or not induced with or without 
D-biotin supplementation was resolved by SDS-PAGE and blotted onto nitrocellulose 
membrane. The membrane was probed with avidin-peroxidase or anti-biotin antibody for the 
presence of biotin.  Free avidin and biotin were incorporated into the assay reagents to block 
the biotin sites on proteins blotted onto the membrane or inhibit the binding of avidin-
peroxidase and anti-biotin antibody to the biotinylated proteins as negative controls.  
 
Recombinant His6-PyBCCP expressed in E. coli resulted in the biotinylation of the 
recombinant protein as observed by a 50 kD major prtein band and some minor bands less 
than 50 kD in lanes resolving total cell proteins from IPTG-induced cells (Figure 5.14), the 
same as Figure 5.10. An E. coli protein at ~ 22 kD and a protein band less than 18.4 kD 
(migrating with the dye front) were also detected by the avidin-peroxidase and anti-biotin 
antibody probes in all lanes. The supplementation of 0.2 mM D-biotin to the expression 
medium appeared not to have a contribution to the in vivo biotinylation of the recombinant 
His6-PyBCCP. Incorporating free avidin or biotin into the assay system appeared to inhibit the 
detection of biotinylated proteins on the membrane.  
 
The avidin-peroxidase and the anti-biotin antibody both detected protein bands at 66 kD 
corresponding to GST-PyBCCP as well as some minor bands less that 66 kD in lanes 
containing lysates from induced IPTG cells (Figure 5.15). However a faint 66 kD protein 
band was detected in the uninduced lanes possibly due to basal transcription as observed in 
the anti-GST blot (Figures 5.11 and 5.13). The 22 kD biotinylated E. coli protein as well as 
the protein band co-migrating with the dye-front were also detected in all lanes. 
Supplementing the expression medium with 0.2 mM D-biotin did not have any visible 
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enhancement of the biotinylation of GST-PyBCCP by the E. coli BL21 strain. The presence 
of free avidin or biotin in the assay medium completely abolished the interaction between the 
biotinylated proteins on the membrane and the avidin-peroxidase or the anti-biotin antibody 
probes. Once again this suggested that there was specificity towards the biotin bound to the 
resolved and blotted proteins. 
 
The biotinylation carried out by the expressing E. coli host was shown to be specific to the 
presence of the VEAMKM biotinylation motif, which is not present in PyCTRNt. Total cell 
proteins from E. coli BL21 cells expressing the recombinant GST-PyCTRNt induced with 
IPTG or not induced, with or without biotin supplemntation, were resolved by SDS-PAGE, 
blotted onto a nitrocellulose membrane and probed with avidin-peroxidase or anti-biotin 
antibody. Figure 5.16 shows that no protein bands were detected at 40 kD corresponding to 
the GST-PyCTRNt recombinant fusion protein in lanes containing proteins from induced 
cells. Supplementing the culture with external biotin did not result in any form of 
biotinylation of the recombinant PyCTRNt. Synonymous with previous results (Figures 5.11 
and 5.13), a biotinylated E. coli protein of 22 kD was detected in all lanes. The results 
therefore support the assumption that the biotinylation of the recombinant His6-PyBCCP and 
GST-PyBCCP by E. coli biotin protein ligase was specific and due to the pr sence of the 
biotinylation motif found on the recombinant proteins. 
 
5.2.9 Large scale expression, purification and refolding of His6-PyBCCP 
In order to obtain a sizable amount of the recombinant His6-PyBCCP to be used for 
oligomerisation studies, expression of His6-PyBCCP was carried out on a larger scale. A 
culture (4.5 L) of E. coli cells expressing His6-PyBCCP was induced with 0.5 mM IPTG for 
5 h at 37°C. His6-PyBCCP proteins in the inclusion bodies were separated with an 
immobilised-cobalt affinity matrix under denaturing conditions. Figure 5.17A illustrates the 
SDS-PAGE analysis of the purification profile of His6-PyBCCP under denaturing conditions. 
Lane 1 is the insoluble fraction that was subsequently purified over the immobilised-cobalt 
affinity matrix and lane 2 contains the supernatant of the 2 M urea wash step prior to 
guanidine solubilisation (see Section 2.6.2). It can be seen that the prominent band at 50 kD 
corresponding to the expressed protein was predominantly in the insoluble fraction and was 
not solubilised by the 2 M urea wash solution. Lanes 3 – 5 contain no visible protein bands 
from the wash steps after binding to the immobilised-cobalt affinity matrix (prior to elution).  
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Figure 5.14 Analysis of the in vivo biotinylation of His6-PyBCCP. Total cell lysate from E. coli cells expressing His6-PyBCCP induced with IPTG (+) or 
uninduced (−), in the presence (+) or absence (−) of biotin, was resolved by SDS-PAGE (10%), blotted on a nitrocellulose membrane and probed with 
avidin-peroxidase alone (A) or incubated with free avidin followed by avidin-peroxidase conjugate (B) or incubated with avidin-peroxidase conjugate in the 
presence of free biotin (C). 
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Figure 5.15 Analysis of the in vivo biotinylation of GST-PyBCCP. Total cell proteins from E. coli cells expressing GST-PyBCCP induced with IPTG (+) or 
uninduced (−), in the presence (+) or absence (−) of biotin, was resolved by SDS-PAGE (10%), blotted on a nitrocellulose membrane and probed with avidin-
peroxidase conjugate alone (A) or incubated with free avidin followed by avidin-peroxidase conjugate (B) or incubated with avidin-peroxidase conjugate in the 
presence of free biotin (C). 
 Mw 1 2 3 4 
IPTG  –    +        –    +      
Biotin  –    –    +        +        
Mw 1 2 3 4 
 –   +        –   +        
 –   –   +        +        
 
Mw 1 2 3 4 
 –   +        –   +        
 –   –   +        +        
 
A B C 
kD 
 
 
 
 
116.0 
 
 
 
 
 
66.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45.0 
 
 
 
35.0 
 
 
25.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
18.4 
 129 
 
 
 
Lane 6 contains proteins eluted with 1 M imidazole in 8 M urea buffer. The dominant protein 
band in lane 6 matches the 50 kD band in lane 1 corresponding to the recombinant His6-
PyBCCP. Proteins that did not bind to the immobilised-cobalt affinity matrix (before the wash 
steps) were not resolved on the acrylamide gel because guanidine forms an insoluble complex 
with SDS in the treatment buffer. Figure 5.17B illustrates the SDS-PAGE analysis of the 
purification profile of His6-PyBCCP under native conditions using the soluble fraction 
obtained from cell culture (500 ml) induced with 0.5 mM IPTG (16 h, 18°C). This condition 
was not used because the level of expression was more than 100-fold less compared to 
expression at 37°C, though the expression at 18°C resulted in recombinant proteins being in 
the soluble fraction. Figure 5.17B also demonstrated that His6-PyBCCP expressed at 18°C 
was capable of binding to the immobilised-cobalt affinity matrix. 
 
The purified His6-PyBCCP was renatured by a series of dialysis steps against decreasing 
concentrations of urea in 20 mM Tris-HCl buffer. At 0.5 M urea, part of the protein 
precipitated out of the solution. Thus, some of the recombinant protein was lost during the 
refolding process. The insoluble protein and the refold d protein were resolved along side 
Figure 5.16 Analysis of the in vivo biotinylat ion of GST-PyCTRNt . Total cell lysate from E. 
coli cells expressing GST-PyCTRNt induced with IPTG (+) or uninduced (−), in the presence (+) 
or absence (−) of biotin, was resolved by SDS-PAGE (10%), blotted on a nitrocellulose membrane 
and probed with avidin-peroxidase conjugate. 
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each other on 10% SDS-PAGE (Figure 5.18). The results showed that part of the refolded 
protein formed precipitates; however, a substantial amount of the recombinant protein was 
renatured and solubilised. Approximately 10 mg of recombinant purified recombinant protein 
per litre of culture was obtained. 
 
 
 
Figure 5.17 Immobilised-cobalt affinity purification of His 6-PyBCCP. The purification profile 
of recombinant His6-PyBCCP was analysed by SDS-PAGE. (A) Under denaturing conditions (10% 
acrylamide gel). Lane 1, insoluble fraction; lanes 2 – 5, wash steps; lane 6, elution with 1 M 
imidazole. (B) Under native condition (12.5% acrylamide gel). Lane 1, soluble fraction of the cell 
lysate; lane 2, flow through fraction; lanes 3 and 4 first and second wash steps, respectively; lane 5 
and 6, elution with 50 mM and 250 mM imidazole respectively. 
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The refolded protein was analysed by non-reducing SDS-PAGE (10%) to ascertain if the 
recombinant protein formed oligomer in the absence of β-mercaptoethanol or DTT (Figure 
5.19). The result showed that the recombinant protein did not form a defined quaternary 
structure but rather aggregated and did not resolve in the running gel (lane 2) when compared 
to the reduced recombinant protein sample (lane 1).  
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Figure 5.19 SDS-PAGE analysis of the oligomerisation of His6-PyBCCP. Purified and refolded 
His6-PyBCCP was treated with reduced with β-mercpatoethanol (lane 1) or not reduced (lane 2) 
and resolved by SDS-PAGE (10%).  
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Figure 5.18 Refolding of immobilised-cobalt affinity purified -His6-PyBCCP. The refolding of 
the purified recombinant His6-PyBCCP was resolved by SDS-PAGE (10%). Lane 1, starting 
material; lane 2, precipitated product; lane 3, solubilised recombinant protein.   
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A similar result was obtained when the acrylamide concentration was reduced to 5.5%, low 
enough to resolve proteins between 45 kD and 350 kD (result not shown). There is no data 
that suggests the precise size of the polymeric form f acetyl-CoA carboxylase. Probably, the 
aghregation of the recombinant protein may be due to the presence of cystine residues, which 
is reduced in the presence of β-mercaptoethanol. 
    
5.3 Discussion 
Biotin dependent enzymes such as carboxylases and decarboxylases in several organisms 
ranging from prokaryotes to higher eukaryotes are st ongly conserved proteins (Athappilly 
and Hendrickson, 1995; Gornicki and Haselkorn, 1993; Li et al., 2006; Reche and Perham, 
1999) with a common MKM biotin binding motif (Chapman-Smith and Cronan, 1999a; 
Chapman-Smith and Cronan, 1999c; Reche et al., 1998). The interest in understanding the 
involvement of the biotin-dependent acetyl-CoA carboxylase in P. yoelii led us to clone, 
express and analyse the recombinant P. yoelii biotinoyl proteins as GST-PyBCCP and His6-
PyBCCP fusion proteins. The fusion protein was exprssed in E. coli under the assumption 
that the E. coli biotin protein ligase would biotinylate the recombinant proteins (Chapman-
Smith et al., 1999; Chapman-Smith et al., 2001; Polyak et al., 2001; Solbiati et al., 2002). 
Comparative sequence analysis of the enzyme revealed the presence of a biotin-binding motif, 
VEAMKM, within the biotinoyl domain of Plasmodium acetyl-CoA carboxylase. This motif 
is 100% identical to the E. coli biotinoyl protein subunit of acetyl-CoA carboxylase (Cronan, 
2001; Cronan, 2002; Cronan and Waldrop, 2002).  
 
The recognition by a biotin protein ligase of a biotin-dependent protein, such as the biotinoyl 
domain of acetyl-CoA carboxylase, is thought to involve residues that are outside the biotin-
binding motif (Chapman-Smith and Cronan, 1999c; Chapm n-Smith et al., 1999; Polyak et 
al., 2001; Solbiati et al., 2002). Therefore, it was important to consider several factors relating 
to the molecular structure and the dynamics of the protein such as (i) the folding of the 
recombinant protein expressed in a heterologous system (ii) the orientation of the VEAMKM 
motif on the surface for proper recognition by the E. coli biotin protein ligase (BirA) will be 
vital for the recombinant protein to be biotinylated and (iii) the role played by some residues 
that are far removed from the VEAMKM motif but are v ry crucial in the recognition by the 
biotin protein ligase. Previous studies on E. coli BCCP have shown that the extent to which a 
truncated BCCP is biotinylated depends on the number of amino acid residues flanking the 
MKM motif (Beckett et al., 1999).  
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With these factors in mind, a region between 324 – 506 bp flanking the 219 bp biotinoyl 
domain was cloned and expressed, thus resulting in a protein with 108 and 169 amino acid 
residues upstream and downstream of the biotinoyl dmain. This stretch of amino acid 
residues outside the domain was hoped to ensure corct folding of the recombinant proteins. 
The presence of the highly charged poly-histidine tag and the GST-tag on the recombinant 
proteins are likely to hinder the activity of the E. coli biotin protein ligase. Studies have 
shown that regardless of the fact that BirA recognizes the consensus MKM motif, the 
recognition is based on the context of a properly fo ded protein (Chapman-Smith and Cronan, 
1999b; Chapman-Smith and Cronan, 1999c; Chapman-Smith et al., 1999; Streaker and 
Beckett, 1999). Therefore, it is possible that improper folding of the recombinant protein may 
result in poor biotin attachment by BirA, which may compromise the study. Sequencing the 
recombinant genes from the expression plasmids confirmed the sequence of the recombinant 
genes. Two expression systems were chosen for this study to affirm that the biotinylation of 
the recombinant protein is independent of expression ystem.  Studies have shown that the 
presence of enhancement tags such as MBP, poly-His and GST often do not alter the activity 
of the recombinant Plasmodium proteins (Flick et al., 2004; Mehlin et al., 2006; Pandey et 
al., 2006).  
 
Both recombinant proteins were found to be insoluble when expressed at 37ºC. Changing the 
expression temperature to 20ºC produced small amounts of soluble recombinant poly-His-tag 
protein product. In both systems, truncated products were obtained. This may be due to the 
nature of the gene transcript products and the inabil ty of the E. coli gene transcriptional 
system to properly transcribe the cloned gene (Makrides, 1996; Mehlin et al., 2006; Sorensen 
and Mortensen, 2005a). The truncations may also be as a result of proteolytic degradation of 
the recombinant protein. Efforts to express the protein as an MBP-fusion protein were not 
successful. Generally, studies have shown that Pl smodium-derived proteins are difficult to 
express heterologously in E. coli  and most Plasmodium proteins expressed in E. coli are 
insoluble (Flick et al., 2004; Mehlin et al., 2006) and often truncated. These pitfalls are 
sometimes related to the property of the protein such as the isoelectric point pH (pI) or the 
gene composition (GC/AT ratio) of the recombinant transcript (Mehlin et al., 2006). 
However, the theoretical pI of the recombinant proteins (6.73 and 6.20 for His6-PyBCCP and 
GST-PyBCCP, respectively) are within the range (3.6– 6.8) that expressed as soluble proteins 
based on the study by Mehlin et al., (2006). 
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Due to long stretches of A or T nucleotides in the Plasmodium gene, expression of 
Plasmodium proteins in E. coli often prove to be difficult. The PYBCCP gene product has 
76% AT content, with approximately 15 stretches of AAAAA and six stretches of TTTT in its 
sequence. The use of Rosetta (DE3) pLysS E. coli strain that expresses the tRNAs for rare 
codons not highly used by E. coli did not prevent the truncation of the recombinant P. yoelii 
biotinoyl protein. Although some studies have shown that E. coli strains engineered to express 
the rare codons improve the quality of the recombinant plasmodial proteins (Baca and Hol, 
2000). These truncations appeared to have occurred at the C-terminal region of the protein 
judging by the patterns obtained when using anti-GST antibody for detection. However, it is 
not known whether the truncation was as a result of errors in transcription of the recombinant 
gene or post-translational proteolysis of the protein. This question may be answered by 
analysis of the mRNA transcript of the recombinant gene in the expressing E. coli cells; 
though this was not within the scope of this study.  
 
The focus of this study was to establish the presence of biotin in the recombinant proteins. 
There are no reports on enzymatic cleavage of the biotin moiety from the biotinylated protein, 
and studies have shown that biotinylated biotin carrier protein is quite resistant to proteolytic 
degradation (Solbiati et al., 2002). The presence of biotin on the recombinant pro ein was 
established in both GST-fusion and poly-His tag recombinant P. yoelii biotinoyl proteins 
using peroxidase-conjugated avidin. This suggests that the recombinant protein folds into a 
conformation that is recognised by the E. coli BirA.  
 
This is in contrast to an earlier study done by (Thelen et al., 2001) on the expression of A.
thaliana biotinoyl protein subunit of acetyl-CoA carboxylase. A remarkable increase in the 
biotinylation of the recombinant protein was observed after the medium was supplemented 
with external D-biotin. Thelen et al., (2001) did not correlate the difference between E. coli 
and A. thaliana biotin binding motifs as the probable cause of the poor biotinylation of the 
recombinant A. thaliana biotin carboxyl carrier protein. The consensus motif in several 
organisms is MKM (Chapman-Smith and Cronan, 1999c). The rate of biotinylation by the E. 
coli BirA correlates to the composition of residues around the biotinylation motif (Lee t al., 
2008). Replacing the residues around the MKM consensus motif in human biotinoyl protein 
with the E. coli sequence improved the activity of the mutant protein compared to the wild 
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type (Lee et al., 2008). This observation may explain why expressing recombinant P. yoelii 
biotinoyl proteins in E. coli resulted in the biotinylation of the recombinant protein.  
 
The specificity of the biotinylation of the recombinant P. yoelii biotinoyl proteins was 
confirmed when the P. yoelii copper transport protein (PyCTRNt) was not biotinylated. 
PyCTRNt lacked the biotin attachment motif (VEAMKM) and contains 14 lysine residues 
that could have been biotinylated if the biotinylation process was not specific. The observed 
biotinylation of the recombinant P. yoelii biotinoyl proteins may be further validated by 
expressing the P. yoelii biotinoyl protein in a BirA-deficient strain of E. coli (Chapman-Smith 
et al., 1994). Inhibitors of biotin synthesis pathway in bacteria may also be useful tools in 
validating this observation. Anti-biotin antibody used as a second detecting agent also 
confirmed the result from avidin-peroxidase detection. However, the results were not included 
due to some non-specific detection of E. coli proteins by the anti-biotin antibody from mouse 
ascites fluid. 
 
One interesting question raised by this study is: Does the rate at which the E. coli biotin 
biosynthesis and BirA match the rate of recombinant protein synthesis? Theoretically it is 
thought that IPTG and chloramphenicol reduce the transcription of the E. coli chromosomal 
genes (Balbás and Bólivar, 1990; Balbás et al., 1986).  But it appeared that the E. coli biotin 
biosynthesis and BirA may have been active in the covalent attachment of biotin on the 
recombinant protein. The E. coli biotin operon contains five structural chromosomal genes 
that are involved in the synthesis of biotin; thus the synthesis of biotin in E. coli is a tightly 
regulated process (Chapman-Smith and Cronan, 1999a; Streaker and Beckett, 2006). The 
transcription of these genes are under control of intracellular biotin-5’-AMP, BirA and the 
biotin acceptor substrate (Chapman-Smith and Cronan, 1999a; Chapman-Smith et al., 1999). 
Overproduction of BirA results in the repression of the biotin operon by BirA (a bifunctional 
enzyme). On the other hand, over production of biotinoyl protein results in the derepression of 
the biotin operon (Chapman-Smith and Cronan, 1999a; Reche, 2000). In this context P. 
yoelii-biotinoyl protein is one of the biotin acceptor molecules, the other being the E. coli 
biotinoyl protein as the only biotinylated E. coli protein (Chapman-Smith et al., 2001).  
 
The over expression of the recombinant proteins may have had a direct influence on the biotin 
operon, therefore leading to the derepression of the operon and consequently biotinylation of 
the recombinant proteins. In order to be a molecular sensor of the biotin operon, the 
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recombinant biotinoyl proteins must have a structural conformation recognised by the BirA 
(Chapman-Smith and Cronan, 1999a; Chapman-Smith and Cronan, 1999c). This is because 
the process of biotinylation occurs post-translationally within the context of a proper folded 
protein domain (Chapman-Smith and Cronan, 1999c). Therefore the tertiary conformation of 
P. yoelii biotinoyl protein may be vital for the recognition f the biotin protein ligase. This 
suggests that the recombinant proteins may have been folded into a proper structured 
conformation prior to their transformation into inclusion bodies. The interaction between 
BirA and its biotin-dependent substrates have been well studied (Chapman-Smith et al., 1999; 
Reche and Perham, 1999). The three dimensional structure of P. yoelii biotinoyl protein with 
regards to interaction with BirA will be discussed in detail in the Chapter 6. 
 
Bacteria, plants and some fungi have the ability to synthesize biotin used for the modification 
of biotin-dependent enzymes in these organisms (Muller and Kappes, 2007). Yeasts such as S. 
pombe and S. cerevisiae do have the ability to transports biotin across their cell membrane 
from the surrounding medium. Biotin dependent enzymes depend on biotin protein ligase for 
activity (Knowles, 1989). A BLAST search of the P. falciparum genome and the other 
Plasmodium genomes using biotin synthase from bacteria and plants reveals that the parasite 
lacks the gene that codes for biotin synthesis. Most Plasmodium species encode two copies of 
biotin protein ligase, in contrast with other apicomplexa parasites such as T. gondii, C. 
parvum and C. hominis, which encode one copy (Muller and Kappes, 2007).  
 
There is no empirical evidence suggesting biotin protein ligase activities in Plasmodium. One 
possible mechanism by which the Plasmodium parasites obtain biotin may be by importation 
from the host. A search of the P. falciparum genome (BLAST) as well as the other 
Plasmodium genomes using putative biotin ABC transporter from Bartonella bacilliformis 
(NCBI accession number YP_989450) detected ABC-like transport protein in P. falciparum 
(Plasmodb ID: PF13_0218) and in other Plasmodium species. ABC transporters belong to a 
family of the ATP-Binding Cassette (ABC) that uses the hydrolysis of ATP to energize the 
transport of a wide array of substrates, ranging from ions to macromolecules, across the 
membrane phospho-lipid bilayer (Holland and Blight, 1999). The transport of nutrients across 
Plasmodium-infected erythrocytes has been studied. Nutrients such as vitamins and amino 
acids are thought to permeate the red blood cell through some form of membrane localized 
transporters on either the red blood cell membrane or parasitophorous vacuole membrane 
(Kirk, 2001). The transport of biotin is yet to be explored in the Plasmodium parasite. The 
 137 
only vitamin that the Plasmodium parasite is thought to transport from the vertebrate host is 
pantothenic acid (vitamin B5), due to its absolute requirement as a precursor of coenzyme-A 
(Kirk, 2001). It would be interesting to investigate the hypothesis that Plasmodium parasites 
imports biotin from the host using radiolabelled biotin.  
 
The presence of biotin on the recombinant P. yoelii protein could further be validated by 
methods such as MALDI-TOF and NMR, and by Edman’s degradation. Producing antibodies 
against the recombinant protein may be an attractive approach towards immunoprecipitation 
of the native enzyme for activity assays. The inability of the cells to express soluble 
recombinant P. yoelii biotinoyl protein in large quantities meant that using denaturing 
immobilised-metal affinity chromatography was the opti n for obtaining a purified 
recombinant P. yoelii biotinoyl protein. The purified recombinant P. yoelii biotinoyl protein 
was re-natured by stepwise dialysis against decreasing concentrations of urea. This resulted in 
solubilisation of the protein, though some the recombinant P. yoelii biotinoyl protein re-
precipitated during this process. During the course of this study using the purified and 
resolubilised P. yoelii biotinoyl protein, it was observed that cycles of freeze-thaw of the 
refolded protein resulted in precipitation. However, the protein remained soluble after several 
cycles of free-thaws when stored in 50% glycerol. Further studies on the recombinant P. 
yoelii biotinoyl protein may be required. 
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CHAPTER 6 
PLASMODIUM YOELII ACETYL-COA CARBOXYLASE: SEQUENCE ANALYSIS, 
PREDICTION OF PROTEIN KINASE PHOSPHORYLATION SITES AND  
HOMOLOGY MODELLING STUDIES 
 
6.0 Introduction 
With numerous genome sequencing projects, large numbers of organisms such as 
Plasmodium, humans, yeast and Arabidopsis have their entire genome sequenced along with 
their proteome and published on several databases. Important information on the evolution of 
protein families can be deduced by comparative amino acid sequence studies. Based on the 
amino acid sequences, amino acid substitutions that affect shape and stability of a protein can 
be studied (Knudsen and Miyamoto, 2001). Data derived from comparative studies could 
reveal the structure, function and it evolutionary relationship with other known protein 
families in a tree diagram referred to as molecular phylogenetic tree. A section of this study 
involved comparative analysis of the published P. yoelii acetyl-CoA carboxylase sequence 
with orthologues from other Plasmodium species and homologues from other organisms. The 
sequence alignment data was used to identify likely modification sites on P. yoelii acetyl-CoA 
carboxylase that appeared to be highly conserved across the selected set of organisms. 
 
The three dimensional (3D) structure of a protein is primarily determined by its amino acid 
sequence composition; and it provides important insight  into the molecular basis of protein 
function (Schwede et al., 2000; Schwede t al., 2003). Progress has been made, over the 
years, towards sequencing the genome of several orgnisms. This has led to large amount 
published protein sequences (Schwede t al., 2003; Sigrist et al., 2002). By 2003, the SWISS-
PROT™ and the TrEMBL™ data bases held about 850 000 protein sequence entries, while 
the Protein Data Bank (PDB) held about 20 000 experimentally-determined protein 3D 
structures (Schwede t al., 2003). This indicates that two crystal structures were resolved for 
every 85 proteins sequenced, despite the high levelof progress made in X-ray crystallography 
and nuclear magnetic resonance (NMR) spectroscopy. These two methods of protein crystal 
structure resolution are time-consuming and success is not absolutely guaranteed (Kopp and 
Schwede, 2004; Schwede et al., 2003). The shortfall in resolving 3D crystal structures of 
proteins has led to a lack of information on numerous proteins with published amino acid 
sequences (Kopp and Schwede, 2004). 
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Computational methods have been developed to predict 3D structures of proteins in order to 
close the gap between published amino acid sequences and their corresponding 3D structures 
(Kopp and Schwede, 2004; Schwede et al., 2000; Schwede t al., 2003; Yang and Honig, 
2000a; Yang and Honig, 2000b). These methods are able to generate the 3D structure of a 
protein de novo or based upon a template of an experimentally-resolv d crystal structure 
(Kopp and Schwede, 2004; Schwede et al., 2000; Schwede t al., 2003; Yang and Honig, 
2000b). The method of predicting the 3D conformation of a protein using an existing crystal 
structure template is called homology or comparative protein modelling (Kopp and Schwede, 
2004; Schwede t al., 2003). The pre-existing 3D structure must share a l vel of homology 
with the protein to be modelled (Kopp and Schwede, 2004; Schwede t al., 2003).  
 
The SWISS-MODEL™ server is one of the several protein structure prediction programmes 
available as a downloadable or a web-based programme (Kopp and Schwede, 2004; Schwede 
et al., 2003). The server is designed to work with a mini al input from the user, sometimes 
limiting the input to just the amino-acid sequence (Kopp and Schwede, 2004; Schwede et al., 
2000; Schwede et al., 2003). This server has three modelling modes, namely the ‘first 
approach’ mode, the ‘alignment’ mode and the ‘project’ mode. The ‘first approach’ mode 
requires only an amino acid sequence as the input data. The server automatically selects a 
suitable template for the protein to be modelled (the target). This mode can only work if the 
template and the target share at least 25% sequence identity (Kopp and Schwede, 2004; 
Schwede et al., 2003). In the alignment mode, the user is requird to identify a template with 
a PDP coordinate for the target. The template and the target are pre-aligned. The alignment 
output is submitted to the server in ClustalW™, FAST  or other formats specified by the 
server. The 3D model of the protein is therefore built on the template. The only difference 
between this mode and the first approach mode is that the user has control over the choice of 
template sequence. The Project mode requires the user to submit a manually optimized 
modelling request to the server. The modelling result i  evaluated by the server to verify the 
accuracy of the predicted model. It has been shown that conserved regions do model better 
than unconserved regions (Kopp and Schwede, 2004; Schwede et al., 2000; Schwede t al., 
2003; Yang and Honig, 2000a; Yang and Honig, 2000b). The SWISS-MODEL™ server uses 
several algorithms such as ANOLEA™ (Melo and Feytmans, 1998) and GROMOS™ (van 
Gunsteren and Billetter, 1996) to evaluate the quality of the predicted model. The predicted 
model is downloaded as a PDP file containing PDB coordinates. The model can be viewed 
with the SWISS-PDP viewer (spdbv). The spdpv programme contains several parameters 
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such as energy minimization algorithms that allow the user to improve the accuracy of the 
model. This is because modelling algorithms introduce errors into the structure resulting in 
deviations in the geometry of the protein structure (Kopp and Schwede, 2004; Schwede et al., 
2003). The root mean square deviation of the predict  3D structure from the template is 
deduced from the spdv programme and expressed in Å. The refined models can be validated 
using the ProCheck™ algorithm found on the PDP web site for advanced deposition input 
tool (ADIT, http://deposit.pdb.org/adit). 
 
Results in Chapter 5 showed that recombinant expression of the biotinoyl domain of P. yoelii 
acetyl-CoA carboxylase led to in vivo biotinylation of the recombinant protein by the E. coli 
host with or without an external supply of D-biotin in the culture. This suggested that the E. 
coli biotin protein ligase (Chapman-Smith et al., 2001; Reche, 2000) recognizes the 
recombinant protein as a substrate for co-translation l modification (Chapman-Smith and 
Cronan, 1999c; Chapman-Smith et al., 1999). To relate this to the conformation of the 
recombinant protein, homology modelling of the recombinant protein was carried out with the 
SWISS-MODEL™ server using the E. coli biotinoyl domain (PDB ID: 1bdo) as the template 
(Athappilly and Hendrickson, 1995). The polyketide, soraphen A (Figure 6.1) has been shown 
to inhibit acetyl-CoA carboxylase activity by bindig to 19 residues on the biotin carboxylase 
domain (Beckers et al., 2007; Shen et al., 2004; Weatherly et al., 2004). The potential of 
soraphen A as an inhibitor of P. yoelii acetyl-CoA carboxylase was examined. The 3D model 
of P. yoelii biotin carboxylase domain was modelled using S. cerevisiae (PDB ID: 1w93) as a 
template. Positive control 3D model of the E. coli biotinoyl subunit and the S. cerevisiae 
biotin carboxylase domain were generated using their coordinates (1bdo and 1w93) as 
templates. For the sake of convenience, the predicted P. yoelii biotinoyl model and the E. coli 
positive control model will be referred to as PyBCCP-model and EcBCCP+, respectively. The 
predicted biotin carboxylase models for P. yoelii, P. falciparum, H. sapiens and the S. 
cerevisiae positive control will be referred to as PyBC-model, PfBC-model, HsBC-model and 
ScBC+, respectively. 
 
6.2 Results 
6.2.1 Identification of conserved sequence motifs using ClustalW™ analysis 
The amino acid sequence coding for the acetyl-CoA carboxylase 1 precursor in P. yoelii yoelii 
strain 17XNL and its orthologues from P. falciparum, P. vivax, P. berghei, P. chabaudi and 
P. knowlesi were retrieved from NCBI and/or Plasmodb database (www.plasmodb.org). These 
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sequences were analysed with the ClustalW™, ProSiteScan™ (Proscan™) and 
InterProScan™ algorithms for alignment and identification of predicted protein domains in 
each polypeptide. The results obtained were compared to published acetyl-CoA carboxylase 
amino-acid sequences from several organisms. Table 6.1 is the list of the amino-acid 
sequences of acetyl-CoA carboxylase from four Plasmodium species and eight eukaryotic 
organisms ranging from unicellular photosynthetic organism (O. lucimarinus) to humans. P. 
berghei and chabaudi were excluded from this study due to incomplete amino acid sequences. 
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Figure 6.1 Structure of soraphen A (Shen et al., 2004). 
 
 
In four orthologues of Plasmodium acetyl-CoA carboxylase, the domain closest to the N-
terminus is the biotin carboxylase domain, followed by the biotin carboxyl carrier protein and 
the carboxyl transferase domains with two (N-terminal and C-terminal) sub-domains. The 
Proscan™ motif and sequence domain prediction programme showed that P. berghei 
(XP_679544) was wrongly annotated in the Plasmodb and NCBI databases as biotin 
carboxylase subunit instead of as a carboxyl transfera e domain. P. berghei (PB000685.01.0) 
and P. chabaudi (XP_743705) hypothetical proteins were identified to be fragments 
containing the biotin carboxylase and the biotin carboxyl carrier protein domains, 
respectively. Using the NCBI BLAST, it was observed that P. yoelii acetyl-CoA carboxylase 
shares 45% identity and 68% similar in amino acid sequence with Oestreococus lucimarinus 
predicted protein (with acetyl-CoA carboxylase sequence motifs). Proscan™ analysis 
revealed that all organisms listed in Table 6.1 all h ve the same array of sequence motifs with 
the same order. This confirms that P. yoelii and other Plasmodium species express the multi-
enzyme-domain type acetyl-CoA carboxylase because the four domains form part of a long 
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polypeptide structure with a single ORF. This is in contrast to the multi-enzyme-subunit 
(complex) acetyl-CoA carboxylase consisting of four separate enzymes found in E. coli and 
plastids of some dicotyledonous green plants (Cronan and Waldrop, 2002; Sasaki and 
Nagano, 2004; Zhang et al., 2004). However some plants encode the multi-enzyme-domain 
type acetyl-CoA carboxylase targeted to their chloroplast, in addition to the multi-enzyme-
subunit (complex) type in their cytoplasm (Sasaki and Nagano, 2004; Zhang et al., 2004). 
 
Table 6.1 Acetyl-CoA carboxylase from the respective organisms used for bioinformatics  
Organism 
 
NCBI or Plasmodb 
access number 
Sequence 
length 
Number of predicted 
domains 
P. yoelii XP_729490 2911 4 
P. falciparum XP_001348838 3336 4 
P. vivax XP_001615692 3061 4 
P. knowlesi PKH_123560a 2921 4 
H. sapiens-1 NP_942131 2346 4 
H. sapiens-2 ABF48723 2458 4 
M. musculus-1 AAS13686 2354 4 
M. musculus-2 NP_579938 2448 4 
A. thaliana-1 AAG40563 2254 4 
A. thaliana-2 AAF18638 2257 4 
O. lucimarinusp XP_001415874 2012 4 
S. cerevisiae NP_014413 2233 4 
G .gallus NP_990836 2324 4 
T. brucei XP_847540 2181 4 
T. gondii AAF04493 2564 4 
D. melanogaster NP_610342 2323 4 
C. parvum XP_667901 2725 4 
a Plasmodb access number,   
p predicted protein (not annotated), 
 
 
6.2.2 Phylogenetic analysis of P. yoelii acetyl-CoA carboxylase  
A molecular phylogenetic tree was constructed from acetyl-CoA carboxylase sequences listed 
in Table 6.1using the CLC Free Workbench™ software. Aligned sequences were used to 
construct the phylogenetic tree (Figure 6.2) with the option of the neighbour joining-
algorithm and 1000 bootstrap analysis (replicates); thus enabling the construction of a reliable 
phylogenetic tree (Brinkman and Weissig, 2001; Felsenstein, 1985). The bootstrap value for 
each node was attached as a measure of confidence for each branch. Thus 1000 bootstrap 
value indicated a perfect cluster. The phylogenetic analysis showed two major clusters shown 
by the arrows on the diagram. Cluster 1 (arrow 1) represents plastid-encoded organisms 
including O. lucimarinus (a unicellular photosynthetic organism), T. gondii, C. parvum and 
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Plasmodium. Plasmodium acetyl-CoA carboxylase sequences clustered to a single orthologue 
group with a perfect cluster (1000 bootstrap value). P. yoelii acetyl-CoA carboxylase 
clustered with P. falciparum with slightly lower bootstrap value (675), which is probably due 
to multiple asparagine repeats in the falciparum sequence. T. gondii and O. lucimarinus both 
formed a cluster with a bootstrap value of 633.  
 
 
 
Figure 6.2 Phylogenetic tree of 17 eukaryotic acetyl-CoA carboxylase sequences. A Neighbour 
joining tree was built from acetyl-CoA carboxylase amino acid sequences aligned by the ClustalW™ 
alignment algorithm in CLC Free WorkbenchTM software. The numbers indicates bootstrap (replicates) 
values corresponding to each branch. The scale bar represents 0.7 mutational changes per amino acid 
residue. The access number for each sequence examined is listed on Table 6.1. Arrows 1 and 2 show 
two major clusters corresponding to apicomplexans and other eukaryotes, respectively. 
 
 
Acetyl-CoA carboxylases sequences from other organisms formed a single cluster with a 
bootstrap score of 978 in cluster 2 (arrow 2). T. brucei acetyl-CoA carboxylase formed an 
outlier. By and large, the phylogenetic study depicted that Plasmodium acetyl-CoA 
carboxylase is closely related to T. gondii, C. parvum and O. lucimarinus, but fairly divergent 
from the other organisms examined. There was no explanation on why T. brucei did not 
cluster in either group. 
 
1 
2 
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6.2.3 Sequence length variation in regions of the selected acetyl-CoA carboxylase 
sequences 
To examine how much the length of the amino acid sequence in the multi-enzyme-domain 
type acetyl-CoA carboxylase varies from one organism to another, the Proscan™ tool was 
used to assemble the lengths of the sequence in each region of the 17 acetyl-CoA 
carboxylases listed in Table 6.1. Figure 6.3 illustrates the comparison of the lengths of amino-
acid sequence of the regions of the acetyl-CoA carboxylase enzymes examined. The regions 
of the polypeptide with no predicted functional sequ nce domains are I, II, III and IV as 
depicted in Figure 6.3. Generally, the results showed that the total length of the polypeptide 
chain changes from one organism to another. Regions I a d IV showed the most variation in 
sequence length with approximately ±2 residues per 3-mer (three monomeric amino acid unit) 
and ±2 residues per 7-mer respectively. The variation in length of the region III was ±1 amino 
acid per 5-mer. The sequence length of region II varied by ±1 amino acid per 26-mer. The 
biotin carboxylase domain varied with ±2 amino acid residues per 29-mer while the carboxyl 
transferase domain varied the most amongst the predicted functional sequence domains with 
±1 amino acid residue per 11-mer. The biotin carboxyl carrier protein domain is the most 
conserved sequence length with ±1 amino acid per 28-mer. The most significant point of note 
of this result is the consistent sequence length of the biotin carboxyl carrier protein domain 
with 73 amino acid residues in all Plasmodium species and 67 amino acid residues in the 
other organisms. This perhaps suggests high degree of volutionary conservation in sequence 
length and structure of the biotin carboxyl carrier protein, thus indicating the importance of 
this domain to the structure and function of acetyl-CoA carboxylase. 
 
6.2.4 Assignment of phosphorylation sites in P. yoelii acetyl-CoA carboxylase using 
predictive algorithms 
Using ClustalW™ alignment (Figure 6.4A), the positions of possible phosphorylation sites 
that appeared to be highly conserved across all the organisms and Plasmodium species were 
mapped using the Proscan™ motif prediction tool. This program is similar to the 
InterProScan™ tool, except that it displays the amino acid sequence corresponding to a 
signature sequence motif as well as the confidence lev l for each identified motif on a 
polypeptide. The basis of this study hinges on the premise that important amino acid sequence 
motifs involved in the functioning or structural architecture of a protein are often maintained 
regardless of evolutionary divergence.  
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Figure 6.3 Quantitative evaluation of the variation in the number amino acid residue of 17 acetyl-CoA carboxylase sequences. Full length or fragments 
of acetyl-CoA carboxylases were scanned by web-based Proscan™. The programme identified the three domains nd the number of amino acid residues 
corresponding to each of the three domains. The number of amino acid residues corresponding to all the regions of the enzyme was subsequently deduced 
based on the Scan ProSite data. pp is partially predicted protein. 
 
 
Organism Length  Length Length Length Length Length Length 
P. yoelii 418 530 140 73 1131 583 35 
P. falciparum 467 643 155 73 1272 609 118 
P. vivax 447 543 139 73 1214 530 117 
P. knowlesi 407 553 139 73 1105 529 117 
H. sapiens-1 116 502 134 67 880 497 152 
H. sapiens-2 258 502 134 67 848 497 153 
M. musculus-1 115 502 134 67 880 497 161 
M. musculus-2 248 503 134 67 848 497 153 
A. thaliana-1 35 508 134 67 788 579 144 
A. thaliana-2 36 508 135 67 792 579 144 
O. lucimarinuspp - 485 136 67 742 484 118 
S. cerevisiae 57 510 134 67 836 491 132 
G. gallus 116 502 134 67 857 497 135 
T. brucei 28 497 138 67 813 527 113 
T. gondii 338 497 138 67 953 500 74 
D. melanogaster 99 497 133 67 873 499 155 
C. parvum 25 491 147 67 1402 503 95 
Biotin carboxylase Biotin carboxyl 
carrier protein 
Carboxyl transferase I  I I  I II  IV 
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Figure 6.4B shows a schematic representation of predicted enzyme modification sites on P. 
yoelii acetyl-CoA carboxylase based upon the ClustalW™ multiple sequence alignment data 
combined with the Proscan™ analysis.  
 
The results predicted five potential phosphorylation sites; one (P1) on the biotin carboxylase 
domain and four (P1 to P5) on the carboxyl transferas  domain (Figure 6.4). The predicted 
protein kinase C (PKC) phosphorylation site (P1) on the biotin carboxylase domain appeared 
to be conserved across the 10 acetyl-CoA carboxylase sequences. The PKC phosphorylation 
site has a consensus sequence SL/IK in Plasmodium and SIR in the other organisms looked at. 
The putative phosphorylation serine (S) residue and C-terminal tryptophan (W) are 
conserved across all the acetyl-CoA carboxylase analysed (P1).  
 
The first phosphorylation site (P2) on the carboxyl transferase domain is predicted to be a 
PKC phosphorylation site with the consensus sequence TSK. This site is not present in other 
organisms, but the phospho-serine residue is highly conserved. P3 is a conserved predicted 
PKC phosphorylation site with the sequence, TGR, in Plasmodium, the sequence, TCR, in 
mammals, and the sequence, SGR, in A. thaliana. This suggests that threonine is a likely 
phosphorylation residue in all the examined organisms at this site, except A. thaliana, which 
has a serine as the possible phosphorylation residu. P. yoelii and other Plasmodium species 
acetyl-CoA carboxylases may be phosphorylated at P4 by either cAMP-dependent protein 
kinase (PKA) or cGMP-dependent protein kinase (PKG) with the KGS sequence 100% 
conserved in Plasmodium. At P5 is a potential PKC site with TGR consensus equence 
synonymous with P3. This site is not present in thehuman and mouse α-acetyl-CoA 
carboxylases. This site also encodes a phosphate-binding consensus sequence GXGXXG 
(Kleiger and Eisenberg, 2002; Kleiger t al., 2002) as GRGKLG, on the C-terminal end 
preceding the phosphorylation site.  
 
The Proscan™ analysis data on protein kinase phosphorylation sites was compared to the 
NetPhos 2.0™ (Blom et al., 1999) prediction algorithm for eukaryotic protein kinase 
phosphorylation site. Using ClustalW™-aligned sequences, conserved positions of possible 
protein kinase sites were identified (Figure 6.5). The programme indicates the possible 
phosphorylation residue flanked by four amino acid residues, but does not indicate the 
possible phosphorylating enzyme. The NetPhos 2.0™ programme predicted a highly 
conserved protein kinase site (N1) on the biotin carboxylase, synonymous with the P1 site 
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generated by Proscan™ analysis in Figure 6.4. The pospho-serine residue is highly 
conserved and flanked by conserved sequences, with a 100% conserved lysine and tryptophan 
at positions –4 and +4 respectively (the phospho-serine residue is at position 0). The serine 
residue at position +5 in H. sapiens 1 and M. musculus is most favoured with a score of 
99.7%.  
 
The only modification site that appeared to be conserved on the BCCP domain is the biotin 
attachment motif. The N-myristoylation sites predicted to be conserved by the Proscan™ tool 
does not precede the N-terminal methionine, and therefore ingnored. N-glycosylation sites 
identified by the Proscan™ analysis were not conserved and were not included in the results.  
 
A threonine phosphorylation site at N2 was identified by the programme on the carboxyl 
transferase domain, which appeared to be highly conserved. Except that the phospho-
threonine residue is not at a conserved position across the sequences examined. The phospho-
threonine residue is flanked by a 100% conserved lysine at position – 4 and + 4 (the phospho-
serine residue is at position 0), in Plasmodium. A phospho-serine protein kinase site that was 
only conserved in Plasmodium was identified by NetPhos 2.0™ algorithm. This site has a 
consensus sequence KTAQSIEDF (phospho-serine in bold), with a 100% conserved lysine 
and phenylalanine residues at – 4 and + 4 positions, respectively. 
 
6.2.5 Homology modelling of the biotinoyl domain of P.  yoelii acetyl-CoA carboxylase 
Of the 347 amino-acid sequence of the P. yoelii recombinant biotin carboxyl carrier protein 
(Chapter 5) submitted to the SWISS-MODEL™ sever in an alignment with 1bdo (template), 
80 residues corresponding to the region with significant identity (20%) with the template 
(1bdo) was modelled by the server. Eighty residues on the target were modelled because the 
template is made up of 80 amino acid residues, which are closely related to the 80 amino acid 
resides on the target model.  The total energy of PyBCCP-model before energy minimization 
was −163.072 kJ/mol, which was 5.5% of the total energy of EcBCCP+ (−2866.027 kJ/mol). 
The final energy of PyBCCP-model reduced to −937.229 kJ/mol; resulting in about 82.6% 
improvement on the packaging quality (Kopp and Schwede, 2004; Melo and Feytmans, 1998) 
after energy minimization. The positive control improved by 3.2% (from −2866.027 kJ/mol to 
−2959.852 kJ/mol).  
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H.sapiens1.          --------------------NKVIEKVLIANNGIAAVKCMRSIRRWSYEMFRNERAIRFV 154 
M.musculus1.         --------------------NKVIEKVLIANNGIAAVKCMRSIRRWSYEMFRNERAIRFV 153 
H.sapiens2.          --------------------DRVIEKVLIANNGIAAVKCMRSIRRWAYEMFRNERAIRFV 296 
M.musculus2.         --------------------NRVIEKVLIANNGIAAVKCMRSIRRWAYEMFRNERAIRFV 286 
P.yoelii.            YINYINERRYPYINYLKMKNEKIIKKLLIANNGMAALKCILSLKEWLFKTFNDENLIQII 456 
P.falciparum.        YVNYINERRYGYFDLLEKKNEKIIRKLLIANNGMAALKCILSLKDWLFKKFYDENLIKII 505 
P.knowlesi.          YTKYIEERRYPYFNFVKNKNGKIIKKLLIANNGMAAMKCILSIKEWLFKSFSEENLIKII 445 
P.vivax.             YTTYIEERRYPYFNFAKEKNGKIIKKLLIANNGMAAMKCILSIKEWLFKTFSEENLIKII 485 
                                          : *..:******:**:* : *:: * :: *  *. * :: 
 
 
 
 
H.sapiens1.          SGMIAGESSLAYNEIITISLVTCRAIGIGAYLVRLGQRTIQVENSHLILTGAGALNKVLG 1859 
M.musculus1.         SGMIAGESSLAYDEVITISLVTCRAIGIGAYLVRLGQRTIQVENSHLILTGAGALNKVLG 1858 
H.sapiens2.          SGMIAGESSLAYEEIVTISLVTCRAIGIGAYLVRLGQRVIQVENSHIILTGASALNKVLG 1970 
M.musculus2.         SGMIAGEASLAYEKTVTISMVTCRALGIGAYLVRLGQRVIQVENSHIILTGAGALNKVLG 1960 
P.yoelii.            SGLIAGETSKAYDEIFTLSYVTGRSVGIGAYLVRLGKRTIQKKGSSLLLTGFNALNKILG 2453 
P.falciparum.        SGLIAGETSKAYEEIFTLSYVTGRSVGIGAYLVRLGKRTIQKKGSSLLLTGFNALNKILG 2771 
P.knowlesi.          SGLIAGETSKAYDEIFTLSYVTGRSVGIGAYLVRLGKRTIQKKGSSLLLTGFNALNKILG 2438 
P.vivax.             SGLIAGETSKAYDEIFTLSYVTGRSVGIGAYLVRLGKRTIQKKGSSLLLTGFNALNKILG 2577 
                     :* ***  * **:: .*:: ** *::***:*:.*** * **  .. ::***  :***:** 
 
 
 
 
H.sapiens1.          VPTKTPYDPRWMLAGRPHPTQKGQWLSGFFDYGSFSEIMQPWAQTVVVGRARLGGIPVGV 1985 
M.musculus1.         VPTKAPYDPRWMLAGRPHPTQKGQWLSGFFDYGSFSEIMQPWAQTVVVGRARLGGIPVGV 1984 
H.sapiens2.          LPSRAPYDPRWMLAGRPHPTLKGTWQSGFFDHGSFKEIMAPWAQTVVTGRARLGGIPVGV 2096 
M.musculus2.         TPTKAPYDPRWMLAGRPHPTLKGTWQSGFFDHGSFKEIMAPWAQTVVTGRARLGGIPVGV 2086 
P.yoelii.            NKINDVDMDNVNEADIIELLKGSDKKQGFLDKNSYFEYMNEWGKGIITGRGKLGSIPIGF 2669 
P.falciparum.        LHINDMDYDHIDDSNIIDLIKGTQEEQGFLDKNTYFEYMNEWGKGIITGRGKLGSIPVGF 3011 
P.knowlesi.          QRINDIDMDNIQNADVIELIKGTDTKQGFLDKNSYFEYMNEWGKGIITGRGKLGSIPVGI 2598 
P.vivax.             QRINDIDMDGLQNADIVELISGTDSKQGFLDKHSYFEYMNEWGKGILTGRGKLGSIPVGV 2737 
                        .         ..  .         *::*  :: * :  *.: ::.**.:**.:*:*. 
 
 
 
 
 
 
Figure 6.4 Prosite™ prediction of protein kinase phosphorylation sites on enzyme domains of 
mammals and Plasmodium acetyl-CoA carboxylases. (A) Alignment produced by the ClustalW™ 
algorithm showing the predicted sites residues (highlighted) in the biotin carboxylase (BC) and the 
carboxyl transferase (CT) domains. (B). Cartoon structure of the multi-domain acetyl-CoA 
carboxylase illustrating the positions of the predicted phosphorylation sites. Double line indicates 
position fully or partially conserved across all organisms examined, broken line indicates position 
conserved only in Plasmodium.* indicates 100% conserved residue. 
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              NetPhos  
       Score  
                (%) 
 
H.sapiens1.    59.0  --------------------NKVIEKVLIANNGIAAVKCMRSIRRWSYEMFRNERAIRFV 154 
M.musculus1.   59.0  --------------------NKVIEKVLIANNGIAAVKCMRSIRRWSYEMFRNERAIRFV 153 
H.sapiens2.    53.9  --------------------DRVIEKVLIANNGIAAVKCMRSIRRWAYEMFRNERAIRFV 296 
M.musculus2.   53.4  --------------------NRVIEKVLIANNGIAAVKCMRSIRRWAYEMFRNERAIRFV 286 
P.yoelii.      79.4  YINYINERRYPYINYLKMKNEKIIKKLLIANNGMAALKCILSLKEWLFKTFNDENLIQII 456 
P.falciparum.  95.3  YVNYINERRYGYFDLLEKKNEKIIRKLLIANNGMAALKCILSLKDWLFKKFYDENLIKII 505 
P.knowlesi.    98.2  YTKYIEERRYPYFNFVKNKNGKIIKKLLIANNGMAAMKCILSIKEWLFKSFSEENLIKII 445 
P.vivax.       98.2  YTTYIEERRYPYFNFAKEKNGKIIKKLLIANNGMAAMKCILSIKEWLFKTFSEENLIKII 485 
                                          : *..:******:**:* : *:: * :: *  *. * :: 
 
 
 
 
H.sapiens1.    91.4  VPTKTPYDPRWMLAGRPHPTQKGQWLSGFFDYGSFSEIMQPWAQTVVVGRARLGGIPVGV 1985 
M.musculus1.   91.4  VPTKAPYDPRWMLAGRPHPTQKGQWLSGFFDYGSFSEIMQPWAQTVVVGRARLGGIPVGV 1984 
H.sapiens2.    66.4  LPSRAPYDPRWMLAGRPHPTLKGTWQSGFFDHGSFKEIMAPWAQTVVTGRARLGGIPVGV 2096 
M.musculus2.   66.4  TPTKAPYDPRWMLAGRPHPTLKGTWQSGFFDHGSFKEIMAPWAQTVVTGRARLGGIPVGV 2086 
P.yoelii.      82.0  NKINDVDMDNVNEADIIELLKGSDKKQGFLDKNSYFEYMNEWGKGIITGRGKLGSIPIGF 2669 
P.falciparum.  82.0  LHINDMDYDHIDDSNIIDLIKGTQEEQGFLDKNTYFEYMNEWGKGIITGRGKLGSIPVGF 3011 
P.knowlesi.    82.0  QRINDIDMDNIQNADVIELIKGTDTKQGFLDKNSYFEYMNEWGKGIITGRGKLGSIPVGI 2598 
P.vivax.       92.6  QRINDIDMDGLQNADIVELISGTDSKQGFLDKHSYFEYMNEWGKGILTGRGKLGSIPVGV 2737 
                        .         ..  .         *::*  :: * :  *.: ::.**.:**.:*:*. 
 
 
 
 
H.sapiens1.          VAVETRTVELSIPADPANLDSEAKIIQQAGQVWFPDSAFKTYQAIKDFNREGLPLMVFAN 2045 
M.musculus1.         VAVETRTVELSIPADPANLDSEAKIIQQAGQVWFPDSAFKTYQAIKDFNREGLPLMVFAN 2044 
H.sapiens2.          IAVETRTVEVAVPADPANLDSEAKIIQQAGQVWFPDSAYKTAQAIKDFNREKLPLMIFAN 2156 
M.musculus2.         IAVETRTVEVAVPADPANLDSEAKIIQQAGQVWFPDSAYKTAQVIRDFNKERLPLMIFAN 2146 
P.yoelii.      99.1  IAVNKNLVTQTVPCDP-ALKTKAIKTTNAPCVFVPDNSYKTAQSIEDFNKENLPLFVFAN 2728 
P.falciparum.  99.3  IAVNKNLVTQSIPCDP-ALKTKAQKLIQAPCVFFPDNSFKTAQSIEDFNKENLPLFIFAN 3070 
P.knowlesi.    99.1  IAVNRNLVTQDVPCDP-ALKTKAVRSTQAPCVFFPDNSYKTAQSIEDFNKENLPLFVFAN 2657 
P.vivax.       99.1  IAVNRNLVTQVTPCDP-ALKTKAVRSTHAPCVFFPDNSYKTAQSIEDFNKENLPLFVFAN 2796 
                     :**: . *    *.**  *.:.     :*  *: **.: ** * : **.:* ***:::** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 NetPhos 2.0™ prediction of protein kinase phosphorylation sites on enzyme domains 
of mammals and Plasmodium acetyl-CoA carboxylases. (A) Alignment produced by ClustalW™ 
algorithm showing phosphorylated residues (highlighted) in the biotin carboxylase (BC) and the 
carboxyl transferase (CT) domains. The residue betwe n the +4 and –4 positions of the 
phosphorylated residues are underlined. The numbers in bold represents the probability score (%). (B
Cartoon structure of the multi-domain acetyl-CoA carboxylase illustrating the positions of the 
predicted phosphorylation sites. Broken and double lin s indicate a position 100% conserved in 
Plasmodium and across all organisms, respectively. Open and closed circles indicate a serine and a 
threonine protein kinase sites, respectively. * indicates 100% conserved residue. 
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The Ramachandran analysis showed that 83.3% of non-glycine and non-proline residues in 
PyBCCP-model have conformational angles (φ andψ) in the most favoured regions of the 
Ramachandran plot (Figure 6.6). This is comparable to EcBCCP+ with 86.6%. 2.8% of the 
residues in PyBCCP-model fall in the disallowed region of the Ramachandran plot, while no 
residues in Ec-BCCP+ falls in the disallowed region. 
 
 
 
Figure 6.6 Ramachandran analyses of the homology modelling of the biotinoyl proteins by 
ProCheck™. The Ramachandran plots were derived after energy minimization of (A) EcBCCP+ (B) 
PyBCCP-model. The different coloured regions indicate “most favoured” (red), “additionally allowed’ 
(yellow), “generously allowed” (light yellow) and “disallowed’ (white). 
 
 
The PyBCCP-model is made of seven β-sheets, one turn and five loops, while EcBCCP+ has 
an extra β-sheet (eight β-sheet), six loops and one turn. The predicted secondary structure can 
be classified as a β-sheet because it lacked α-helix secondary structures (Figure 6.7). 
EcBCCP+ has the “protruding thumb” structure connecting β2 to β3; this is consistent with the 
experimentally resolved structure (Athappilly and Hendrickson, 1995) as well as previously 
determined computer models of the E. coli biotinoyl protein (Chapman-Smith et al., 2001; 
Cronan, 2001; Reche t al., 1998; Reche and Perham, 1999; Streaker and Beckett, 2006). A 
similar structure is also present in PyBCCP-model. Figure 6.8 shows that the β-sheets in 
PyBCCP-model and EcBCCP+ are completely superimposable, except the extra β-sheet on 
the EcBCCP+. 
A B 
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Figure 6.7 Predicted three dimensional molecular models of biotinoyl protein. (A) EcBCCP+ and 
(B) PyBCCP-model. The structure is coloured according to secondary structure succession using the 
spdbv programme. Blue secondary structure is at the N-terminus and red secondary structure is at the 
C-terminus of the protein. The residues represent the conserved MKM biotinylation motifs situated at 
β4→ β5 turn.  
 
 
 
 
 
The PyBCCP-model was superimposed (Figure 6.9) on EcBCCP+, and the root mean square 
deviation of the α-carbon was deduced to be 0.22 Å. Figure 6.9 shows that the two models are 
Figure 6.8 Superimposed image PyBCCP-model and EcBCCP+ β-sheets. The β-sheets with 
yellow (EcBCCP+) and blue (PyBCCP-model) coloured β-sheets are completely superimposed, while 
the red β-sheet is the EcBCCP+ extra sheet 
N-terminal  
C-terminal  
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N-terminal  
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virtually super-imposable. Although the “protruding thumb” loop structure connecting β2 to β3 
of the PyBCCP-model protrudes out side the molecular surface of the positive control 3D 
model, as shown (arrow) in Figure 6.9A   
 
 
 
 
 
 
Figure 6.9 Superimposed image of E. coli biotinoyl protein positive control model and P. yoelii 
biotinoyl domain model. (A) Ribbon structure of PyBCCP-model superimposed in the molecular 
surface map of EcBCCP+. (B) Ribbon structure of EcBCCP+ superimposed with the backbone 
strcurure of PyBCCP-model.  
 
 
 
The E. coli biotin-binding motif is identical to the Plasmodium acetyl-CoA carboxylase 
biotin-binding motif with a consensus sequence, VEAMKM. The lysine residue is the 
biotinoyl lysine (Beckett et al., 1999; Blanchard et al., 1999a; Chapman-Smith et al., 1999; 
Cronan, 2002). Studies have shown that the E. coli biotin protein ligase interacts with the 
glutamic acid residue (Glu115) within the consensus sequence, as well as Glu147 (Chapman-
Smith et al., 1999; Chapman-Smith et al., 2001; Polyak et al., 2001; Solbiati et al., 2002; 
Streaker and Beckett, 2006). In P. yoelii, Lys1152 is at the equivalent position of the E. coli 
Glu147. Figure 6.10 shows that the side chain of Glu147 sticks out of the surface of EcBCCP+ 
(Figure 6.10A), with a similar orientation to Lys1152 in the PyBCCP-model (Figure 6.10B). 
However Glu115 as well its equivalent in the PyBCCP-model is buried inside the structure. 
The consensus biotinylation motif MKM forms a knob-like structure on the molecular surface 
B A 
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of both predicted biotinoyl 3D structures. This is consistent with previous studies on the 
orientation of the MKM motif with respect to the whole molecule (Cronan, 2001; Reche and 
Perham, 1999; Solbiati et al., 2002; Yao et al., 1999). The VEAMKM and E115/K1152 residues 
are super-imposable (Figure 6.11) with a root mean square deviation (between PyBCCP-
model and EcBCCP+) of 0.03 Å and 0.31 Å of equivalent α-carbon atoms and equivalent side 
chains, respectively.   
 
 
 
A 
E147 
B 
E147 
C 
K 1152 
D 
K 1152 
Figure 6.10 Position of the biotinylation motif with respect to the molecular surface of the 
biotinoyl protein models. (A and B) EcBCCP+ and (C and D) PyBCCP-model. The backbone and 
side chain structures of the amino-acid residues ar coloured green. A and C are in a similar 
orientation. B and D are in a similar orientation. The selected residues ar  coloured as follows: Val 
and Ala (cyan), Glu and Lys1152 (red), Met (yellow), biotinyl-Lys (blue). 
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6.2.6 Homology modelling of mutant forms of the biotinoyl domain of P. yoelii acetyl-
CoA carboxylase 
The models obtained by the homology modelling using the SWISS-MODEL™ server were 
verified by carrying out a comparative modelling with modified P. yoelii biotinoyl sequence 
(Figure 6.12). We deliberately made adjustments to the amino acid sequence on the target to 
verify the models. The sequence was modified by deletion as well as by insertion of glycine 
residue(s) at positions within or around the VEAMKM biotin-binding motif. Glycine was 
chosen because it is not charged and lacks a side chain residue. The modified sequence was 
aligned with the E. coli biotinoyl sequence (PDP ID: 1bdo) and submitted to the SWISS-
MODEL™ server for homology modelling. The mutant models generated from the modified 
sequences will be referred to as PyBCCP-mut1 and PyBCCP-mut2. These correspond to 
Figure 6.11 Superimposed image of the E. coli and the P. yoelii VEAMKM biotinylation motif 
sequence residues. The residues were coloured by selection (EcBCCP+ residues are yellow; P. 
yoelii residues are blue) using the spdbv programme. The E. coli residues are labelled. 
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M1127G and M1129G double mutation (Figure 6.12 A) and K1128G single mutation (Figure 
6.12 B), respectively. 
 
 
 
 
Figure 6.12 Modified amino acid sequences used to generate the mutant models. (A) Sequence 
used to produce PyBCCP-mut1. (B) Sequence used to produce PyBCCP-mut2. The mutated residues 
(in red) are shown.  
 
 
These alterations in the amino acid sequence of the biotinoyl domain of P. yoelii acetyl-CoA 
carboxylase severely or slightly altered the alignme t with the E. coli biotinoyl protein 
(1bdo). The total energy after energy minimisation by GROMOS was 14 991 kJ/mol and 
−963 kJ/mol for PyBCCP-mut1 and PyBCCP-mut2, respectively. The quality of PyBCCP-
mut1 was poor due to the severe perturbation on the sequence alignment. Figure 6.13 shows 
the predicted secondary structure prediction of the residues spanning the VEAMKM motif of 
the mutant models. The overall predicted 3D structure (Figures 6.14 A and B) of PyBCCP-
mut1 cannot be superimposed on EcBCCP+, while PyBCCP-mut2 can be super imposed with 
EcBCCP+. This shows that the modifications resulted in erroneous prediction of the position 
of the biotinyl lysine using the E. coli biotinoyl protein (1bdo) as a template for alignment and 
for secondary structure prediction. The root mean square deviation of the mutant models and 
EcBCCP+ were 12.5 Å (for 26 α-carbons) and 0.8 Å (for 75 α-carbons) for PyBCCP-mut1 
and PyBCCP-mut2, The VEAMKM and the K1152 backbone structure of the mutant models 
 
 
TEDSLNREDIAIKSENNINDISLNGKMKRAHIFDIIFQNVKYKFKGYNTGEDLYKLNIND 
QEIEILAKYDKENNKIFASFHNQTYIYTCIEDSLGTHMNLGKDNVFIPVITNPYHLISNT 
NGKIVKYLIKDGEKINKFDDYIEVEAGKGIMTFKSTETGILKHKMSEGAMIKIGDLLGVI 
EKEKDNQNYQNDDNNNKIIDFIGHLNLSNKNAYELNGTFVPDLAEESHNNEVCCKNIEKE 
KMENLRKIEDPKNNKIYPTKHTNRNSQVNTTNESVSVQDIKTENMKKDESQFCTEDKQIQ 
NNQVNRRNKLFLKKNNGKNNKNNMFRLFSQKNDNDSKIIDSNIESNSRD 
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B 
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also deviated from the EcBCCP+ with root mean square deviation of 6.45 Å and0.6 Å for 
PyBCCP-mut1 and PyBCCP-mut2, respectively (Figures 6.14 C and D). 
 
Figure 6.13 Secondary structure predictions around the biotinylation motif . (A) EcBCCP+ (B) 
PyBCCP-model (C) PyBCCP-mut1 and (D) PyBCCP-mut2. (S) denotes residues forming a β-sheet, 
while (.) represents residues forming a loop or a turn. Theglycine residues in red were added 
sequence. 
 
 
6.2.7 Homology modelling of the biotin carboxylase domains of P. yoelii, P. falciparum 
and H. sapiens acetyl-CoA carboxylases 
A homology-base approach was also used to predict the 3D structures of the biotin 
carboxylase domain of P. yoelii (PyBC-model), P. falciparum (PfBC-model) and H. sapiens 
(HsBC-model) acetyl Co-A carboxylases u ing the S. cerevisiae (1w93) as template (Shen t 
al., 2004). The sequence identity between PyBC-model, PfBC-model and HsBC-model and 
the templates were 48%, 44% and 68% respectively. The S. cerevisiae biotin carboxylase 
sequence was modelled on itself (1w93) to generate a positive control (ScBC+) 3D model. 
The total energy of the models before energy minimisation were −16 440 kJ/mol (82.4% of 
ScBC+), −10 421 kJ/mol (52.2% of ScBC+) and −13 567 kJ/mol (68 % of ScBC+) for PyBC-
model, PfBC-model and HsBC-model, respectively. After energy minimisation carried out 
using the GROMOS™ algorithm the final energy of themodels reduced to −20 602 kJ/mol, 
−26 393 kJ/mol, −18 070 kJ/mol and −22 944 kJ/mol for PyBC-model, PfBC-model, HsBC-
model and ScBC+, respectively, showing an improvement of the models. The Ramachandran 
plots of the models (Figure 6.15) showed that the conformational angles (φ andψ) of non-
proline and non-glycine are within the sterically alowed regions of the Ramachandran plot. 
(A)  EcBCCP+:    DTLCITLCIVEAMKMMNQIE 
                  SSSSSSSSSSSS..SSSSSS 
 
 
(B)  PyBCCP-model: NKFDDYIEVEAMKMIMTFKS 
                  SSSSSSSSSSS..SSSSSSS 
 
 
(C)  PyBCCP-mut1: NKFDDYIEVEAGKGIMTFKS 
                    SSSSS..SSSSS.SSSSSSS 
 
 
(D)  PyBCCP-mut2: NKFDDYIEVEAMGMIMTFKS 
                    SSSSSSSSSSS..SSSSSSS 
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Figure 6.14 Structures predicted from mutated sequences of the P. yoelii biotinoyl protein . (A 
and C) PyBCCP-mut1, (B and D) PyBCCP-mut2. The side chains represent the MKM biotinylation 
motif. The structure is coloured according to secondary structure succession using the spdbv 
programme. C and D are superimposed images of the E. coli and the mutant models of P. yoelii 
VEAMKM biotinylation motif residues. The residues were coloured by selection using the spdbv 
programme (E. coli residues are yellow; P. yoelii residues are blue). The E. coli residues are labelled. 
 
 
Although, few residues fall outside the allowed region of the Ramachandran plot as defined 
by ProCheck™. Generally, the Ramachandran analysis of PyBC-model, PfBC-model and 
HsBC-model showed a similar pattern with ScBC+. Table 6.2 illustrates the Ramachandran 
analyses derived from the ProCheck™ algorithm. 
A B 
C D 
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Table 6.2 Ramachandran scores for the predicted biotin carboxylase models of P. yoelii, P. 
falciparum, H. sapiens and S. cerevisiae using ProCheck™   
 
Ramachandran analysis 
 
PyBC-
model 
PfBC-
model 
HsBC-
model 
ScBC+ 
(1w93b) 
Number of proline residues 18 18 28 24 
Number of glycine residues 28 30 38 46 
Number of non-proline and non-glycine residues 481 592 433 481 
Residues in the most favoured regiona (%) 70.7 71.3 70.2 69.6 
Residues in the additional allowed regiona (%) 28.5 24.4 26.6 27.7 
Residues in the generously allowed regiona (%) 3.1 3.7 2.5 2.7 
Residues in the disallowed regiona (%) 0.4 0.5 0.7 0 
 
a non-proline and non-glycine residues 
b PDB identity number for crystal structure of S. cerevisiae (Shen et al., 2004). 
 
 
The overall 3D topology of the models (Figure 6.16) can be classified as α+β conformation 
with a mix of β sheets and α helices in α→α, α→β and β→β super secondary structure 
topology. The secondary structures are connected with loops of varying lengths. Most of these 
loops are conserved between the targets and the templates. The signature motif of the biotin 
carboxylase is the carbamoyl phosphate synthatase signature (Blanchard et al., 1999b; 
Galperin and Koonin, 1997). The carbamoyl phosphate synthetase signature strands are 
situated on a loop structure in the four predicted models. The carbamoyl phosphate synthetase 
signature of PyBC-model, PfBC-model and HsBC-model (Figure 6.17) are completely super-
imposable with the ScBC+ with a root mean square deviation of equivalent α-carbons was 
0.04 Å, for PyBC-model and PfBC-model, and 0.03 Å for HsBC-model. The 3D structures 
were superimposed using the spdbv programme. The root means deviation between the entire 
predicted 3D structure and ScBC+ is 0.27 Å (for 493 α-carbons), 0.32 Å (492 α-carbons) and 
0.15 Å (for 493 α-carbons) for PyBC-model, PfBC-model and HsBC-model, respectively. 
The minimum deviation between the HsBC-model model and ScBC+ model could be due to 
the higher amino-acid sequence identity compared to the Plasmodium models. 
 
Nineteen amino acid residues have been shown to interact with soraphen A (Shen t al., 2004; 
Weatherly et al., 2004) in S. cerevisiae biotin carboxylase (PDB ID: 1w93 and 1w96). These 
residues and their equivalent in P. yoelii, P. falciparum and H. sapiens are highlighted in 
Figure 6.18. The 3D models showed that these residu in PyBC-model, PfBC-model and 
HsBC-model are completely superimposable with ScBC+ (Figure 6.19).  
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Figure 6.15 Ramachandran analysis of the homology modelling of the biotin carboxylase 
domains by ProCheck™. The Ramachandran plots were derived after energy minimization of (A) S. 
cerevisiae positive control (B) P. yoelii (C) P. falciparum and (D) H. sapiens (acetyl-CoA 
carboxylase-β). The different coloured regions indicate “most favoured” (red), “additionally allowed’ 
(yellow), “generously allowed” (light yellow) and “disallowed’ (white). 
 
 
The root mean square deviations are 0.04 Å (for PyBC-model and PfBC-model) and 0.03 Å 
(for HsBC-model). The positions of the 20 soraphen-interacting residues on the 3D structure 
revealed that they are situated on the surface of the molecule rather than buried inside the 
structure (Figure 6.20). This result is consistent with the study carried out by Shen et al. 
(2004) who suggested that the soraphen-A binds at the dimer interface of the crystallised 
A B 
D C 
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biotin carboxylase. Although 47% of these residues are completely identical while 73.7% are 
similar by ClustalW™ alignment.  
 
6.3 Discussion 
Bioinformatics tools were used to study the structure and assign protein kinase 
phosphorylation sites on P. yoelii acetyl-CoA carboxylase based upon comparative analysis 
with acetyl-CoA carboxylases from several organisms that encodes the multi-domain acetyl-
CoA carboxylase. It was necessary to compare P. yoelii acetyl-CoA carboxylase with 
orthologues from other Plasmodium parasites and homologues from other eukaryotic 
organisms in order to be confident with inferences that were drawn from the results.  
 
The ClustalW™ alignment data (data not shown) involving 17 acetyl-CoA carboxylase 
sequences enable the accurate prediction of the structural organisation of P. yoelii acetyl-CoA 
carboxylase as well as other Plasmodium acetyl-CoA carboxylases. The biotin carboxylase 
and the carboxyl transferase protein domains with a fairly high degree of conservation were 
the points of focus. By and large, P. yoelii acetyl-CoA carboxylase appears to be a multi-
domain type enzyme like that found in other eukaryotes. 
 
The phylogenetic analysis derived from aligned sequences showed that there was 
evolutionary divergence of Plasmodium acetyl-CoA carboxylase from other species. The 
Plasmodium acetyl-CoA orthologues clustered with T. gondii and the primitive unicellular 
photosynthetic diatom, O. lucimarinus (Lanier et al., 2008), suggesting that Plasmodium 
acetyl-CoA carboxylase is closely related T. gondii (an apicomplexa) and O. lucimarinus 
acetyl-CoA carboxylases. T. gondii is a plastid encoding organism (Jelenska et al., 2001; 
Jelenska et al., 2002; Zuther et al., 1999) with a plastid genome of ~ 35 kb (Ralph et al., 
2004a; Ryall et al., 2003; Waller et al., 2003; Zuegge t al., 2001), a size synonymous with 
the size of the Plasmodium plastid (Gleeson, 2000; Ralph et al., 2004a; Waller et al., 2003; 
Wilson, 2002). 
 
During analysis of the 17 acetyl-CoA carboxylase sequences using PrositeScan™ to establish 
the amino acid sequence corresponding to the various domains of the enzyme, it was 
discovered that all organisms examined have 67 amino acid residues in their biotinoyl 
domain, except Plasmodium, which has 73 residues.  
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A B 
C D 
Figure 6.16 Predicted 3D molecular models of biotin carboxylase domain. (A) S. cerevisiae positive control 
model, (B) P. yoelii, (C) P. falciparum and (D) H. sapiens. The structure is coloured according to secondary 
structure succession using the spdbv programme. Blu secondary structure is at the N-terminal and red secondary 
structure is at the C-terminal of the protein. 
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Figure 6.17 Structural comparison of the biotin carboxylase carbamoyl phosphate synthetase 
signature structures. (A) ScBC+, (B) PyBC-model (C) PfBC-model and (D) HsBC-model. The 
long chain (blue) and the short chain (green) are coloured by selection using the spdbv programme.  
 
 
B 
D C 
A 
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Figure 6.18 Sequence alignment of the biotin carboxylase domains of S. cerevisiae, P. yoelii, P. 
falciparum and H. sapiens. Residues involved in binding soraphen A are highlighted red; residues 
corresponding to the carbamoyl phosphate synthetase signature are coloured blue (long) and green 
(short). 1w93 represents the PDB-deposited amino acid sequences. 
 
P-yoelii.          --------------------------------------------IIKKLLIANNGMAALK 16 
P-falciparum.      --------------------------------------------IIRKLLIANNGMAALK 16 
1W93_A.            MEYEITNYSERHTELPGHFIGLNTVDKLEESPLRDFVKSHGGHTVISKILIANNGIAAVK 60 
H-sapiens-B.       --------------------------------------------VIEKVLIANNGIAAVK 16 
                                                               :* *:******:**:* 
 
P-yoelii.          CILSLKEWLFKTFNDENLIQIIVLATEDDIKSNSKYISLSDKVIKVPPGKNSYNYANVSL 76 
P-falciparum.      CILSLKDWLFKKFYDENLIKIIVMATDEDIKSNAKYISLADKVIKVPGGKNIHNYANVPL 76 
1W93_A.            EIRSVRKWAYETFGDDRTVQFVAMATPEDLEANAEYIRMADQYIEVPGGTNNNNYANVDL 120 
H-sapiens-B.       CMRSIRRWAYEMFRNERAIRFVVMVTPEDLKANAEYIKMADHYVPVPGGPNNNNYANVEL 76 
                    : *:: * :: * ::. ::::.:.* :*:::*::** ::*: : ** * *  ***** * 
 
P-yoelii.          IVDIAKKENVDAVWPGWGHCSENPLLSSMLEKEN--IIFVGPTDNVMEALGDKISANILA 134 
P-falciparum.      IVELAKSENVDAVWPGWGHSSENPLLSTLLEKEN--IIFIGPTGNVMEALGDKISANILA 134 
1W93_A.            IVDIAERADVDAVWAGWGHASENPLLPEKLSQSKRKVIFIGPPGNAMRSLGDKISSTIVA 180 
H-sapiens-B.       IVDIAKRIPVQAVWAGWGHASENPKLPELLCKNG--VAFLGPPSEAMWALGDKIASTVVA 134 
                   **::*:   *:***.****.**** *.  * :.   : *:**..:.* :*****::.::* 
 
P-yoelii.          QSVNVPVVKWSGDNLKIKDFE-------NNSISQDIYNKSTIHSLEECIRECKRIGYPVM 187 
P-falciparum.      QSVEVPVVKWSGDNIRIDKFE-------NNKINDELYNNATIHSLDDCIKECKRIGFPVM 187 
1W93_A.            QSAKVPCIPWSGTGVDTVHVDEKTG---LVSVDDDIYQKGCCTSPEDGLQKAKRIGFPVM 237 
H-sapiens-B.       QTLQVPTLPWSGSGLTVEWTEDDLQQGKRISVPEDVYDKGCVKDVDEGLEAAERIGFPLM 194 
                   *: :** : *** .:     :         .: :::*::.   . :: :. .:***:*:* 
 
P-yoelii.          IKASQGGGGKGIRKVENENEIKKYYEQVQNELPNSPIFLMKVCSNVRHIEIQVVGDMYGN 247 
P-falciparum.      IKASQGGGGKGIRKVENEYEIKKAYEQVQNELPNSPIFLMKVCNNVRHIEIQVVGDMYGN 247 
1W93_A.            IKASEGGGGKGIRQVEREEDFIALYHQAANEIPGSPIFIMKLAGRARHLEVQLLADQYGT 297 
H-sapiens-B.       IKASEGGGGKGIRKAESAEDFPILFRQVQSEIPGSPIFLMKLAQHARHLEVQILADQYGN 254 
                   ****:********:.*   ::   :.*. .*:*.****:**:. ..**:*:*::.* **. 
 
P-yoelii.          VCSLSGRDCTTQRRFQKIFEEGPPSIVPPHTFREMEKASIRLTKMIKYRGAGTIEYLYDQ 307 
P-falciparum.      VCSLSGRDCTTQRRFQKIFEEGPPSVVPYPIFREMEKSSIRLTKMIKYRGAGTIEYLYDQ 307 
1W93_A.            NISLFGRDCSVQRRHQKIIEEAPVTIAKAETFHEMEKAAVRLGKLVGYVSAGTVEYLYSH 357 
H-sapiens-B.       AVSLFGRDCSIQRRHQKIVEEAPATIAPLAIFEFMEQCAIRLAKTVGYVSAGTVEYLYSQ 314 
                     ** ****: ***.***.**.* ::.    *. **:.::** * : * .***:****.: 
 
P-yoelii.          VNNKYYFLELNTRLQVEHPVSEGITDTNIVAIQLQVAMGIPLQNIDDIKKLYKIE--EKT 365 
P-falciparum.      INKKYFFLELNPRLQVEHPVSEGITNCNLISIQLQVAMGIPLQNIDDIRNLYQIDKIEKI 367 
1W93_A.            DDGKFYFLELNPRLQVEHPTTEMVSGVNLPAAQLQIAMGIPMHRISDIRTLYGMN----- 412 
H-sapiens-B.       D-GSFHFLELNPRLQVEHPCTEMIADVNLPAAQLQIAMGVPLHRLKDIRLLYGES----- 368 
                      .:.*****.******* :* ::. *: : ***:***:*::.:.**: **  .      
 
P-yoelii.          KK------------NTSSSSVS-------------------------------------- 375 
P-falciparum.      KKKDEQKKEFELTDNLCNDTINKDNINNDNIYKDNINNDNIYKDNIYKDNINNDNIYKDN 427 
1W93_A.            ------------------------------------------------------------ 
H-sapiens-B.       ------------------------------------------------------------ 
                                                                                
 
P-yoelii.          --------------------IVNDKLKLPISEKDNNKTVKTNLSEQLG------------ 403 
P-falciparum.      IYKDNINNDNIYKDNIYKDNIYNDNIYKDNINNDNIHHIDNTTNEQNNKNLLHYNNYRNQ 487 
1W93_A.            --------------------------------PHSASEIDFEFKTQDA------------ 428 
H-sapiens-B.       --------------------------------PWGVTPISFETPSN-------------- 382 
                                                     .   :.     :               
 
P-yoelii.          -----------------------------MFDFYNNMPHTKNHVIAARITAENSNDSFKP 434 
P-falciparum.      NLCNNNSIKSLLNYDTNENVNRKYNLLNEHFDFYNNKPYIKNHVIAARITAENSNDSFKP 547 
1W93_A.            -------------------------------TKKQRRPIPKGHCTACRITSEDPNDGFKP 457 
H-sapiens-B.       ------------------------------------PPLARGHVIAARITSENPDEGFKP 406 
                                                        *  :.*  *.***:*:.::.*** 
 
P-yoelii.          TSGLVKNVNFQNSKDVWGYFSIN-NGFVHEFSDSQIGHIFAKGETREIARKNLILALRKL 493 
P-falciparum.      TSGNVRRINFQNWKDVWGYFSIN-DGFVHEFSDSQIGHIFAKGETREVARKNLILALRKL 606 
1W93_A.            SGGTLHELNFRSSSNVWGYFSVGNNGNIHSFSDSQFGHIFAFGENRQASRKHMVVALKEL 517 
H-sapiens-B.       SSGTVQELNFRSSKNVWGYFSVAATGGLHEFADSQFGHCFSWGENREEAISNMVVALKEL 466 
                   :.* ::.:**:. .:******:   * :*.*:***:** *: **.*: : .::::**::* 
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Figure 6.19 Superimposition of the residues at the quivalent positions with the S. cerevisiae biotin carboxylase soraphen A-binding residues. (A) 
PyBC-model (B) PfBC-model (C) HsBC-model. Labelled residues correspond to the ScBC+ residues. 
 
 
 
 
A B C 
 165 
 
Figure 6.20 Molecular surface representation showing positions of the soraphen A-binding 
residues. (A) ScBC+, (B) PyBC-model, (C) PfBC-model and (D) HsBC-model. The soraphen A-
binding residues are coloured blue using the spdbv rogramme.  
 
 
The additional six amino acid residues at the N-terminal region (Figure 6.21) of Plasmodium 
may be as a result of gene insertion since T. gondii (a close relative of Plasmodium) has 67 
amino acid residues in its biotinoyl domain. This observation strongly suggested that 
regardless of the evolutionary divergence of the enzymes in the various organisms, the 
biotinoyl domain maintained a consistent number of residues. The reason for this consistency 
A 
C D 
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is not understood, though it may be related to the functional relevance of this domain to the 
structure and function of the enzyme as well as the biotin protein ligase, an enzyme that 
attaches biotin moiety on biotin-dependent proteins as a form of post/co-translational 
modification. This domain was studied in Chapter 5 by recombinant protein expression and 
analysis for the presence of biotin. 
  
Mapping phosphorylation sites either by experiment of by prediction algorithm is a crucial 
step towards understanding the catalytic mechanism of an enzyme and the resulting effects 
this enzyme exerts on other enzymes or metabolic pathways (Blom et al., 1999). Protein 
kinase mediated phosphorylation of acetyl-CoA carboxylase has been well studied (Boone et 
al., 2000; Hamilton et al., 2002; Hardie, 2003; Hardie and Pan, 2002; Munday, 2002; Pan 
and Hardie, 2002), however, there are conflicting results on the actual phosphorylation sites 
from both in vivo and in vitro studies (Boone t al., 1999; Locke et al., 2008; Munday, 2002). 
Prediction algorithms are fast, reproducible and have been shown to be accurate in terms of 
optimizing experiments (Doytchinova et al., 2006; Flower, 2003).  
 
This study focused on identifying putative phosphorylation sites that are conserved in each of 
the domains of the enzyme. It was thought that the catalytic activities of the two enzyme 
domains may be regulated by a protein kinase; and that the phosphorylation sites will be 
conserved across several eukaryotes including Plasmodium. Biotin carboxylase is a member 
of the ATP-dependent carbamoyl phosphate synthetase family of enzymes (Blanchard et al., 
1999b; Galperin and Koonin, 1997). These enzymes catalyse the phosphorylation of a 
carboxylate ion and the transfer of carbamoyl phospate to an amino receptor on a protein 
substrate (Blanchard et al., 1999b; Galperin and Koonin, 1997). The carbamoyl phosphate 
synthatase family depends on Mg2+ and consists of a phosphate binding signature (Javid-
Majd et al., 1996; Stapleton et al., 1996). Previous studies on protein kinase phosphrylation 
sites did not identify any phosphorylated residue on the biotin carboxylase as well as the 
carboxyl transferase domains of acetyl-CoA carboxylase. This may not imply that these 
enzyme domains may not be phosphorylated. Moreover, th se studies were based upon 
enzymes that were recombinanatly expressed in a system not native to the enzyme (Boone et 
al., 1999; Locke et al., 2008; Munday, 2002). 
 
Two predictive algorithms were used to identify possible protein kinase modification sites on 
P. yoelii acetyl-CoA carboxylase by comparative analysis with P. falciparum, vivax, 
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knowlesi and mammalian acetyl-CoA carboxylase sequences. The Proscan™ algorithm 
(Bairoch et al., 1997) and NetPhos 2.0™ (Blom et al., 1999) algorithm designed to predict 
putative protein kinase sites on a protein sequence with sensitivities of 69% to 96% (Blom et
al., 1999). The Proscan™ algorithm is the most widely used method for predicting protein 
kinase phosphorylation sites (Blom et al., 1999). The NetPhos 2.0™ is superior to the 
Proscan™ algorithm because the NetPhos 2.0™ neural network used to train its algorithm 
caters for a proteome wide prediction ability (Blom et al., 1999). This algorithm recognizes 
up to nine residues ±4 residues around the phosphorylati n residue. This is because there is a 
general consensus that the protein kinase physically interacts with a stretch of 7 – 12 residues 
surrounding the phosphate acceptor residue (Alessi et al., 1996; Blom et al., 1999; Obata et 
al., 2000; Songyang et al., 1994).  
 
Other species of Plasmodium including P. berghei and P. chabaudi were excluded from the 
study due to unavailability of the complete enzyme sequence (Plasmodb). However, the 
observations made in this study could be extrapolated to other species of Plasmodium not 
included in the study. Previous studies had employed the use of peptides containing 
phosphorylation motifs (Boone t al., 1999; Hardie et al., 1998; Munday, 2002). Some of 
these peptides are in an unconserved region of the prot in (data not shown). Human α-acetyl-
CoA carboxylase has been previously shown to be phosphorylated at Ser 79, the residue that 
has been implicated in the regulation of the enzyme (Boone et al., 1999; Hardie et al., 1998; 
Munday, 2002). This residue and its equivalent in β-acetyl-CoA carboxylase are not 
conserved in Plasmodium, though the NetPhos 2.0™ algorithm identified these sites with a 
probability of 99.1% (data not shown).  
 
The Proscan™ algorithm predicted PKC, PKG and PKA phos horylation sites; though only 
two of these sites corresponded to the NetPhos 2.0™ algorithm-predicted sites (P1/N1 and 
P5/N2, in Figures 6.4 and 6.5). cGMP-dependent protein kinase (PKG) and cAMP-dependent 
protein kinase (PKA) have being identified and characterised in Plasmodium (Deng and 
Baker, 2002; Diaz et al., 2006). The P1/N1 site is located at the N-terminal region of the 
biotin carboxylase domain, shown to be ATP dependent (Blanchard et al., 1999b; Galperin 
and Koonin, 1997; Javid-Majd et al., 1996; Stapleton et al., 1996). Although, the NetPhos 
2.0™ score for mammalian acetyl-CoA carboxylase wasles  than 55% at this site. Some of 
these sites may be false positive results due to errors in the neural network used to train the 
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algorithms (Blom et al., 1999). However, there is a possibility that these sites may be 
phosphorylation sites yet to be experimentally established (Blom et al., 1999). 
 
In the NetPhos-predicted serine phosphorylation sites, lysine appeared to be the predominant 
residue at position – 4, while tryptophan or phenylalanine (both are aromatic amino acids) 
are at the + 4 positions. These amino acids at posiion  + 4 and – 4 were 100% conserved. 
This suggests that these residues may be involved with the interaction of the Plasmodium 
protein kinase. The two serine phosphorylation sites predicted by NetPhos 2.0™ appear to be 
attractive options for the study of the protein kinase regulation of Plasmodium acetyl-CoA 
carboxylase. With site-directed mutagenesis on a recombinant Plasmodium biotin 
carboxylase domain or peptides derived from regions corresponding to these phosphorylation 
sites, the predicted sites could be experimentally va idated, using recombinant Plasmodium 
protein kinases (Deng and Baker, 2002; Diaz et al., 2006; Dorin et al., 1999; Dorin et al., 
2005; Nunes et al., 2007).  
 
In this study, homology modelling was used to model th  structures of the biotinoyl protein 
and the biotin carboxylase domains of P. yoelii acetyl-CoA carboxylase. Homology is widely 
used for predicting the possible function of a protein and for drug design (Brown et al., 2004; 
Keenan and Welsh, 2004; Singh et al., 2006). The predicted models of P. yoelii biotinoyl 
protein and biotin carboxylase were derived from the crystal structures of the E. coli 
biotinoyl protein (Athappilly and Hendrickson, 1995) and the S. cerevisiae biotin 
carboxylase domain of acetyl-CoA carboxylase (Shen et al., 2004; Waldrop et al., 1994). The 
models were refined using various algorithms provided by the spdbv v3.7 programme and 
validated by the ProCheck™ algorithm (Laskowski et al., 1996). This study supported the 
experimental data where the recombinant protein was biotinylated in an E. coli expression 
system. The study identified the potential interaction of the biotin carboxylase domain of P.
yoelii acetyl-CoA carboxylase with soraphen A, a fungicide that inhibits acetyl-CoA 
carboxylase (Beckers et al., 2007; Shen et al., 2004; Shirra et al., 2001; Weatherly et al., 
2004). 
 
In most homology modelling studies, it is crucial to evaluate the structure predicted by the 
modelling programme used (Kleywegt, 1997; Kleywegt and Jones, 1996; Schwede et al., 
2000; Schwede et al., 2003). This evaluation often requires a control structure for 
comparative assessments. Therefore the amino acid sequence (submitted to PDB) of the 
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protein used as a template for the study was modelled on its 3D structure in an attempt to 
produce a ‘predicted’ control model. Visual comparison (Schwede t al., 2000; Schwede t 
al., 2003) between the control model and the predicte protein was carried out as the first 
evaluation step. The total energy (kJ/mol) of the models were negative, suggesting highly 
relaxed structures (Melo and Feytmans, 1998). The refinement of the models carried out with 
an incremental energy reduction steps using GROMOS™ (van Gunsteren and Billetter, 
1996) showed differences between the original model and the refined model in terms of total 
energy. This resulted in an improvement on the number of amino acid residues in the core 
regions of the Ramachandran plot. The minute differences in energy of the control models 
before and after refinement by GROMOS™ authenticated th  modelling algorithm. The root 
mean square deviation (RMSD) of the predicted model from the experimental control model 
is another parameter that was used to assess the quality of the models (Chothia and Lesk, 
1986; Wells et al., 2006). It is expected that there should be a minimal deviation between the 
back bone structure of the predicted model and its experimental control. A model could be 
declared inaccurate if its atomic coordinates are more than 0.5 Å RMSD of an experimental 
control (Chothia and Lesk, 1986; Lesk, 1997). In this study, the RMSD between the 
predicted models and their respective model controls were well within this limit. 
 
The measure of the stereochemical properties of residu  in a protein or peptide is the 
definitive means of validating a protein structure (Kleywegt, 1997; Kleywegt and Jones, 
1996; Schwede t al., 2000; Schwede t al., 2003). The main chain of a polypeptide assumes 
a preferred energetically favourable conformation, which is characterised by the value of two 
torsion angles, φ andψ; the third angle, ω, is largely restricted to 180º and 0º for trans-
peptides and cis-peptides, respectively (Kleywegt and Jones, 1996; Ramakrishnan and 
Ramachandran, 1965). The plot of the torsion angles of the residues in a polypeptide, often 
referred to as the Ramachandran plot (Ramakrishnan a d Ramachandran, 1965), is widely 
used in protein prediction algorithms. The protein structure validation algorithm, ProCheck™ 
(Laskowski et al., 1996) uses Ramachandran analysis to evaluate the quality of predicted 
protein models. This algorithm is used for protein structure quality assessment when 
depositing a protein structure into the Protein Data Bank (http://deposit.pdb.org/adit). The 
ProCheck™ algorithm further divided the original Ramachandran plot from three to four 
regions namely: “most favoured”, “additional allowed”, “generously allowed” and 
“disallowed”. The predicted models in this study showed the majority of residues to lie in the 
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most favoured regions and a small fraction in the disallowed regions. Typically, a good 
model should not only have very many residues in the allowed regions, but very few in the 
disallowed regions (Kleywegt, 1997; Kleywegt and Jones, 1996). Some published predicted 
models confirmed the presence of few residues in the disallowed regions (Choubey t al., 
2006; Joshi et al., 2008; Singh et al., 2006; Wells et al., 2006). By and large, the 
stereochemical properties of the predicted models wre comparable to the controls structures 
used to generate the models. 
 
The SWISS-MODEL™ homology modelling algorithm was further tested using mutations 
introduced to the P. yoelii biotinoyl protein region. Given that the modelling algorithm is 
typically based on sequence identity and proper alignment (Schwede t al., 2000; Schwede t 
al., 2003), it was expected that major alterations such as deletion, insertion or replacement of 
residues at regions conserved between the target and the template will result in major 
perturbations in the overall structure predicted by the algorithm, while minor alterations such 
as substituting an amino acid with a similar one will result in minor perturbations. The 
mutant models generated by the modelling algorithm showed major alterations on the 3D 
structure when the residues forming the loop structure between β3 and β4 were deleted before 
alignment, and when the methionine residues flanking the biotinyl-lysine were replaced with 
glycine. No alteration on the structure compared to the predicted PyBCCP-model was 
observed when the biotinyl lysine was replaced with glycine, arginine and glutamic acid 
(data not shown). This was because the sequences maintained a proper alignment with these 
minor alterations in amino acid sequence. 
 
The E. coli biotinoyl protein, though a separate subunit polypeptide of the acetyl-CoA 
carboxylase complex, shares structural similarity with the P. yoelii biotinoyl protein domain. 
Alignment of the biotinoyl protein domain of P. yoelii with the E. coli-1bdo sequence used to 
resolve its crystal structure (PDB-deposited sequence) showed 20% identity and 52% 
similarity. Although the percentage identity is lower than the 25% threshold stipulated by the 
SWISS-MODEL™ algorithm (Schwede t al., 2000; Schwede t al., 2003), studies have 
shown that residues at an environmentally or evolutionarily conserved position on two 
similar proteins with dissimilar residues play similar structural roles (Kleiger et al., 2000). 
The predicted 3D model of P. yoelii biotinoyl was found to be similar to both experimentally 
resolved (Athappilly and Hendrickson, 1995) and algorithm-predicted (Chapman-Smith et
al., 1999; Chapman-Smith et al., 2001; Reche t al., 1998) 3D structures of E. coli biotinoyl 
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protein. The structural relationship between the two proteins could have led to the 
biotinylation of P. yoelii biotinoyl protein expressed in E. coli by the E. coli biotin protein 
ligase. Both structures are made up of β-sheets without an α-helix and the consensus MKM 
motif in both structures is located at a tight β-turn joining two sheets. This conformation is 
consistent with the resolved crystallographic structures of the human acetyl-CoA carboxylase 
biotinoyl domain (Lee et al., 2008) and P. shermanii transcarboxylase biotin carboxyl carrier 
domain (Reddy et al., 2000). 
 
Site directed mutagenesis studies aimed at determining the residues on BirA involved with 
the interaction with E. coli biotinoyl protein showed that E147K mutation on thebiotinoyl 
protein minimally affected its biotinylation by BirA (Chapman-Smith et al., 2001). A lysine 
residue (K1152) is at an equivalent position on the P. yoelii biotinoyl domain (Figure 6.22), 
and 100% conserved across P. falciparum, vivax, berghei, chabaudi and knowlesi domains. 
This residue is orientated on the surface of the structure in the model, comparable to E147 of 
the E. coli biotinoyl protein. Conversely, E119K mutation resulted in significant alteration in 
the activity of BirA activity on the biotinoyl protein (Chapman-Smith et al., 2001).  This 
glutamic acid residue is conserved in P. yoelii and other Plasmodium biotinoyl protein 
domain of acetyl-CoA carboxylase. The observations made from these studies clearly 
indicated that, while residue charge is essential in the recognition process, an interaction 
between single amino acids residues is not sufficient enough for the interaction between BirA 
and its biotin-dependent substrate (Chapman-Smith et al., 2001; Reche et al., 1998; Reche 
and Perham, 1999; Reche, 2000). The negligible RMSD between the back bone α-carbon 
atoms of the VEAMKM-(X)n-E/K (147/1152) residues clearly suggested that it is a 
conserved pattern common between the two structures and may be involved in conserving 
the conformation vital for biotin protein ligase interaction (Kleiger et al., 2000; Yang and 
Honig, 2000a; Yang and Honig, 2000b). This conformation may be the determining factor 
for the interaction between the recombinant P. yoelii biotinoyl protein and the E. coil BirA 
(Reche et al., 1998; Reche and Perham, 1999; Reche, 2000). A significant contribution made 
by the homology modelling study is that site directed mutagenesis on key amino acid 
residues on P. yoelii biotinoyl protein can be carried out based on the spatial organisation of 
the residues on the surface of the 3D structure. 
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                     10        20        30        40        50        60        70              
                 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
H. sapiens-1.    ------SVMRSPSAGKLIQYIVEDGGHVFAGQCYAEIEVMKMVMTLTAVESGCIHYVKRPGAALDPGCVLAKM 67  
H. sapiens-2.    ------TVLRSPSAGKLTQYTVEDGGHVEAGSSYAEMEVMKMIMTLNVQERGRVKYIKRPGAVLEAGCVVARL 67  
M. musculus-1.   ------SVMRSPSAGKLIQYIVEDGGHVFAGQCYAEIEVMKMVMTLTAVESGCIHYVKRPGAALDPGCVIAKM 67  
M. musculus-2.   ------TVLRSPSAGKLMQYTVEDGDHVEAGSSYAEMEVMKMIMTLNVQESGRVKYIKRPGVILEAGCVVARL 67  
G. gallus.       ------SILRSPSAGKLIQYVVEDGGHVFAGQCFAEIEVMKMVMTLTAGESGCIHYVKRPGAVLDPGCVIAKL 67  
D. melanogaster  ------SLLRSPSAGKLINMIVEDGAHVSKGQAYAEIEVMKMVMTLTSQEAGTVTFVRRPGAVLDAGSLLGHL 67  
A. thaliana-1.   ------SKLMAETPCKLMRYLISDNSNIDADTPYAEVEVMKMCMPLLSPASGVIHFKMSEGQAMQAGELIANL 67  
S. cerevisiae.   ------TQLRTPSPGKLVKFLVENGEHIIKGQPYAEIEVMKMQMPLVSQENGIVQLLKQPGSTIVAGDIMAIM 67  
O. lucimarinus.  ------SELRTDVTGKLIRFLQDDGAEVVAGKPFAEVEAMKMVMPLIATESGNVSHAKSAGAVIEAGDLLASL 67  
T. brucei.       ------TKLFAAVPGRFVRYLVCDGGHVEEGTIVAEVEVMKMILPLRASTVGALHHKVAPGSTIALGTLVAEI 67  
C. parvum.       ------RQVRAPVSGKLVRWLIQNGGQGEKGQAYVEIEIMKTYMQLTLSHSGILEHAKPQGASFNVGDILAML 67  
T. gondii.       ------SELRSDVTGKVVRYLVPDKGQVKKGEPYVEVEAMKMIMTLTAGETGVLSHTKSPGSVVNTGDVLGTL 67  
P. yoelii.       PVITNPYHLISNTNGKIVKYLIKDGEKINKFDDYIEVEAMKMIMTFKSTETGILKHKMSEGAMIKIGDLLGVI 73  
P. vivax.        PKMSNPFHLVSNTNGKIVKYLIKDGEKVGKNEDYIEVEAMKMIMTFKSTEKGILRHRMSEGTIVKVGDLLGVI 73  
P. knowlesi.     PKISNPFHLVSNTNGKIVKYLIKDGEKIEKNEDYIEVEAMKMIMTFKSTEKGILRHKMSEGTIVKIGDLLGVI 73  
P. falciparum.   PNVRNPYHLISNTNGKIVKYLINDGEEVKKNDDYIEVEAMKMIMTFKSTESGILRHKLSEGTIIKIGDLLGII 73  
 
 
 
Figure 6.21 Sequence conservation in the biotinoyl domain of the multi-enzyme-domain type acetyl-CoA carboxylase. Acetyl-CoA carboxylase 
sequences (16) from various organisms were submitted to the ScanProsite™ database to identify the amino-acid sequence corresponding to the biotinoyl 
domain. The sequences were extracted and aligned with the ClustalW™ algorithm (1000 bootstrap analysis). Residues are shaded based on the degree of 
conservation, with black shading indicating 100% conservation. The double underline indicates the five amino-acid residues that may have been inserted ino 
the Plasmodium sequence by evolution. A. thaliana 1 and 2 shares 100% sequence identity in their biotinoyl domain, hence A. thaliana-2 was excluded.  
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Figure 6.22 ClustalW™ alignment of E. coli biotinoyl protein and P. yoelii biotinoyl protein 
domain. Residues in red and blue are at equivalent position , corresponding to the previously studied 
BirA interacting residues (Chapman-Smith et al., 2001). The residues highlighted yellow corresponds 
to the “thumb” structure on the E. coli protein (Cronan, 2001; Lee et al., 2008). 
 
 
One key observation made from the predicted structue of E. coli biotinoyl protein is the 
presence of the “thumb” structure connecting β2 and β3 (see Figure 6.7). This structure is also 
found in both the experimentally-resolved crystal sructure as well as the predicted structures 
of E. coli biotinoyl protein (Cronan, 2001; Lee et al., 2008). The residues involved in the 
“thumb” structure are 64% similar with P. yoelii biotinoyl protein (highlighted residues in 
Figure 6.21). A ClustalW™ alignment between the E. coli biotinoyl protein and human 
biotinoyl protein domain revealed a gap (data not sh wn) at an equivalent position, indicating 
the absence of this structure in the human protein, as recently suggested (Lee t al., 2008). 
This structure is also absent in the biotinoyl protein domain of P. shermani transcarboxylase 
(Lee et al., 2008; Reddy et al., 2000). The relevance of this structure to the protein is still not 
clear. A number of studies have shown that the “thumb” structure contributes to the overall 
stability of the biotinoyl protein to proteolysis (Solbiati et al., 2002). Other studies have also 
shown that it contributes to the stability of the transient biotinylated structure of the holo 
enzyme by interacting with the biotin moiety (Roberts et al., 1999; Yao et al., 1999). The 
deletion of the thumb structure in E. coli leads to a decrease in fatty acid biosynthesis hence 
growth of the cells (Cronan, 2001). However, lack of the “thumb” structure in some other 
biotinoyl subunits or domains of acetyl-CoA carboxylase (Lee et al., 2008; Reddy et al., 
2000) and the long half life of carboxy-biotin (Knowles, 1989) contradicts these suggestions 
about the involvement of the “thumb” structure in the stability of the holo-biotinoyl protein 
(Solbiati et al., 2002). The biotinoyl domain of the human acetyl-CoA carboxylase β crystal 
structure would have been a good template to model the P. yoelii protein considering the 
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E.coli.         HIVRSPMVGTFYRTPSPDAKAFIEVGQKVNVGDTLCIVEAMKMMNQIEADKSGTVKAILV  
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E.coli.         ESGQPVEFDEPLVVI  
P.yoelii.       E-GAMIKIGDLLGVI  
                * *  :::.: * ** 
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evolutionary relationship between the two enzymes. It may be important to use the 2dn8 
(deposited in the PDB by Ruhul Momone et al., 2006) template for more comparative studies 
of the P. yoelii biotinoyl protein domain with regards to its structural evolution. 
 
The inhibition of acetyl-CoA carboxylase activity bsoraphen A has been studied in humans 
and yeast (Beckers et al., 2007; Shen et al., 2004; Shirra et al., 2001). This compound has 
been shown to inhibit the activity of biotin carboxylase by interacting with 20 residues within 
the domain (Shen et al., 2004). The crystal structure of S. cerevisiase (Shen et al., 2004) 
provided a good template to model the P. yoelii acetyl-CoA carboxylase biotin carboxylase 
domain, in an effort to investigate the structural organisation of this domain and the 
possibility of inhibiting the enzyme with soraphen A or close analogues. The structures of the 
P. falciparum orthologue, as well as the human version of the enzyme domain were also 
predicted for comparison. Although, there is a resolved crystal structure of the S. cerevisiase 
biotin carboxylase (PDB ID: 1w96) in complex with soraphen A (Shen et al., 2004), the 
coordinates of the domain without the inhibitor was preferred. This was to prevent errors that 
may be introduced in the models due to the influence of the inhibitor interaction with the 
general conformation of the protein structure (Schwede et al., 2003). Generally, the high 
sequence identity between the target and the template sequence correlated to the good quality 
of the predicted models (Joshi et al., 2008; Keenan and Welsh, 2004; Schwede t al., 2003). 
The GROMOS™ refinement data suggested good quality structures based upon the total 
energy (kJ/mol) before and after the energy minimisation processes. This was also evident in 
the marginal RMSD of the α-carbon backbone structures between predicted models and the 
control model. Therefore, it was vital to carry out energy minimisation before subsequent 
studies on the predicted structure, such as inhibitor or ligand interactions. 
 
The key enzyme subdomain in the biotin carboxylase is the carbamoyl phosphate synthetase 
signature (Galperin and Koonin, 1997). Enzymes belonging to this super family have been 
well studied (Blanchard et al., 1999b; Javid-Majd et al., 1996; Stapleton et al., 1996) and 
they catalyse the phosphorylation of the carboxylate anion (COO−) and subsequent transfer 
of the carbamoyl phosphate to an amine acceptor molecule, in this case a biotin molecule 
attached to the biotin carrier protein. This reaction forms part of the commited step of acetyl-
CoA carboxylase (Brownsey et al., 2006; Hardie and Pan, 2002). The predicted models 
revealed similarity in the conformation of the carbamoyl phosphate synthetase signatures, 
with negligible RMSD of the α-carbon backbone conformation between the models and the 
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control model. This observation structurally characterised this domain, and suggested a 
possible similarity in the enzyme function of the biotin carboxylase domains of S. cerevisiae 
and Plasmodium.  
 
The Ramachandran analysis using the ProCheck™ algorithm showed a lower percentage of 
the non-glycine and non-proline residues in the most favoured region; however, this appeared 
to be consistent with the control model. In addition, very few residues were in the disallowed 
region of the Ramachandran plot. This shortfall in the stipulated percentage (Laskowski et 
al., 1996) of residues in the most favoured region may be traced to the original structure 
deposited in the PDB database (Kleywegt and Jones, 1996). When the crystal structure of S. 
cerevisiae biotin-carboxylase in complex with soraphen A (1w96) was used as a template to 
build a control model and a P. yoelii biotin carboxylase model, ProCheck™ analysis reveal d 
that 90.6% and 86.7% of the residues in the control and P. yoelii models, respectively, were 
in the most favoured region of the Ramachandran plot (results not shown). However, the P. 
yoelii models derived from the different templates of S. cerevisiae biotin carboxylase (PDB 
ID: 1w93 and 1w96) deviated by 0.7 Å (RMSD of the backbone α-carbon atoms), despite an 
equal number of residues between the two models. Beides, the control models generated 
from the two crystal structures also deviated by 0.6 Å. The differences in the resolution of the 
crystals (2.5 Å for 1w93 and 1.8 Å for 1w96) may have influenced the observed constraints 
in the predicted models (Kleywegt and Jones, 1996). The interaction of the protein with the 
inhibitor may have resulted in the more relaxed conformation of the 1w96 crystal structure 
compared to the 1w93 crystal structure. The biotin carboxylases consist of a highly 
conserved ATP-binding subdomain that is characteristics of this class of enzymes (Galperin 
and Koonin, 1997). Perhaps, the binding of ATP stabilises the structure, which may occur 
with soraphen A binding; though soraphen A is not a structural analogue of ATP. Studies 
have shown that ligand interaction stabilises the structure of a protein. For example, the 
interaction between apo-haemoglobin and the porphyrin ring results in stability of 
haemoglobin (Fontana et al., 1997) and the structural stability of ATP-sulfurylase increases 
with ATP-binding (Ullrich et al., 2001; Yu et al., 2007). 
 
The residues at equivalent positions involved in soraphen A binding were superimposeable 
with negligible RMSD. None of these residues are in the disallowed regions of the 
Ramachandran plot as determined by the ProCheck™ algorithm (data not shown). Four out 
of these 19 residues were not conserved. Such structural dissimilarities may prove to be 
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advantageous in designing soraphen A analogues that may interact with higher specificity 
with Plasmodium biotin carboxylase (Keenan and Welsh, 2004). However, th  interaction of 
soraphen A with apicomplexa biotin carboxylase is experimentally characterised. It would be 
interesting to investigate the inhibition of Plasmodium acetyl-CoA carboxylase using in vitro 
Plasmodium culture. The observation made from this predicted models can be further 
evaluated using automated molecular docking algorithms such as GOLD (Genetic 
Optimisation for Ligand Docking) (Jones et al., 1997) to examine hydrogen bonding 
formations between these 19 residues and the soraphen A molecule. Molecular docking 
studies in combination with protein structure prediction is widely applied in drug design and 
synthesis (Bjelic and Åqvist, 2004; Keenan and Welsh, 2004; Singh et al., 2006). The 
inference made from this study could be strengthened by applying other homology modelling 
programmes and compare the models generated from two or more different homology 
modelling algorithms. 
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CHAPTER 7 
FINAL DISCUSSION   
 
7.1 Introduction 
The clinical manifestations of malaria in humans, which occurs only when infected by one of 
the four species of the human malaria parasites, remain a major health and economic burden 
in most tropical regions of the world, where the disease is highly endemic. To date there is no 
effective malaria vaccine and the parasite has developed resistance to most drugs available 
for the treatment of malaria (Gregson and Plowe, 2005; Wainwright and Amaral, 2005; 
White, 2004). This has led to a search for new drug tar ets against malaria, enhanced by the 
complete sequencing of the genome of the falciparum species in addition to other species of 
the parasite. Although the malaria parasite has been studied for several decades, the 
parasite’s biochemistry and interactions with the immune system in humans is not clearly 
understood (McKean, 2002). This may be as a result of the unique nature of the parasite’s 
genome, which is the only organism with an AT-rich genome identified so far. Besides, more 
than 60% of the predicted proteins in the parasite proteome do not have any functional 
similarity with proteins in many other organisms (Gardner et al., 2002a). 
 
The first port of call when investigating preliminary anti-malaria drug effectiveness and 
immune response towards vaccine candidates are the rodent malaria models (Carlton et al., 
2002). These species of Plasmodium parasites, originally isolated from African thicket rats, 
are laboratory-adapted and can be established efficiently in rodents (Sanni et al., 2002). 
Nevertheless, the usefulness of the rodent malaria models as a study alternative to the human 
malaria parasites is still debatable (Carlton et al., 2002). This is because different species 
have been shown to develop different mechanisms of drug resistance, regardless of a similar 
mechanism of action of the particular drug (Carlton et al., 2001). In addition, different 
species of the parasite display different modes of immune invasion in the host. By and large 
studies have shown that regions, where a gene is involved in house keeping, are highly 
conserved between P. falciparum and P. yoelii, but regions where a gene is involved in 
antigenic variation and immune invasion are located are not conserved (Carlton et al., 2002; 
Carlton et al., 2001). This may be interpreted as a pitfall in using rodent malaria parasites to 
model vaccine efficacy; while on the other hand, it shows that malaria models could be 
selected based on genes that best fits the phenotypic trait under study (Kaiser et al., 2004). 
Therefore identifying a protein or enzyme mediating an important pathway for study as a 
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drug target should be based on the presence of orthol gues of the protein in other species and 
the degree of sequence identity between the orthologues of the protein under study.  
 
The “post-genomics” era has witnessed major milestones in malaria research based upon 
deductions made from “in silico”  analyses of the published genomes of the parasite. Several 
genes encoding proteins that were previously thought to be lacking in the Plasmodium 
parasite have been identified as a result of the malaria genome sequencing projects. Genome-
wide studies on the expression profile of the P. falciparum transcriptome (Le Roch et al., 
2003) has revealed the pattern of expression of several genes encoding potential drug targets. 
This has contributed to understanding the importance of a potential drug or vaccine target to 
the stage of the parasite life cycle based on the expression level of protein at the particular 
stage of the parasite development. Generally, it is believed that only genes encoding proteins 
essential for the survival and progression of the parasite at a particular stage are expressed 
(Kaiser et al., 2004; Le Roch et al., 2004). However, care must be taken when making 
deductions from these gene transcriptions profile data, because these data were derived from 
a P. falciparum isolate grown in vitro (Le Roch et al., 2003). There have been recent efforts 
to establish the expression profile of P. falciparum transcriptome from field isolates (Daily et
al., 2007; Siau et al., 2007). 
 
Fatty acid biosynthesis is vital in any organism for membrane biogenesis and survival. The 
ability of the Plasmodium parasite to synthesise fatty acid precursors de novo has been a 
subject of controversy. Initial studies showed the parasite synthesises or imports fatty acid 
based on the dramatic elevation of lipid metabolism n Plasmodium-infected erythrocytes, 
which is almost absent in uninfected erythrocytes (Mitamura and Palacpac, 2003). Central to 
fatty acid metabolism in most organisms is acetyl-CoA carboxylase. This enzyme, which 
catalyses the commitment step in fatty acid biosynthesis, has been shown to be inhibited by 
herbicides and fungicides (Gornicki, 2003; Shen et al., 2004). These observations have led to 
increased attention on this enzyme as a possible drug ta get for anti-parasite and anti-obesity 
chemotherapy. The presence of this enzyme in the Plasmodium parasite was, until now, 
based upon comparative sequence analysis with characterised acetyl-CoA carboxylases from 
other organism (Plasmodb database). 
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7.2 RT-PCR and Northern blotting analysis of P. yoelii acetyl-CoA carboxylase mRNA 
This is the first study to specifically verify the presence of acetyl-CoA carboxylase and 
characterise the highly conserved biotin-binding domain of the enzyme in a Plasmodium 
parasite. This was demonstrated in this study using P. yoelii propagated in mice by 
employing RT-PCR analysis to show that the parasite expresses the enzyme at the 
erythrocytic stage of the parasite life cycle. The results were further confirmed by sequencing 
of the RT-PCR products. Although the quantitative levels of expression of this gene at the 
blood stage of P. yoelii was not determined. Northern blot analysis using total RNA isolated 
from infected mouse blood confirmed the presence and size of the transcript, which was 
greater than the published size of the ORF. This perhaps suggests that the extended 5’ and 3’ 
untranslated regions may be involved in the regulation of the gene translation. This 
observation shows that the parasite is capable of d  novo fatty acid biosynthesis. Studies have 
shown that acetyl-CoA carboxylase is transcriptionally regulated (Barber et al., 2003; 
Munday, 2002), therefore studying the transcription profile and the UTR of this gene 
transcript could to be important for understanding the regulation of acetyl-CoA carboxylase 
activity.  
 
Analysis of the transcription profile of the genes encoding acetyl-CoA carboxylase and fatty 
acid synthase complex in P. falciparum suggests that these enzymes, though very crucial in 
fatty acid synthesis, are down regulated in the blood stage of the parasite cycle and up 
regulated in (the predominant insect stages) the gametocyte and sporozoite stages (Plasmodb 
database). Conversely, enzymes possibly involved in the trafficking and processing of 
imported lipid precursors are up regulated at the erythrocyte stages and down regulated at the 
gametocyte and sporozoite stages. This is an important observation that suggests that de novo 
fatty acid biosynthesis in the parasite may be stage-specific. In other words: why make fatty 
acid when it can easily be extracted from the host? This remains to be investigated. 
 
7.3 Production of anti-PyACC peptide antibodies used for the detection of P. yoelii 
acetyl-CoA carboxylase 
The availability of the published amino acid sequence of P. yoelii acetyl-CoA carboxylase 
enabled the selection of immunogenic peptides from the enzyme for antibody production in 
chickens using an epitope prediction algorithm. The use of synthetic peptides for the 
production of antibodies is a useful approach when the whole protein cannot be easily 
isolated and/or purified to homogeneity. Studies carried out in our laboratory have showed 
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that synthetic peptides coupled to a carrier induce immunogenic response in chickens to 
produce up to 30 mg of affinity purified anti-peptide antibodies. These antibodies have been 
used to successfully characterise several novel Plasmodium protein kinases (Dorin et al., 
2005; Merckx et al., 2003). The anti-peptide IgY directed against P. yoelii acetyl-CoA 
carboxylase detected the enzyme in parasite lysates obtained from a mixed stage P. yoelii-
infection. The enzyme was also detected in situ by immunofluorescence microscopy. The 
detection of the enzyme in both lysate and i  situ is a clear indication of the ability of the 
parasite to synthesise acetyl-CoA carboxylase for de novo fatty acid metabolism. The precise 
localisation of the enzyme in the parasite needs to be established by either 
immunotransmission electron microscopy or confocal microscopy. This would confirm 
previous speculations that fatty acid biosynthesis in apicomplexans occurs in the plastid.  
 
7.4 Expression of the biotinoyl domain P. yoelii acetyl-CoA carboxylase in E. coli 
A major observation drawn from the in silico characterisation of P. yoelii acetyl-CoA 
carboxylase by comparative sequence analysis is the consistency in the number of amino acid 
residues in the biotin-binding domain in all organisms examined. This consistency in the 
number of amino acid residues, coupled with the 100% sequence identity in the biotinylation 
motif of E. coli and Plasmodium, led to the possibility that expressing the P. yoelii acetyl-
CoA carboxlase biotin-binding domain in E. coli may result in the attachment of biotin to the 
recombinant protein by the E. coli biotin protein ligase (Chapman-Smith and Cronan, 1999c; 
Chapman-Smith et al., 1994; Lee et al., 2008). The biotinylation of the recombinant P. yoelii 
protein suggested a structural feature of the enzyme.  The expression of P. yoelii biotinoyl 
protein in lon-protease deficient E. coli strains using two different expression systems 
yielded full protein products, in addition to some truncated recombinant protein products. 
This is not uncommon when Plasmodium proteins are expressed in heterologous systems, 
including yeast (Mehlin et al., 2006). Studies on improving the quality of recombinant 
Plasmodium proteins expressed have led to the use of synthetic codon-optimised genes due 
to the bias in codon usage between the AT-rich-genome Plasmodium and heterologous 
protein expression cells such as yeast and E. coli. The use of synthetic codon-optimised 
genes for the expression of Plasmodium proteins have so far improved the quality and 
quantity of recombinant Plasmodium proteins expressed heterologously in different 
expression systems (Flick et al., 2004; Nagata et al., 1999; Narum et al., 2001; Yadava and 
Ockenhouse, 2003; Zhou et al., 2004). The use of synthetic codon-optimised genes was not 
applied in this study. One major benefit of this approach is that a plasmodial protein can be 
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effectively expressed and characterised without the need to culture parasites. Secondly, RT-
PCR-mediated cloning of an intron-rich gene is bypassed when using the synthetic codon-
optimised gene approach. 
 
7.5 Characterisation of recombinant P. yoelii biotinoyl proteins 
Biotin was enzymatically attached in vivo on the recombinant P. yoelii biotinoyl protein in E. 
coli as shown by a peroxidase-conjugated avidin detection system. Several controls were 
included to ensure that the reaction between the avidin and the biotinylated proteins were 
specific. The distinguishing feature of the avidin-b otin detection system is the extraordinary 
affinity (Ka=10
15 M-1) and specificity that characterises the complex formed between biotin 
and avidin or streptavidin (Bayer t al., 1979). Peroxidase-conjugated streptavidin was the 
choice for detection in a recent study on the activity of E. coli BirA on recombinantly 
expressed biotinoyl protein of human acetyl-CoA carboxylase (Lee et al., 2008). The absence 
of biotin in recombinant P. yoelii putative copper transporter supported the specificity of the 
biotinylation reaction in E. coli. An effort made to renature the recombinant protein was 
successful, though cycles of freeze-thaw of the refold d protein resulted in re-precipitation of 
the protein.  
 
7.6 Prediction of protein kinase phosphorylation sites on the biotin carboxylase and 
carboxyltransferase domains of P. yoelii acetyl-CoA carboxylase 
Protein kinases have been shown to regulate the activity of acetyl-CoA carboxylase in yeast, 
and mammals. Although, the actual protein kinases involved in the “phospho-regulation” of 
acetyl-CoA carboxylase are yet to be established (Locke et al., 2008; Munday, 2002). Two 
algorithms designed to predict potential phosphorylation sites and the potential protein 
kinases identified three sites in the enzyme domains based on evolutionary conservation 
across several organisms. However, these sites were not identified in previous studies, which 
appeared to focus on phosphorylation motifs conserved in the mammalian and insect acetyl-
CoA carboxylases. 5’-AMP-activated protein kinase has been shown to be involved in the 
regulation acetyl-CoA carboxylase and other enzymes in higher eukaryotes (Hardie and Pan, 
2002). The only protein kinase found in the Plasmodium kinome that is similar to AMPK and 
SNF1 (the yeast version of AMPK) is PF14_0516, which has orthologues in other 
Plasmodium species (Personal observation). Remarkably, the expression profile of this gene 
(PF14_0516) is similar to the expression profile of acetyl-CoA carboxylase gene 
(PF14_0664). The genes encoding acetyl-CoA carboxylase and this putative protein kinase 
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are located on the same chromosome (chromosome-14 in P. falciparum and chromosome-13 
in P. yoelii). Although this may be inconsequential, the involvement of this protein kinase in 
the regulation of acetyl-CoA carboxylase and other enzymes in Plasmodium should not be 
overlooked. Efforts made to recombinantly express the P. yoelii orthologue, PY06885 in E. 
coli and P. pastoris were not successful in this study. 
 
7.7 Homology modelling of the biotinoyl and biotin carboxylase domains of P. yoelii 
acetyl-CoA carboxylase 
Predicting the 3D structure of a protein by homology modelling typically proceeds in an 
ordered sequence of well defined steps, namely: amino acid sequence alignment between the 
target and the modelling template, building the preliminary model, refining the preliminary 
model and validating the refined model (Kopp and Schwede, 2004). Prior to this study, there 
were no reported crystal structures of any parasitic protozoan acetyl-CoA carboxylase. In 
fact, the biotinoyl domain of the human acetyl-CoA carboxylase was the first domain of the 
multi-domain acetyl-CoA carboxylase to be resolved by NMR (Lee et al., 2008), which was 
“in press” by the time this study was concluded. Nevertheless, reasonable inferences were 
made from the work by Lee t al. (2008). This study has revealed an insight to the likely 
structural conformations of biotin carboxylase and the biotinoyl protein domains of P. yoelii 
acetyl-CoA carboxylase. The amino acids within the active sites are conserved between the 
target and their respective templates. Model refinement and validations studies indicated that 
the stereochemical attributes of the residues in the models were satisfactory to make valid 
deductions from the predicted structures. The structu e of the carboxyltransferase domain of 
P. yoelii acetyl-CoA carboxylase was not predicted for this study because the amino acid 
sequence does not completely align with a single PDB template. This may require more 
computational adjustment to model both ends of the protein to derive a single structure, 
similar to the study by de Matos Guedes et al., (2007). By and large, the predicted models 
showed prospects on the possibilities of extending the study towards structure-based designs 
to develop effective inhibitors against the enzyme for testing in vitro on malaria parasites. 
 
7.8 Conclusion and future directions 
A classical approach towards understanding the functio s of a protein that is not established 
in an organism is to demonstrate that (i) the gene r sponsible for the expression of the protein 
is present in the genome (ii) the gene is transcribed nto mRNA, (iii) the mRNA transcript is 
translated into the protein and (iv) the protein displays features common to that class of 
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proteins or enzymes. The first approach was establihed by the sequencing of the 
Plasmodium parasites genomes. This study has empirically demonstrated steps two to four, 
therefore confirming the ability of P. yoelii, and perhaps other Plasmodium species, to 
synthesise fatty acids de novo via acetyl-CoA carboxylase-mediated metabolic pathw y. 
Nevertheless, further characterisation employing the native enzyme or recombinantly 
expressed enzyme domains (biotin carboxylase and carboxyltransferase) may be required. 
 
Two major questions that present possible future dir ctions about P. yoelii acetyl-CoA 
carboxylase and the prospects of targeting this enzyme for anti-plasmodial chemotherapy 
were raised by this study.  
(1) What is the fate of biotin in the Plasmodium parasite? The relevance of biotin as a 
cofactor to several enzymes including acetyl-CoA carboxylase and transcarboxylase 
is evident. A BLAST study of the Plasmodium proteome and genome showed that 
biotin synthetase and biotinidase, an enzyme that recycles biotin in the mammalian 
system (Kothapalli et al., 2005; Wolf, 2005) appear not to be present (Personal 
observation). No Plasmodium proteins have been annotated for biotin transport at 
present. The likely explanation is that Plasmodium derives its biotin from the host. 
Previous studies stated that the only vitamin that e Plasmodium parasite imports is 
B5 (pantothenic acid) due to its involvement with Coenzyme-A synthesis (Kirk, 
2001). Establishing the fate of biotin in the parasite is important to understanding the 
role of acetyl-CoA carboxylase in the life cycle ofthe Plasmodium parasite. In 
addition, it would be useful to characterise the Plasmodium biotin protein ligase. 
 
(2) Is acetyl-CoA carboxylase a good target for anti-plasmodial chemotherapy? One of 
the criteria for choosing a protein target for anti-plasmodial drug design is that the 
target must be relevant to the survival of the parasite (White, 2004; White et al., 
1999). Besides, the protein must be expressed at all s ages of the parasite life cycle, 
especially the asexual blood stage where the parasite exerts its pathological features. 
The expression profile of the gene that codes for acetyl-CoA carboxylase suggests 
that the parasite may not absolutely require the enzyme at the blood stage, but rather 
at the gametocyte and sporozoite stages. The importance of this enzyme in the 
initiation of fatty acid biosynthesis makes it a good target for chemotherapy. 
However, the need for acetyl-CoA carboxylase at the blood stage of the parasite life 
cycle needs to be investigated.  
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